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Abstract 
During the course of HIV pathogenesis, the virus induces multiple defects in immune 
cells, altering their functional ability to efficiently control HIV itself and other 
infections.	Whilst the widespread implementation of antiretroviral therapy (ART) has 
led to reduced morbidity and mortality in most HIV-infected individuals having access 
to treatment, we still do not know whether full restoration of immune function occurs. 
The aim of this study was to assess the extent to which ART restores both phenotypic 
and functional T and B cell immunity.  
HIV-infected women were studied before and 1 year after ART initiation. In Chapter 
2, the effect of ART on T cell activation and differentiation profiles was evaluated in 
HIV-infected individuals (n=28; pre- and post-ART), and compared to HIV-
uninfected age- and sex-matched controls (n=23). In Chapter 3, the restoration of co-
pathogen specific CD4+ T cells was determined by comparing their cytokine secretion 
ability and memory differentiation profiles in response to Mycobacterium tuberculosis 
and cytomegalovirus in HIV-infected (n=15; pre- and post-ART), compared to 
uninfected (n=9) individuals. Finally, Chapter 4 examined changes in B cell activation 
and memory profiles in HIV-infected persons (n=19; pre- and post-ART), and 
compared profiles to HIV-uninfected individuals (n=19). Multiparameter flow 
cytometry was performed to address the study objectives.  
T cell activation, as measured by CD38 and HLA-DR expression, was significantly 
reduced one year after ART for both CD4+ and CD8+ T cells, but normalisation to 
levels in HIV-uninfected individuals did not occur, despite suppression of viral load. 
In addition, skewed CD4+ and CD8+ T cell memory profiles were not completely 
restored. Furthermore, no change in the cytokine production capacity and memory 
profile of pathogen-specific CD4+ T cells was found before and after ART, but 
pathogen-specific CD4+ T cells exhibiting a late differentiated profile (CD27-
CD45RO+) had a lower ability to replenish (p=0.02; r=-0.5) compared to cells with an 
early differentiated profile (CD27+CD45RO+; p=0.04; r=0.45) prior to ART. Similar 
to T cells, activated B cells (CD40+CD86+) were only partially normalised post-ART, 
and remained significantly higher than B cells of HIV-uninfected individuals. The 
frequency of all B cell memory subsets were comparable between HIV-treated and 
uninfected individuals, with the exception of plasmablasts, whose frequency was still 
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significantly higher than in HIV-uninfected subjects. 
In summary, these results demonstrate that HIV-infected women on suppressive ART 
show a substantial but only partial normalisation of T cell and B cell memory subsets, 
and lower levels of T cell and B cell activation. In addition, restoration of co-pathogen 
specific memory CD4+ T cells upon treatment was dependent on their memory profile 
before ART. Understanding the impact of HIV on T and B cell dysfunction and 
restoration upon ART may provide important insights into the mechanisms of HIV 
pathogenesis in the era of ART.	
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1.1 Introduction 
1.1.1 Epidemic burden of HIV 
In 1983, the human immunodeficiency virus (HIV) was discovered (Barre-Sinoussi et 
al., 1983), and three decades later it remains a huge public health threat globally. The 
number of people living with HIV worldwide rose from 33.3 million to 36.7 million 
in the period from 2010 to 2015 (Figure 1.1; UNAIDS, 2016a). This is the result of 
both new infections, of which there were roughly 2.1 million in the last year, as well 
as more people with HIV surviving longer than before. In fact, for the past 5 years, the 
number of newly HIV-infected people per year remained stable, but death rates were 
reduced by roughly one third, attributed to an increase in antiretroviral therapy (ART) 
coverage. Even though Sub-Saharan Africa accounted for a 13% and 38% decrease in 
HIV incidence and death cases respectively, it remains the region of the world most 
impacted by the HIV epidemic. More than half (~52%) of all adults and children living 
with the virus reside in Sub-Saharan Africa, where 46% of all new HIV infections 
occurred (UNAIDS, 2016a). In South Africa, the number of people living with HIV 
rose from 4.72 million in 2002 to 7.03 million in 2016 making it currently the country 
with the highest HIV prevalence of 18.9% in the world (Statistic South Africa, 2016). 
Women aged 15 years and more are the most affected in the country with a prevalence 
of 22.3%. However, ART is available at no cost via the public health system and 3.4 
million South Africans are accessing treatment as of March 2016, making South Africa 
the largest ART programme compared to any country in the world 
(https://africacheck.org/reports/yes-south-africa-has-the-worlds-largest antiretroviral 
-therapy-programme/). This has resulted in a 10 years increase in life expectancy since 
2004. 
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Figure 1. 1. A total estimate of the number of people infected with HIV in 2015 (taken 
from UNAIDS, 2016a). 
1.1.2 HIV structure and life cycle 
HIV-1 is classified within the family Retroviridae, belonging to the Lentivirus genus. 
(Fanales-Belasio et al., 2010). HIV has a genome consisting of two copies of single-
stranded RNA (ssRNA) encoding nine genes (Frankel & Young, 1998). The virus is 
composed of three main proteins that are important for the effective synthesis of new 
virions: the enzyme Pol, and the structural proteins, Gag and Env. The Pol protein 
codes for three enzymes: a reverse transcriptase, which transcribes HIV RNA into 
DNA for incorporation into the host cell, an integrase and a protease which allow the 
integration of the viral DNA into the host chromosome, and the cleavage of Gag and 
Gag-Pol polyproteins for packaging, respectively (Yang et al., 2012). The Gag and 
Env proteins form the nucleocapsid and envelope glycoproteins, respectively (Frankel 
& Young, 1998). HIV also encodes regulatory (Tat, Rev) and accessory (Vif, Vpr, 
Vpu, Nef) proteins that control the transcription and translation of the viral RNA as 
well as its transport from the nucleus to the cytoplasm (Lever, 2005). Despite the fact 
that the HIV accessory proteins are dispensable for viral infection in vitro, these 
proteins contribute to pathogenesis in vivo by escaping the host antiviral responses 
(Collins & Collins, 2014). For example, Vif counteracts the function of the host 
restriction factor apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 
3G (APOBEC3G) by preventing the deamination of cysteine residues in the viral 
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genome, enabling viral replication (Simon et al., 2015). Vpu neutralises the bone 
marrow stromal cell antigen-2 (BST-2) restriction factor, allowing infected cells to 
release viral particles at budding (van Damme et al., 2008; McNatt et al., 2013). The 
Nef protein downregulates CD4 and major histocompatibility complex (MHC) class I 
expression, and can also antagonise the function of the host cell factor serine 
incorporator (SERINC), enhancing viral infectivity (Fackler, 2015). 
HIV uses specific receptors to infect different immune cell types. To enter and 
replicate in CD4+ T cells, the major target of HIV, the virus uses the CD4 receptor 
and the chemokine receptors CXCR4 or CCR5 (Berger et al., 1999). The replication 
cycle of HIV consists of several distinct steps; first, the virus binds to CD4 via its 
gp120 glycoprotein (Myszka et al., 2000), inducing a conformational change that 
allows the virus to further attach to CCR5 or CXCR4 (Wu, 2010). This interaction 
results in viral and host cell membrane fusion through gp41, enabling entry of the viral 
RNA into the host cell (Figure 1.2; Melikyan, 2008). To prevent viral sensing by 
cytoplasmic restriction factors, nucleotides can be recruited via pores within the capsid 
for the synthesis of DNA by reverse transcriptase enzyme (Jacques et al., 2016). The 
newly formed DNA is then transported to the nucleus for integration into the host 
chromosome (Fanales-Belasio et al., 2010). Once integrated, the provirus uses the host 
cell RNA polymerase II to start transcribing more copies of the multiply spliced 
messenger (mRNA) transcripts that are initially translated into the regulatory proteins, 
Tat and Rev (Scherer et al., 2007). Both proteins migrate back to the nucleus, where 
Tat enhances viral transcription and Rev directs the transport of RNA transcripts to the 
cytoplasm via the nuclear pores (Lever, 2005). Finally, these RNA molecules are 
translated into enzymatic and structural proteins, and transported to the cell surface for 
packaging into viral particles. A capsid structure forms and immature virions bud from 
the cell to form infectious particles (Lever, 2005). 
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Figure 1. 2. Replication steps of HIV. 1) Delivery of the capsid containing HIV RNA and 
reverse transcriptase into the cytoplasm upon membrane fusion. 2) Reverse transcriptase 
converts the viral RNA into DNA. 3) Viral DNA known as provirus is integrated into the host 
genome. 4) The transcription of the integrated provirus into mRNA is followed by the 
translation and packaging of viral proteins into new virions. 5) Immature virions bud out from 
the cell membrane, acquiring the ability to produce mature particles (Taken from 
https://www.learner.org/courses/biology/archive/images/1922.html). 
 
1.2 Pathogenesis of HIV infection 
This section describes the mechanisms associated with the loss of CD4+ T cells during 
the course of HIV infection, the consequences of this depletion and how the immune 
system attempts to control the virus. 
1.2.1 Loss of CD4+ T cells 
HIV infection is marked, in most infected individuals, by a gradual decrease of CD4+ 
T cells resulting in AIDS if left untreated. Early in infection, a significant loss in 
memory CD4+ T cells occurs predominantly in the gastrointestinal mucosa, which has 
been demonstrated in both SIV-infected rhesus macaques and HIV-infected 
individuals (Mattapallil et al., 1998; Veazey et al., 1998; Mehandru et al. 2004). In 
this tissue, HIV mainly targets memory CD4+ T cells with an activated phenotype and 
expressing the HIV co-receptor CCR5, amplifying viral replication for further 
systemic spread (Veazey et al., 2000). Unlike the peripheral blood and lymph nodes, 
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the gut-associated lymphoid tissue (GALT) is rich in memory CCR5+CD4+ T cells, 
comprising more than 60% of these cells, hence their profound depletion in this 
compartment (Li et al., 2005; Mattapallil et al., 2005). Brenchley and colleagues 
reported that this loss in memory CCR5+CD4+ T cells does not only occur during the 
early stages of HIV infection, but continues during chronic infection (Brenchley et al., 
2004). 
To date, we do not have a complete understanding of how HIV causes CD4+ T cell 
depletion. Direct and indirect mechanisms have been proposed to contribute to the loss 
of CD4+ T cells. Direct killing of HIV-infected CD4+ T cells may occur either by 
virus-induced cytolysis or HIV-specific CD8+ T cells targeting HIV-infected CD4+ T 
cells for destruction (Appay et al., 2002b; Mattapallil et al., 2005). Direct killing of 
virally infected CD4+ T cells alone cannot account for the loss of these cells, since 
only a small proportion of CD4+ T cells (0.001-1%) are infected during chronic HIV 
infection (Douek et al., 2002). Thus, indirect mechanisms are thought to play a major 
role in CD4+ T cell loss. Apoptosis of bystander cells has been reported in lymphoid 
tissues of HIV-infected individuals (Finkel et al., 1995). More recently, it has been 
proposed that the majority (>95%) of CD4+ T cells die due to abortive HIV infection, 
when non-permissive, resting cells undergo caspase-1-mediated pyroptosis, whilst 
only a small proportion of productively infected CD4+ T cells die by caspase-3-
mediated apoptosis (Doitsh et al., 2010; 2014). With regard to indirect ways by which 
CD4 count declines, one such mechanism is the inability of the host immune system 
to replenish the CD4+ T cells killed by HIV (Ho et al., 1995; Wei et al., 1995). Okoye 
and colleagues have also reported a progressive loss of central memory (CM) CD4+ T 
cells, which then fail to renew the pool of effector memory (EM) CD4+ T cells (Okoye 
et al., 2007). Furthermore, thymic dysfunction as a result of HIV infection impedes 
the de novo synthesis of naive CD4+ T cells (Douek et al., 1998). Another major 
contributor to CD4+ T cell loss appears to be systemic immune hyperactivation 
(Hazenberg et al., 2000), a concept that is dealt with in detail in Section 1.3. 
Taken together, these studies demonstrate that upon HIV infection, different 
mechanisms are initiated to drive the loss of CD4+ T cells observed during the acute 
and chronic stages of HIV infection. This renders the immune system vulnerable to 
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opportunistic infections, leading to disease progression and AIDS in the absence of 
treatment. 
1.2.2 Opportunistic infections 
Clinically, disease progression in HIV-infected persons is associated with the severity 
of CD4 loss and the development of opportunistic infections (Egger et al., 2002; Sterne 
et al., 2009). These opportunistic diseases are caused by different viral, bacterial or 
fungal pathogens, such as Cytomegalovirus (CMV), Mycobacterium tuberculosis 
(Mtb) or Candida, among others. In the cohort of African women studied in this thesis, 
during acute HIV infection, some of the women had vaginal discharge and genital tract 
disease of unknown aetiology, as well as upper respiratory tract infections (Mlisana et 
al., 2014). Furthermore, skin rashes and fungal infections were found in these women 
over the full course of infection (approximately 4 years), while lower respiratory tract 
infections, shingles and tuberculosis (TB) emerged at later stages of infection. Similar 
opportunistic infections were reported in HIV-infected individuals from Uganda 
(Rubaihayo et al., 2016). However, it is worth mentioning that the development of 
opportunistic infections is not always associated with low CD4 counts, since both TB 
and Candida infection may occur at any CD4 count (Saharia & Koup, 2013). 
Altogether, these data show that HIV infection is associated with a range of co-
infections, further overwhelming the immune system of the HIV-infected individual. 
Therefore, it is of crucial importance to clearly define the relationship between HIV 
and these pathogens in HIV-infected patients, and whether adjunctive therapy (in 
addition to ART) may be of benefit against other infections, as discussed in Sections 
1.4 and 1.5. 
1.2.3 Host immune responses to HIV 
During the interaction between HIV and the host immune system, the innate arm 
directs the adaptive arm of the immune system to initiate specific immune responses 
in an attempt to control and clear the virus. These events are summarised in Figure 
1.3 below.  
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Figure 1. 3. The early wave of innate and adaptive immune responses following HIV 
infection. During the eclipse phase, elevated levels of plasma acute phase reactants are 
initially detected when viral replication occurs mostly in mucosal tissues and draining lymph 
nodes. An increase in cytokine levels in the plasma is observed when plasma viral load is first 
detected (T0). A few days later, the first antibody-virus immune complexes emerge with the 
exponential increase in plasma viral load. After the initial rise in viral load, HIV-specific 
CD8+ T cell responses develop with a subsequent appearance of circulating gp41-specific 
non-neutralising IgM antibodies. Within 10 days, the virus can evolve to escape recognition 
from CD8+ T cells. In addition, viral reservoirs are likely established during this time. 
Approximately 80 days after infection, the detection of neutralising antibodies against the 
infecting virus occurs; CD8+ and neutralising antibody responses coincide with the decrease 
in plasma viraemia before viral set point is established. Shortly thereafter, viruses able to 
escape antibody neutralisation can arise in plasma (taken from McMichael et al., 2010). 
Upon pathogen encounter, the immune system resorts to innate immunity, known as 
the first line of defence against invading pathogens. The innate immune system is 
composed of a range of cell types, including phagocytes (macrophages, monocytes 
and dendritic cells; DCs), professional antigen presenting cells (DCs), as well as 
cytolytic cells (neutrophils and natural killer; NK cells; Carrington & Alter, 2012). 
Using pathogen recognition receptors (PRRs), innate cells can recognise diverse 
pathogens by sensing molecular structures (pattern associated molecular patterns; 
PAMPs) commonly found as part of their cell walls, or involving recognition of their 
nucleic acid (Thompson et al., 2011). Innate cells possess a range of surface and 
intracellular PRRs (toll-like receptors, TLRs; C-type lectin receptors, CLRs; the 
retinoic acid-inducible gene (RIG)-like receptors, RLRs and the nucleotide binding 
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oligomerisation domain (NOD)-like receptors, NLRs), whose triggering results in the 
secretion of proinflammatory cytokines and chemokines for the recruitment and 
further activation of immune cells, as well as for the inhibition of viral replication 
(Mogensen et al., 2010; Carrington & Alter, 2012; Altfeld & Gale, 2015). One study 
showed that TLR triggering on DCs induced the production of type I interferons, hence 
decreasing the ability of DCs to spread HIV to CD4+ T cells (Thibault et al., 2009). 
However, HIV can affect the function of innate cells. For instance, a reduction in the 
number of circulating DC subsets, namely plasmacytoid DC (pDC) and myeloid DC 
(mDC) was observed during acute and chronic HIV infection (Barron et al., 2003; 
Donaghy et al., 2003). The decline in pDC numbers was further associated with 
decreased IFN-α secretion (Feldman et al., 2001), possibly due to the suppression of 
TLR signalling (Martinelli et al., 2007). Despite the negative effect of HIV on innate 
immune cells, these cells remain indispensable as they shape adaptive immune 
responses (Carrington & Alter, 2012). In line with this, a direct association between 
NK cell activity and HIV viral load was reported in the absence of HIV-specific CD8+ 
T cell responses in very early acute HIV infection, prior to seroconversion (Alter et al., 
2007). 
HIV-specific T cells have been associated with the control of HIV infection. For CD8+ 
T cells, it has been shown that during primary HIV infection the reduction in viral load 
coincides with the emergence of CD8+ T cells specific for HIV (Koup et al., 1994). 
This observation was also observed in SIV-infected rhesus macaques during the 
primary stage of infection (Matano et al., 1998). In these animals, depletion of CD8+ 
T cells resulted in failure to control SIV infection, demonstrated by an increase in viral 
load, which was suppressed upon re-appearance of SIV-specific CD8+ T cells 
(Schmitz et al., 1999). In addition, in vivo depletion of CD8+ T cells in SIV-infected 
rhesus macaques at 70 days post infection resulted in increased viral load that was 
more obvious in SIV-controllers compared to progressors (Chowdhury et al., 2015). 
To control HIV infection, CD8+ T cells can eliminate infected cells via non-lytic 
(production of HIV suppressive factors known as RANTES, MIP-1α and MIP-1β) and 
lytic (release of cytotoxic granules or triggering of the Fas-Fas ligand pathway) 
mechanisms (Cocchi et al., 1995; Gulzar & Copeland, 2004). 
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During HIV infection, intensive research has been conducted on the quantity and 
quality of HIV-specific T cell responses to define what aspects of the immune response 
are associated with the control of HIV. Some studies have looked at the quantity by 
measuring the magnitude and breadth of T cell responses in HIV-infected individuals 
(Addo et al., 2003; Masemola et al., 2004; Gray et al., 2009). Using the IFN-γ ELISpot 
assay, these studies measured HIV-specific T cell responses across the full HIV 
genome and found that plasma viral load was not associated with the magnitude or 
breadth of HIV-specific CD8+ T cells, suggesting that the overall quantity of HIV-
specific T cell responses is not related to viral control when using IFN-γ as a readout. 
However, others have indicated that CD8+ T cells targeting specific HIV proteins 
associate with HIV pathogenesis, where high breadth of Gag-specific responses 
correlates with low viral load while the breadth of Env-specific CD8+ T cell responses 
were related to high viral load (Kiepiela et al., 2007; Rolland et al., 2008). Other 
studies have rather focused on the quality of HIV-specific T cell responses, assessing 
the polyfunctional potential (i.e. the capacity of cells to simultaneously produce 
multiple cytokines), the proliferative and cytotoxic capacities or memory 
differentiation profile of these cells (Migueles et al., 2002; Betts et al., 2006; Addo et 
al., 2007; Almeida et al., 2007; Day et al., 2007; Burgers et al., 2009; Kunwar et al., 
2013). In one study, Long-term non progressors (LTNPs) were characterised by 
increased frequencies of polyfunctional CD8+ T cells (co-expressing CD107a, IFN-γ, 
TNF-α, MIP-1β and IL-2) when compared to individuals with chronic HIV infection 
(Betts et al., 2006). In LTNPs, HIV-specific CD8+ T cells also showed increased 
proliferating potential compared to progressors (Migueles et al., 2002). Furthermore, 
in LTNPs, in vitro activated HIV-specific CD8+ T cells exhibited enhanced capacity 
to lyse HIV-infected CD4+T cells, as measured by higher levels of perforin and 
granzyme B than progressors (Migueles et al., 2008; Hersperger et al., 2011). It is 
important to point out that the majority of these studies were focusing on the functional 
features of HIV-specific CD8+ T cells from LTNPs, a sub-group of individuals 
representing less than 5% of HIV-infected individuals (Kumar, 2013) and are not 
hence representative of the total HIV population. Riou and co-workers then reported 
in acutely HIV-infected individuals an association between lower viral set point and 
elevated frequencies of Gag-specific CD8+ T cell responses with polyfunctional 
ability (expression of IFN-γ, TNF-α, MIP-1β and CD107a; Riou et al., 2014). 
Collectively, these studies indicate that the quality of HIV-specific T cell responses 
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may play a pivotal role in the control of viral replication, showing that CD8+ T cells 
endowed with polyfunctional capacity, high proliferative potential and/or enhanced 
cytotoxic function favour HIV control. 
CD4+ T cells are also essential for the control of HIV infection, as they provide help 
to DCs in order to trigger HIV-specific CD8+ T cell responses (Ostrowski et al., 2000; 
Huang et al., 2008). In addition, the capacity of HIV-specific CD4+ T cells to acquire 
cytolytic function (expression of granzyme and perforin) has been reported in HIV-
infected individuals (Appay, 2004; Zheng et al., 2009). Zheng and colleagues 
demonstrated the killing of HIV-infected macrophages, and activated CD4+ T cells 
expressing HLA-DR by Nef-specific CD4+ T cells (Zheng et al., 2009). Furthermore, 
elevated levels of HIV-specific CD4+ T cells expressing granzyme A were associated 
with a lower viral load set point during acute infection (Soghoian et al., 2012). From 
these reports, it appears that CD4+ T cells can thus contribute to control of HIV either 
via cytotoxic function or their capacity to induce CD8+ T cell responses, or indeed to 
provide help to B cells for the initiation of antibody responses (Sant & McMichael, 
2012). 
HIV infection can elicit antibody-mediated immune responses that can be both non-
neutralising and neutralising. The initial B cell response to HIV is detected as antibody 
complexes 8 days after the appearance of plasma virus, while free antibody specific to 
HIV envelope gp41 emerged around 13 days later (Tomaras et al., 2008). On the other 
hand, the detection of envelope gp120-specific antibodies only occurred 2 weeks after 
the appearance of envelope gp41 antibodies. Although these antibodies are able to bind 
virions, they are non-neutralising, and do not appear to inhibit viral replication 
(Tomaras et al., 2008). The generation of neutralising antibodies (nAb) against 
autologous viruses occurs months after HIV infection but whilst these antibodies can 
neutralise autologous virus, HIV escape renders them unable to neutralise 
heterologous viruses, which evolve rapidly in response to selective antibody pressure 
(Moog et al., 1997; Richman et al., 2003; Wei et al., 2003; Gray et al., 2007). However, 
roughly 20% of HIV-infected individuals can induce broadly cross neutralising (BCN) 
antibodies against heterologous viruses years after infection (Gray et al., 2009; Simek 
et al., 2009; Gray et al., 2011). Although still incompletely understood, some factors 
could explain why some individuals are able to develop BCN antibodies. 
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Neutralisation breadth was related to the length of infection and levels of virus, as well 
as to continuous viral escape from broadly neutralising antibodies uncovering novel 
and various target sites (Gray et al., 2011; Wibmer et al., 2013). Due to the difficulties 
encountered in inducing these antibodies through vaccination, the infusion of broadly 
neutralising antibodies to chronically SHIV-infected rhesus macaques and humans led 
to a robust decrease in plasma viral load (Barouch et al., 2013; Caskey et al., 2015; 
Lynch et al., 2015) , and a large clinical trial is currently underway in South Africa to 
test this concept in humans (Rubens et al., 2015). 
Despite the induction of the host immune response, the control of HIV is only partial 
and the majority of HIV patients develop AIDS without therapy. This is in part due to 
viral escape, where HIV mutates in the face of selection pressure and avoids 
recognition by HIV-specific CD8+ T cells and antibodies; this occurs during both 
acute and chronic infections (Borrow et al., 1997; Cao et al., 2003). Some regions of 
HIV are conserved and required for replicating efficiently (viral ‘fitness’), and viruses 
that are selected for mutations in these regions may display fitness impairment, leading 
to partial immune control and lower viral replication (Lewis et al., 2012). It is well 
known that CD4+ T cells are the principal targets of HIV, and there is some evidence 
that HIV preferentially infects HIV-specific CD4+ T cells (Douek et al., 2002), 
resulting in CD4+ T cells providing suboptimal or no help to CD8+ T cells and B cells 
for effective responses (Kuerten et al., 2008; Boswell et al., 2014). In addition, T cell 
and B cells can lose their function as they become “exhausted” and non-functional due 
to the persistence of viral replication (Day et al., 2006; Moir et al., 2008).  
1.3 Systemic immune hyperactivation during HIV infection 
This section introduces the concept of immune activation during HIV infection and its 
effects on immune cells, with an emphasis on T cells and B cells, the focus of this 
thesis. The potential mechanisms causing this aberrant immune activation and its 
consequences in the absence of treatment are also discussed. 
Now recognised as a main contributor to HIV pathogenesis, immune activation is 
associated with a number of cellular events including activation, proliferation and 
apoptosis, that affect both innate and adaptive immune cells (d’Ettorre et al., 2011). 
The activation of NK cells, DCs, monocytes and macrophages has been previously 
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reported in the context of HIV infection (Brown et al., 2008; Burdo et al., 2011; 
Yonkers et al., 2011; Hearps et al., 2012; Campillo-Gimenez et al., 2014). Elevated 
proportions of inflammatory monocytes with an activated phenotype 
(CD11b+CD62L-) were found in the blood of HIV-infected compared to HIV-
uninfected patients (Hearps et al., 2012). In addition, DCs from HIV-infected 
individuals displayed increased levels of activation and maturation markers (CD83 and 
CD86) compared to HIV-uninfected controls (Yonkers et al., 2011). These activated 
cells in turn secrete high levels of proinflammatory cytokines (such as IFN-α, IL-1β, 
IL-6, IL-8 and TNF-α) and chemokines (MIP-1α, MIP-1β, RANTES) to further drive 
immune activation (Appay & Kelleher, 2016). Immune cells from the adaptive arm, 
namely T cells and B cells are also activated during HIV infection (Appay & Sauce, 
2008). 
1.3.1 T cell activation 
Previous analyses of chronically HIV-infected individuals have reported higher levels 
of activation markers (CD38, HLA-DR or co-expression of both markers) on CD4+ 
and CD8+ T cells in blood (Liu et al., 1997; Giorgi et al., 1993; 1999; 2002; Hazenberg 
et al. 2003). These studies found T cell activation to predict CD4+ T cell loss and 
disease progression more strongly even than plasma viral load. Others further showed 
that T cell activation before or at the set point (when activation reaches a plateau, in 
most cases 6 months post-acute infection) predicted CD4+ T cell loss independently 
of the degree of viral replication (Deeks et al., 2004; van Ansten et al., 2004; Hunt et 
al., 2008). 
During HIV infection, T cell activation is also associated with markers of 
inflammation and coagulation. In acutely HIV-infected individuals, a substantial 
increase in plasma cytokine levels was found to be associated with high viral load 
(Stacey et al., 2009). The levels of certain cytokines (IL-1α and IL-7) were predictive 
of CD4+ T cell loss, while others were associated with T cell activation set point (TGF-
β1 and IL-8) and rapid disease progression (IP-10; Roberts et al., 2011; Liovat et al., 
2012). In addition, faster disease progression was associated with elevated levels of 
IL-6 in the plasma of chronically HIV-infected subjects compared to uninfected 
controls (Eller et al., 2011). Equally, there are increased levels of coagulation markers 
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during untreated HIV infection (Funderburg et al.; 2010). Before the start of 
antiretroviral therapy, elevated levels of D-dimers were found to be associated with 
higher risk of AIDS and death in individuals with advanced HIV disease (Boulware et 
al., 2011). Overall, high levels of these inflammatory (IL-6 and hsCRP) and 
coagulation (D-dimers) biomarkers are predictive of cardiovascular disease and 
mortality in HIV patients (Baker & Duprez, 2010). 
1.3.2 B cell activation 
Apart from T cells, B cells are also highly activated in HIV infection. Studies on B 
cells, primarily in the peripheral blood, have reported higher expression of activation 
markers (CD70, CD71, CD80 and CD86) in individuals with chronic HIV infection 
(Martínez-Maza et al., 1987; Malaspina et al., 2003; De Milito et al., 2004). In addition, 
chronically HIV-infected individuals showed high levels of proliferating B cells 
(Kovacs et al., 2001). B cell hyperactivity is also manifested by a polyclonal B cell 
activation and hypergammaglobulinaemia (Lane et al., 1983; Morris et al., 1998; 
Levesque et al., 2009). Morris and colleagues found elevated frequencies of B cells 
spontaneously producing immunoglobulin (Ig) in the serum of chronically HIV-
infected individuals (Morris et al., 1998). Moreover, elevated levels of soluble markers 
of B cell activation (such CXCL13) and B cell-stimulatory cytokines (IL-10 and IL-6) 
have been found in HIV-infected persons (Martínez-Maza & Breen, 2002; Widney et 
al., 2005). 
Altogether, these studies underline the importance of immune activation, described 
here by the activation of T cells and B cells, to drive disease progression. A range of 
mechanisms can contribute to this hyperimmune activation.  
1.3.3 Causes of immune activation 
The mechanisms contributing to immune activation can be both direct and indirect. 
HIV-derived antigens can activate the immune system directly. The interaction 
between HIV gp120 and CD4 receptors enhanced the activity of the protein tyrosine 
kinase p56lck, resulting in CD4+ T cell activation (Hivroz et al., 1993). In addition, 
Zimmermann and co-workers recently showed that the activation of CD4+ T cells 
depends on the alignment of gp120–CD4 receptor binding with respect to T cell 
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receptor (TCR) engagement site, where proximal CD4-TCR signalling in response to 
gp120 favoured complete CD4+ T cell activation (Zimmermann et al., 2015). The HIV 
Nef protein can contribute to immune activation by downmodulating the TCR-CD3 
complex from infected T cells (Schindler et al., 2006). Even though B cells are not 
directly infected by HIV, the binding of HIV gp120 to the CD21 receptor on B cells 
can result in polyclonal B cell activation and transfer of viral particles to activated T 
cells (Moir et al., 2000). Furthermore, B cells were found to become activated 
(expressing the activation marker Fas) following exposure to HIV Tat protein (Huang 
et al., 1997). B cell activation was linked to the direct triggering of the spleen tyrosine 
kinase (SYK) and c-Jun N-terminal kinase (JNK) signalling pathways by HIV (Perisé-
Barrios et al., 2014). 
The activation of innate cells via direct interaction either with HIV proteins or TLR 
ligands within the viral genomic RNA can also lead to immune activation. Uridine-
rich sequences within HIV ssRNA mediated the activation of pDC, monocytes and 
NK cells through TLR 7/8 ligation (Alter et al., 2007; Meier et al., 2008). The 
activation of pDC to produce IFN-α occurred in response to HIV RNA upon CD4-
mediated endocytosis and endosomal acidification followed by sensing primarily 
through TLR7 (Beignon et al., 2005). Furthermore, IFN-α production was mediated 
upon activation of the IRF7 pathway in early endosomes, where HIV localises 
depending on the interaction between HIV envelope protein and the CD4 receptor on 
pDC (O’Brien et al., 2011; Reszka-Blanco et al., 2015; O’Brien et al., 2016). 
Moreover, it has been recently proposed that the accumulation of HIV DNA in the 
cytoplasm of abortively infected cells can induce the release of the proinflammatory 
cytokine IL-1β upon caspase-1 activation (Doitsh et al., 2010). In summary, these 
studies show that viral components can directly induce immune activation. 
The process of immune activation proves to be more complex than being mediated by 
HIV components alone in this direct manner, and there are also indirect contributors 
to hyperimmune activation. During HIV infection, the epithelial barrier of the 
gastrointestinal tract is disrupted due to a massive loss in CD4+ T cell helper (Th) 
subsets (such as Th17 cells) that are key players in gut homeostasis and in the defence 
against invading microbes at mucosal sites (Brenchley et al., 2004; 2007; 2008). As a 
result, HIV-infected individuals display an increased permeability of the gut 
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epithelium (Mudd & Brenchley, 2016). Consequently, the process of microbial 
translocation occurs, allowing bacterial components (such as LPS and bacterial DNA) 
to access the systemic circulation (Brenchley et al., 2007; Jiang et al., 2009). 
Brenchley and colleagues showed that individuals with chronic HIV infection had high 
levels of plasma LPS, which associated directly with the extent of CD8+ T cell and 
pDC activation. The first report to link the gut microbiome to systemic immune 
activation demonstrated a significant correlation between the proportions of 
Bacteroidales (through 16S rDNA quantification) and the levels of activated CD8+ T 
cells in chronically HIV-infected subjects (Ellis et al., 2011). Furthermore, changes in 
the gut microbial environment of chronically HIV-infected persons resulted in 
elevated Prevotella bacteria, which strongly associated with microbial translocation 
(measured by LPS and sCD14 plasma levels) and T cell activation (CD38 and HLA-
DR expression; Dillon et al., 2014). Different classes of bacteria can induce the release 
of proinflammatory cytokines (IL-1β, IFN-γ and TNF-α) further promoting immune 
activation (Dinh et al., 2015). 
Besides microbial translocation, co-infections with other pathogens may also play a 
role in chronic immune activation (Haas et al., 2011). Elevated frequencies of CD8+ 
T cells expressing CD38 and HLA-DR were reported in women co-infected with HIV 
and HCV relative to those infected with HIV alone (Kovacs et al., 2008). This CD8+ 
T cell activation was substantially higher in viraemic than non-viraemic women 
(HIV+HCV+ and HIV+HCV-, respectively). In addition, frequencies of activated B 
cells (expression of CD69 and CD86) correlated with EBV DNA load, which 
associated with higher levels of IL-6 and TNF-α (Petrara et al., 2012). Furthermore, 
increased expression of CD38 on CD8+ T cells specific for CMV and EBV was found 
in acutely HIV-infected individuals and correlated strongly with HIV viral load 
(Doisne et al., 2004).  
Overall, these findings demonstrate that multiple processes occur and function 
together to drive immune activation and HIV disease progression, leading to serious 
consequences for the immune system. 
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1.3.4 Consequences of immune activation 
Hyperimmune activation of the immune system can fuel further HIV replication. 
During HIV infection, the release of proinflammatory cytokines such as TNF-α, IFN-
α and IL-1β can contribute to T cell activation, which directly results in elevated levels 
of NF-κB, inducing the transcription of HIV provirus, and providing more viruses for 
the infection of new target cells (Kawakami et al., 1988; Decrion et al., 2005; Doitsh 
et al., 2014). In addition, these cytokines may promote the translocation of bacterial 
products into the systemic circulation by altering epithelial barrier function, thereby 
further driving immune activation and HIV replication (Stockmann et al., 2000; 
Brenchley et al., 2007; Nazli et al., 2010). Even under antiretroviral therapy, where 
HIV replication is suppressed, immune activation may persist and there are 
consequences associated with this (Lederman et al., 2011; Sandler et al., 2011), as 
discussed in Section 1.5. Generalised immune activation in HIV-infected individuals 
may also lead to secondary lymphoid tissues fibrosis, primarily in the lymph nodes, as 
demonstrated by collagen deposition in paracortical T cell zones (Schacker et al., 
2002). In addition, within the first 80 days of infection, nearly 50% of germinal centers 
were shown to be lost in secondary lymphoid tissues in the terminal ileum Peyer’s 
Patches in HIV-infected individuals (Levesque et al., 2009). These data suggest that 
changes in lymph node architecture affecting both the paracortical T cell zone and B 
cell follicles (germinal centers), where the generation of T cell and B cell responses to 
antigens occurs, respectively, may impede the initiation of these immune responses 
(Estes, 2013). Furthermore, a reduction in the number of hematopoietic progenitor 
cells with functional alterations were demonstrated in HIV-infected individuals, as 
well as decreased thymopoiesis possibly due to thymic involution or HIV infection of 
the thymus (Stanley et al., 1993; Douek et al., 1998; Kalayjian et al., 2003; Sauce et 
al., 2011). Consequently, this alters the ability of the immune system to produce new 
lymphocytes to replenish those destroyed or rendered dysfunctional. Therefore, HIV-
infected patients are unable to compensate for the immune activation-induced 
increased cell turnover (proliferation and/or apoptosis) and differentiation from naive 
to antigen-experienced cells displaying an exhausted phenotype, possessing a reduced 
ability to proliferate and exert effector functions (Appay & Sauce, 2008; Moir & Fauci, 
2009). Collectively, these reports suggest that continuous viral replication and immune 
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activation can induce defects in the phenotype and function of immune cells, discussed 
in the next Section. 
1.4 HIV-induced phenotypic and functional defects in lymphocytes 
This section focuses on defects in T and B lymphocytes and their subsequent 
impairment to effectively coordinate immune responses. 
1.4.1 T cell defects 
Chronic immune activation can drive the expansion of memory T cells causing an 
imbalance in T cell subset distribution (Papagno et al., 2004). T cells can be grouped 
into naive, central memory, transitional memory (TM), effector memory and terminal 
effector cells, according to their differentiation phenotype and function (Paiardini & 
Müller-Trutwin, 2013). Upon antigen encounter and activation, naive T cells undergo 
clonal expansion, and become long-lived memory or effector T cells that migrate to 
sites of infection, with cytotoxic and cytokine secretion abilities (Pennock et al., 2013). 
Effector T cells are generally short-lived and the majority of these cells disappear once 
an infection has resolved, with the residual cells becoming memory T cells (Broere et 
al., 2011). Memory T cells are generally long-lived cells and the hallmark of re-
encountering antigen is a rapid and more potent secondary response (Jameson & 
Masopust, 2009). In turn, based on the expression of the chemokine receptor CCR7 
required for T cell homing to lymphoid tissues, memory T cells have been classified 
as CCR7+ central memory T cells (TCM), self-renewing cells located in lymphoid 
tissues or CCR7- effector memory T cells (TEM) with the ability to migrate to 
peripheral tissues (Lanzavecchia & Sallusto, 2005). 
Chronic HIV infection drives the exhaustion of CD8+ T cells, limiting cell 
proliferative and polyfunctional abilities. T cell exhaustion is often characterised by 
increased expression of various inhibitory receptors including programmed cell death 
protein-1 (PD-1), the T cell immunoglobulin mucin-3 (Tim-3), lymphocyte activation 
gene-3 protein (LAG-3) and CD160 (Trautmann et al., 2006; Jones et al., 2008; 
Blackburn et al., 2009; Peretz et al., 2012). In chronically HIV-infected individuals, 
the expression of Tim-3 was upregulated on HIV-specific CD8+ T cells and Tim-
3+CD8+ T cells were unable to secrete cytokine (IFN-γ) or undergo proliferation (as 
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measured by Ki67 expression) following stimulation with antigens likely due to 
impaired triggering of Stat5, Erk1/2, and p38 pathways (Jones et al., 2008). 
Furthermore, compared to both HIV-uninfected subjects and elite controllers, 
individuals with chronic HIV infection had higher expression of HIV-specific CD8+ 
T cells co-expressing CD160+PD-1+ and these cells had lower ability to perform 
effector functions (CD107a, IFN-γ and TNF-α) in response to TCR stimulation 
relative to HIV-specific CD8+ T cells expressing only CD160+ or PD-1+ (Peretz et 
al., 2012). More recently, Pombo and colleagues demonstrated that even in elite 
controllers HIV-specific CD8+ T cells can exhibit an exhausted phenotype (PD-
1+CD160+2B4+) and the frequency of these cells were comparable to those found in 
chronic progressors (Pombo et al., 2015). However, unlike progressors, elite 
controllers appear to maintain a subset of HIV-specific CD8+ T cells that, despite co-
expressing CD160 and 2B4, are endowed with cytolytic activity (perforin expression) 
possibly playing a role in the control of HIV (Pombo et al., 2015).  
Studies of HIV-infected persons have demonstrated a loss of naive CD4+ and CD8+ 
T cells that is likely as a result of thymic dysfunction or increased differentiation of 
these cells into memory and effector cells due to chronic immune stimulation (Rabin 
et al., 1995; Roederer et al., 1995; Douek et al., 1998; Sallusto et al., 1999; Li et al., 
2011). In the blood of HIV-infected persons, TCM and TTM CD4+ T cells were 
identified as the main reservoirs of HIV (Chomont et al., 2009). In SIV-infected rhesus 
macaques, the progressive decline of TCM CD4+ T cells sets the tempo of disease 
progression to AIDS (Okoye et al., 2007). The maintenance of TCM CD4+ T cells has 
been associated with lower viraemia and prolonged survival (Letvin et al., 2006; Potter 
et al., 2007). For instance, Potter and colleagues have shown that the frequencies of 
TCM CD4+ T cells were significantly lower in viraemic individuals compared to elite 
controllers who had similar percentages of TCM CD4+ T cells as uninfected controls. 
Moreover, in response to p24 Gag, TCM CD4+ T cells in elite controllers had a greater 
ability to secrete cytokines (IFN-γ or IL-2 or both; but largely IL-2) than cells from 
viraemic patients (Potter et al., 2007). The depleted memory T cells during the course 
of HIV infection may also include memory cells for a range of opportunistic pathogens, 
impairing T cell responses against these co-pathogens (Saharia & Koup, 2013). 
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Specialised CD4+ Th subsets, based on their cytokine and transcriptional profiles 
(namely Th1, Th2, Th17, Th22, regulatory T cells (Treg) and follicular helper T cells 
(Tfh) cells; Paiardini & Müller-Trutwin, 2013) can be affected differentially during 
HIV infection. The loss of Th17 and Th22 subsets has been demonstrated in HIV-
infected individuals (El Hed et al., 2010; Kim et al., 2012; Alvarez et al., 2013; Page 
et al., 2014). Alvarez and co-workers reported a selective depletion of Th17 cells, as 
shown by a decrease in the frequency of CD4+ T cells producing IL-17 from the blood 
of chronically HIV-infected subjects in comparison to uninfected controls (Alvarez et 
al., 2013). In addition, in vitro co-culture of sorted CCR6+CD4+ T cells in the 
presence of polyclonal stimulus and cytokines (IL-1β and IL-23) showed a preferential 
infection and depletion of Th17 cells by CCR5 or CXCR4-tropic HIV isolates 
(Alvarez et al., 2013). A lower frequency of peripheral Th22 cells in HIV-infected 
compared to HIV-uninfected individuals has also been demonstrated (Page et al., 
2014), and this study also showed that a lower frequency of Th22 cells was associated 
with higher CD8+ T cell activation in HIV-infection. 
In contrast to the loss of Th17 and Th22 cells, there is expansion of Treg and Tfh 
during HIV infection. Treg can suppress HIV-specific T cell responses, thereby 
contributing to HIV-induced immune dysfunction (Aandahl et al., 2004; Kinter et al., 
2007). Increased frequencies and numbers of CD4+ Treg (CD25+FoxP3+) were found 
in mucosal tissues of chronically HIV-infected subjects with respect to uninfected 
controls, while in the blood the frequencies of CD4+ Treg were marginally elevated 
in viraemic patients (Epple et al., 2006). Other studies of HIV and SIV infection have 
reported the accumulation of CD4+ Tfh cells in secondary lymphoid tissues (Hong et 
al., 2012; Lindqvist et al., 2012; Petrovas et al., 2012). For example, Petrovas and 
colleagues have shown that the majority of rhesus macaques with chronic SIV 
infection had higher frequencies of CD4+ Tfh cells in their lymph nodes than acutely 
SIV-infected or uninfected control animals (Petrovas et al., 2012). The expansion of 
CD4+ Tfh cells did not appear to be because these cells were resistant to SIV infection, 
but rather was associated with SIV-induced immune activation and increased IL-6 
levels in the plasma of chronically SIV-infected animals. In line with this, another 
study group demonstrated increased frequencies of SIV-infected CD4+ Tfh cells (by 
SIV DNA quantification) in lymph nodes of rhesus macaques with chronic infection 
compared to sooty mangabeys, natural primate hosts of SIV (Brenchley et al., 2012). 
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More recently, it has been shown in chronically HIV-infected individuals that CD4+ 
Tfh cells were enriched with HIV-specific CD4+ T cells following stimulation of 
lymph node mononuclear cells with Gag, Pol and Env peptide pools (Perreau et al., 
2013). In addition, plasma viral load positively associated with the frequencies of Tfh 
cells that had the highest quantity of HIV DNA and supported productive HIV 
infection in in vitro culture (Perreau et al., 2013). However, how HIV infection affects 
the function of Tfh remains unclear. Expansion of CD4+ Tfh cells was associated with 
elevated germinal center B cells and increased levels of IgG and IgA antibodies in 
response to SIV antigens in the plasma of chronically SIV-infected animals, 
underlining the key role of Tfh in the stimulation of B cell responses (Petrovas et al., 
2012; Perreau et al., 2013). Furthermore, the accumulation of Tfh in individuals with 
chronic HIV infection was associated with skewed B cell differentiation (Lindqvist et 
al., 2012). 
1.4.2 B cell defects 
Another hallmark of HIV infection is the occurrence of severe B cell defects that are 
associated with HIV-induced immune activation (Moir & Fauci, 2009). HIV induces 
phenotypic alterations in peripheral blood by provoking a skewing of B cell 
subpopulations (Moir & Fauci, 2013). Immature transitional B cells, having newly 
emigrated from bone marrow, and mature naive B cells, represent antigen-
inexperienced B cells (Sims et al., 2005; Bemark, 2015). Memory B cells, that have 
responded to antigen and undergone somatic hypermutation upon antigen encounter, 
are characterised by their capacity to rapidly respond and produce high affinity 
antibodies when they are re-exposed to the same antigen (Kaminski et al., 2012; 
Bemark, 2015). Previous studies have identified classical memory B cells based on the 
expression of three markers, namely IgD, IgM and CD27 (Black et al., 1978; Klein et 
al., 1998). These memory B cells consist of roughly 60% unswitched B cells 
(IgM+IgD+ and IgM+IgD-), and 40% class-switched (IgM-IgD-), expressing other Ig 
isotypes such as IgG, IgA and IgE, and <1% of IgD+IgM- B cells (Yoshida et al., 
2010; Kaminski et al., 2012). More recently, with the use of other markers such as 
CD21 and CD10, classical CD27+ memory B cells may additionally be grouped into 
activated and resting, memory B cells (Ho et al., 2006; Moir et al., 2008). However, a 
low proportion (1-4%) of memory B cells lacking the expression of CD27 has been 
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described in the blood of HIV-infected persons and represent tissue-like memory B 
cells (Fecteau et al., 2006; Moir et al., 2008; 2010). Terminally differentiated antibody 
producing B cells encompass plasmablasts (partially differentiated and proliferating) 
and plasma cells (fully differentiated and rare in peripheral blood; Montezuma-Rusca 
et al., 2015). 
HIV infection results in the skewing of B cell subpopulations, creating an imbalance 
of some subsets. A number of studies have shown a substantial decrease in the 
frequency of naive B cells, while the frequency of immature transitional B cells 
increased in the blood of HIV-infected individuals relative to HIV-uninfected 
individuals (Malaspina et al., 2006; Moir et al., 2008; Pensieroso et al., 2013a). In 
addition, one study reported the depletion of CD27+ memory B cells in the blood of 
HIV-infected persons (De Milito et al., 2001). Furthermore, Moir and colleagues 
reported elevated frequencies of activated memory B cells and plasmablasts in 
individuals with chronic HIV infection, while resting memory B cell frequencies were 
reduced compared to uninfected controls (Moir et al., 2010). The loss of resting 
memory B cells can translate into a decrease in T cell-dependent or –independent 
antigen-specific memory B cell responses (Titanji et al., 2006; Hart et al., 2007; Moir 
et al., 2010), as well as compromised antibody responses to vaccination (Malaspina et 
al., 2005; Ho et al., 2011). For instance, there were lower tetanus toxoid and 
pneumococcal antibody (Ab) levels in HIV-infected than uninfected controls, and 
tetanus toxoid IgG and pneumococcal IgM levels positively associated with 
frequencies of switched memory and IgM memory B cells, respectively, in HIV-
infected persons (Hart et al., 2007). In addition, two months after a single dose of the 
trivalent inactivated influenza vaccine, HIV-uninfected subjects showed substantially 
higher influenza-specific memory B cell responses relative to HIV patients (Malaspina 
et al., 2005). This could be explained by the lack of CD4+ T cell help due to B cells 
expressing low levels of CD25, impeding their ability to respond to activated CD4+ T 
cells or due to increased ligation of PD-1 on Tfh cells resulting in inadequate help to 
B cells, hence affecting the generation of B cell responses (Moir et al., 2003; Cubas et 
al., 2013). As opposed to resting memory B cells, higher frequency of tissue-like 
memory B cells were observed in HIV-infected than uninfected individuals (Moir et 
al., 2008). In this study, the frequency of antigen secreting cells (ASCs, measured by 
B cell ELISpot) against HIV gp120 were enhanced in these tissue-like memory B cells 
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after polyclonal stimulation. In contrast, a more recent study using gp140 probes 
showed that HIV-specific B cell responses were enriched not only in tissue-like 
memory B cells but also in activated memory and resting memory B cells, the latter 
two making up most (activated memory, 50.9% and resting memory, 31.2% vs tissue-
like memory, 16.1%) of the total HIV-specific responses (Kardava et al., 2014). 
Differences in the techniques used may explain these contrasting findings. Unlike with 
the use of HIV envelope probes, the ELISpot assay requires in vitro culture, and it is 
possible that memory B cells may have not survived due to the susceptibility of these 
cells, primarily activated memory B cells to apoptosis in HIV infection (Kardava et 
al., 2014). 
Overall, HIV infection dysregulates the differentiation pattern of lymphocytes and 
preferentially depletes some subsets, crippling their capacity to induce effective 
immune responses. However, whether HIV-induced dysregulation of these subsets are 
completely corrected following antiretroviral therapy remain to be clarified, and is still 
the subject of intensive research. 
1.5 Antiretroviral therapy (ART) for HIV 
The widespread availability of ART for HIV has had a major impact on the pandemic. 
This section summarises current ART guidelines for when to start ART and the 
benefits of early ART, elaborating on its effect on the immune system as well as 
transmission, and highlighting factors that influence CD4+ T cell recovery and 
whether phenotypic and functional alterations caused by HIV are reversed upon ART. 
In addition, the consequences and limitations of ART are discussed, along with new 
strategies proposed to improve or complement the efficacy of ART. 
1.5.1 Current guidelines for ART initiation 
According to the recent WHO guidelines on HIV treatment, HIV-infected persons 
should initiate ART irrespective of their CD4 count or WHO clinical stage, with 
priority being given to patients with CD4 counts ≤350 cells/ml and displaying serious 
or progressive HIV disease (WHO, 2015). This recommendation was proposed based 
on a systematic review of collective data from a range of studies demonstrating that 
HIV patients who commence ART early (at least at a CD4 counts of 500 cells/mm3) 
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have a lower risk of developing AIDS and non-AIDS-related diseases and better 
immune recovery compared to those initiating ART late (WHO, 2015). A large 
randomised controlled trial conducted in 2076 HIV-infected Africans with baseline 
CD4 counts of 500 cells/mm3 or more showed that patients who started ART 
immediately had a reduced risk of AIDS and non-AIDS-related diseases, and death in 
comparison to individuals who were in a deferred ART group, who received ART 
when they met the WHO criteria for starting ART at CD4 counts less than 200 or 350 
or 500 cells/mm3 (TEMPRANO ANRS12136 Study Group, 2015). Further evidence 
supporting early HIV treatment has also come from two published clinical trials, one 
of them being the Strategic Timing of Antiretroviral Treatment (START) trial with a 
similar design to the TEMPRANO study. The START trial determined the occurrence 
of severe AIDS and non-AIDS-related diseases or mortality in HIV patients (with CD4 
counts ≥500 cells/mm3) who were taking ART either immediately or later (when CD4 
counts fell below 350 cells/mm3). Compared to the 96 events reported in deferred ART 
arm, only 42 events occurred in the immediate therapy group, representing roughly a 
56% decrease in serious AIDS- and non-AIDS-defining events (INSIGHT START 
Study Group et al., 2015). In addition, the HIV Prevention Trials Network (HPTN) 
052 study randomised HIV serodiscordant couples with baseline CD4 counts ranging 
between 350 and 550 cells/mm3 to receive early therapy or late therapy (when CD4 
counts dropped below 250 cells/mm3). A staggering 93% reduction in the overall risk 
of HIV transmission was reported in HIV-infected individuals receiving early ART 
(Cohen et al., 2016). Taken together, the outcomes of these studies underline the 
enormous benefits of early ART. However, the implementation of these new 
guidelines involve the scaling-up and sustainability of national ART programmes for 
maximum and life-long coverage of all HIV-infected individuals, which is a major 
challenge in resource-limited regions, particularly in Sub-Saharan African, where 
most HIV-infected persons reside. Interestingly, Kuznik and colleagues showed that 
early initiation of ART (CD4 counts >500 cells/ml) in HIV-infected persons from a 
range of countries (South Africa, Nigeria, Uganda and India) was cost-effective 
relative to a deferred ART group (Kuznik et al., 2016). Given these benefits to 
individual health, reducing transmission and cost-effectiveness, WHO issued 
guidelines recommending initiating ART irrespective of CD4 count (UNAIDS, 2016b). 
In response to this, South Africa modified its policy and began offering ART to all 
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HIV-infected persons in September 2016, regardless of their CD4 counts (Department 
of Health, 2016).  
1.5.2 Classes of drugs, toxicity and treatment switch 
The use of combination ART for the treatment of HIV infection has proven to be of 
great benefit, leading to sustained decreases in HIV viral load within 6 months, and 
these levels remain stable and below the limit of detection within a year of treatment, 
resulting in immune reconstitution (Autran et al., 1997; Lederman et al., 1998). The 
antiretroviral (ARVs) drugs currently available target distinct stages of the HIV life 
cycle and may be divided into different classes based on their mode of action (Arts & 
Hazuda, 2012). These include: 1) nucleoside reverse transcriptase inhibitors (NRTIs), 
2) nucleotide reverse transcriptase inhibitors (NtRTIs), 3) non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), 4) integrase inhibitors (INIs), 5) protease inhibitors 
(PIs) and 6) entry inhibitors. Briefly, NRTIs, NtRTIs and NNRTIs inhibit the function 
of HIV reverse transcriptase by preventing the copying of viral RNA into DNA. While 
INIs inhibit the integration of HIV DNA into the host chromosome, PIs prevent 
processing of viral proteins and packaging into mature forms. Entry inhibitors block 
the binding of HIV gp120 to CD4 or CCR5 on target cells (Arts & Hazuda, 2012). The 
recommended combination of ARVs consists of a backbone of two drugs from the 
nucleoside/nucleotide family and a third drug from any other class of ARVs, including 
NNRTIs, INIs, PIs and entry inhibitors (Akanbi et al., 2012). In South Africa, the 
preferred first-line regimen given to HIV-infected individuals consists of two NRTIs 
(tenofovir, TDF and emtricitabine, FTC or lamivudine, 3TC) and one NNRTI 
(efavirenz, EFV; Meintjes et al., 2014). Unlike other classes of drugs like INIs and PIs, 
NNRTIs can be used over the long-term as they are well-tolerated and more affordable 
(Meintjes et al., 2014). However, HIV-infected individuals may be required to switch 
regimens due to virological failure caused by the accumulation of resistance mutations 
to certain drugs, or drug toxicity. For instance, TDF, 3TC and EFV are associated with 
renal failure, anaemia and neuropsychiatric side effects, respectively (Meintjes et al., 
2014). 
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1.5.3 Factors associated with CD4 restoration and immune recovery 
ART is without a doubt highly effective, as it has reduced the emergence of 
opportunistic infections in HIV patients resulting in clear improvements in morbidity 
and mortality (Lawn & Wood, 2011). However, one early study demonstrated that 
roughly 60% and 16% of HIV-infected individuals on long-term ART failed to 
reconstitute their CD4 counts to levels above 500 and 200 cells/mm3, respectively, 
even though viral load was maintained at undetectable levels (Kaufmann et al., 2003). 
These so-called ‘immunological non-responders’ spend a greater length of time at low 
CD4 counts and are thus more susceptible to AIDS and non-AIDS related illnesses 
(like opportunistic infections, renal and cardiovascular events) as well as death relative 
to immunological responders (Tan et al., 2008; Lapadula et al., 2013). Several factors 
have been identified that influence the extent of CD4+ T cell recovery upon ART, the 
strongest being baseline CD4 count prior to the start of ART (Corbeau & Reynes, 
2011). Other factors, summarised in Table 1.1, include age, co-infections, time since 
HIV infection and cellular senescence. 
Table 1. 1. Parameters influencing CD4+ T cell restoration upon ART  
Factors Main results References 
Baseline CD4 counts 
prior to ART 
Lower CD4 counts at start of ART were 
associated with CD4 counts 
<500cells/mm3 at 5 years of ART 
(Kaufmann et al., 2005) 
Age 
Younger age independently predicted 
higher gain in CD4 counts at 4 years of 
ART 
(Kaufmann et al., 2002) 
Co-active infections 
After 1 year of ART, HCV seropositivity 
was associated with lower CD4+ T cell 
recovery 
(Greub et al., 2000) 
Timing of ART 
Early ART start (within 1 year) 
normalised CD4 counts better than late 
ART start (after 1 year) 
(Okulicz et al., 2015) 
Senescence 
Highest frequency of CD27+CD8+ T cells 
was associated with high CD4+ T cell 
recovery at 1 to 2 years of ART 
(Seu et al., 2013) 
Another important parameter influencing CD4+ T cell reconstitution is prolonged 
immune activation during ART (Anthony et al., 2003; Hunt et al., 2003), discussed in 
further detail below. 
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1.5.4 ART and normalisation of immune activation 
Despite a substantial decrease in the levels of immune activation in chronically HIV-
infected individuals on ART, abnormal immune activation, measured by cell surface 
or soluble markers, can persist and has been linked to lower CD4+ T cell reconstitution 
and increased mortality (Hunt et al., 2011; Hunt, 2012). A study assessing T cell 
activation levels before and 1 year after ART showed that increased CD8+ T cell 
activation before ART could predict slower CD4+ T cell recovery, while continued 
CD8+ T cell activation predicted higher risk of mortality in HIV patients on ART 
(Hunt et al., 2011). In addition, elevated levels of microbial products such as LPS or 
markers of monocyte/macrophage activation (e.g. sCD14), the proinflammatory 
cytokine IL-6 and cycling T cells have been associated with poor CD4+ T cell 
reconstitution (Lederman et al., 2011). It is also unclear whether the levels of immune 
activation measured upon ART decrease to the extent of those found in HIV-
uninfected individuals. Whole genome transcriptional profiling of CD4+ T cells 
showed increased gene transcripts associated with immune activation (cell cycling, 
cytokines and chemokines) in ART-treated patients with mean CD4 counts of 789/µl 
and undetectable viral load compared to HIV-uninfected controls (Vigneault et al., 
2011). In addition, the increased percentages of activated T cells and NK cells (as 
measured by HLA-DR expression) as well as plasma levels of monocyte/macrophage 
(sCD163) and B cell (IgG, IgA and IgM) activation markers in HIV-infected 
individuals did not return to normal after 8 years of ART compared to an HIV-
uninfected control group (Psomas et al., 2016). A further study assessed the effect of 
ART on the serum levels of immune activation, examining B cell activation and 
markers of inflammation in HIV-infected individuals on therapy (Regidor et al., 2011). 
A substantial decrease in serum levels of sCD27, sCD30, CXCL13, IgG and IgA was 
observed in HIV-infected subjects on ART for 2 to 3 years, but this did not reach levels 
found in HIV-uninfected controls. On the contrary, compared to HIV-uninfected 
controls, Wada and co-workers showed normalisation of seven biomarkers of immune 
activation and inflammation, including three (IL-2, IFN-γ, sIL-2Ra) that were 
associated with T cell activation following one year of ART, although sCD14 and 
TNF-α, related to monocyte/macrophage activation, did not normalise (Wada et al., 
2015). It is worth noting that the timing of ART commencement can determine the 
levels of immune activation in HIV-infected individuals on treatment (Burdo et al., 
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2011; Chevalier et al., 2013; Jain et al., 2013). Lower CD4+ and CD8+ T cell 
activation (measured by CD38 and HLA-DR expression) and a reduced HIV reservoir 
were reported in HIV patients who initiated ART within 6 months of infection 
compared to HIV patients who started ART late (a minimum of 2 years after infection) 
(Jain et al., 2013). Similarly, the start of ART during acute HIV infection resulted in a 
decrease in monocyte activation (sCD163) levels to comparable levels in HIV-
uninfected controls, which was not the case when ART was initiated during chronic 
HIV infection (Burdo et al., 2011). Overall, the results indicate that immune activation 
is not completely normalised upon ART and may influence the extent of immune 
recovery. Consequently, sustained immune activation is associated with non AIDS-
related events (such as cardiovascular disease) which are currently the main cause of 
morbidity and mortality in ART-treated patients (Kuller et al., 2008; Sandler et al., 
2011; Duprez et al., 2012). For example, after 6 months of ART, lower levels of sCD14, 
IL-6 and kynurenine-tryptophan ratio were found to predict a lower common carotid 
intima media thickness (a marker for cardiovascular events) in a longitudinal study of 
HIV patients on ART for a median of 7 years (Siedner et al., 2016). 
1.5.5 ART and normalisation of lymphocyte differentiation 
In addition to sustained immune activation, Lederman and colleagues showed 
decreased TCM and TEM CD4+ T cell subsets in patients with immunologic failure 
despite suppressive ART (Lederman et al., 2011). There is evidence for full or partial 
normalisation of previously skewed memory subsets in HIV-infected individuals on 
ART. In HIV-infected individuals who initiated ART at CD4 counts >350 cells/mm3, 
the number of naive and memory CD4+ T cells regularised by 1 year of ART with 
respect to uninfected controls (Robbins et al., 2009). On the contrary, another study 
showed partial restoration of naive and memory T cell counts after 3 years ART 
(Valdez et al., 2002). Although long-term ART (8 years) normalised the quantity of 
TEM and effector CD4+ T cells, the number of naive and TCM CD4+ T cells did not 
return to levels found in uninfected subjects (Rallon et al., 2013). A recent cross-
sectional study of HIV-infected persons who started ART either early or late in 
infection reported that the frequencies of terminally differentiated CD4+ T cells 
remained elevated after a year in both treated groups and did not reach levels found in 
uninfected controls, suggesting that even early ART may not restore some HIV-
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induced T cell perturbations (Amu et al., 2016). The incomplete normalisation of stem 
memory T cells (TSCM), known to differentiate into other memory subsets like TCM and 
TTM, has been shown in SIV-infected rhesus macaques on ART and may explain 
irreversible normalisation of these subpopulations of T cells (Cartwright et al., 2016). 
With regards to B cells, it has been previously demonstrated that ART did not improve 
the percentages of classical memory (CD27+) B cells lost in HIV patients, as 
normalisation did not occur compared to HIV-uninfected controls (De Milito et al., 
2001; Chong et al., 2004). Other studies have investigated the effect of ART on the 
subset distribution of B cells (Moir et al., 2008; 2010; Rethi et al., 2013; Amu et al., 
2014; Rainwater-Lovett et al., 2014). One year of ART resulted in an increase in the 
frequency of naive and resting memory B cells with a concomitant decrease in 
immature transitional, activated memory, tissue-like memory B cells and plasmablasts 
in chronically HIV-infected persons although only naive B cells and plasmablasts were 
normalised relative to uninfected controls (Moir et al., 2010). ART during the early 
stages of HIV infection corrected the frequency of resting memory B cells, improving 
the memory B cell responses to influenza vaccine (Moir et al., 2010). In addition, 
while the frequency of activated and tissue-like memory B cells improved upon 
prolonged ART, those of resting memory B cells remained reduced in HIV-infected 
individuals (Amu et al., 2014). Therefore, except for resting memory B cells, 
normalisation of activated and tissue-like memory B cells were reported in virally-
suppressed ART-treated patients (Pensieroso et al., 2013b). However, another study 
indicated that there is correction of resting memory B cells counts in younger HIV-
infected subjects on ART for approximately 4 years (van Epps et al., 2014). Equally, 
Rainwater-Lovett and colleagues reported that following 1 year ART, the frequency 
of resting memory B cells were comparable between HIV-infected children at the age 
of 2-5 years old and uninfected controls (Rainwater-Lovett et al., 2014). In sum, 
despite somewhat contrasting data, ART can partially correct the skewed 
differentiation profiles of both T cells and B cells. 
1.5.6 Restoration of antigen-specific responses 
Numerous studies have assessed whether antigen-specific immunity is reconstituted 
during ART (Keane et al., 2004; Migueles et al., 2009; Moir et al., 2010; Cellerai et 
al., 2011; Hsu et al., 2013; Jambo et al., 2014). In a group of HIV-infected individuals 
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on ART for a median of 5 years, CD8+ T cell proliferation (CFSE labelling) and 
polyfunctional (simultaneous production of multiple cytokines) abilities in response to 
autologous HIV-infected CD4+ T cell targets were not restored compared to LTNPs 
matched for viral load (Migueles et al., 2009). In contrast, Cellerai and co-workers 
reported that HIV seroconverters on ART for at least 4 years restored T cell 
functionality (as measured by IFN-γ, IL-2 and TNF-α) in response to Gag relative to 
LTNPs (Cellerai et al., 2011). Others have investigated the reconstitution of other 
pathogen-specific T cell responses in ART-treated HIV-infected individuals. A slow 
rise in T cell IFN-γ responses to Candida antigens peaked 5 years after ART in the 
majority of HIV patients, but remained lower than responses found in HIV-uninfected 
controls (Burgess et al., 2006). For CMV, in one study elevated levels of CMV-
specific T cell responses were found in the HIV treated group on long-term ART 
compared to the untreated group, while another study showed an early increase in the 
frequency of CMV-specific CD4+ T cells after 1 month ART, with a decline at 12 and 
24 months ART relative to baseline levels (Naeger et al., 2010; Hsu et al., 2013). 
Likewise, for Mtb, while one study demonstrated no change in CD4+ T cell 
polyfunctional ability (IFN-γ, IL-17 and TNF-α) in response to Mtb purified protein 
derivative (PPD) post-ART, another study rather reported higher polyfunctional 
responses (IFN-γ, IL-2 and TNF-α) to PPD in these subjects post- compared to pre-
ART (Sutherland et al., 2010; Jambo et al., 2014). With regards to B cells, using gp140 
probes, lower frequencies of HIV-specific B cell responses were reported in HIV-
infected subjects on ART for roughly 5 years compared to untreated elite controllers 
(Buckner et al., 2016). In addition, memory B cell responses to influenza 
hemagglutinin were similar between elite controllers and ART-treated individuals, 
whereas memory B cell responses to tetanus toxin C fragment were substantially 
reduced in HIV patients on ART compared to elite controllers. Overall, these 
conflicting studies highlight the need for additional research to clarify the recovery of 
antigen-specific immunity upon effective ART, a subject dealt with, at least for 
functional T cell responses, in Chapter 3 of this thesis. 
1.5.7 Paradoxical ART and Immune reconstitution inflammatory syndrome (IRIS) 
IRIS is an inflammatory response resulting in the deterioration of clinical status in a 
subgroup of patients early (within 6 months) after the start of ART (Wilkinson et al., 
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2015). Globally, an estimate of 10-27% of HIV-infected individuals on ART develop 
IRIS (Haddow et al., 2012). The disease can manifest itself as paradoxical IRIS, 
namely when a pre-existing opportunistic infection initially responding to treatment 
worsens after ART; or unmasking IRIS, when a previously undetected infection 
appears after ART with excessive inflammatory responses (Murdoch et al., 2008; 
Meintjes et al., 2008). A number of risk factors have been associated with the 
development of IRIS, including low CD4 counts and high HIV RNA levels at the start 
of ART, a rapid decrease in viral load with an increase in CD4 counts post-therapy, as 
well as the presence of opportunistic infections closer to the time of ART initiation 
(Grant et al., 2010; Müller et al., 2010; Wilkinson et al., 2015). The most common 
pathogens associated with IRIS are Mtb, CMV, Cryptococcus neoformans and 
Hepatitis C and B viruses (Sharma & Soneja, 2011). A higher risk of paradoxical TB-
IRIS has been associated with lower pre-ART levels of IL-6 and LPS-binding protein 
(LBP) and higher levels of CRP (Haddow et al., 2011; Goovaerts et al., 2013). Anti-
inflammatory compounds like corticosteroids and non-steroidal anti-inflammatory 
drugs (NSAIDs) have been used for the treatment of IRIS. A randomised placebo-
controlled trial of 4 weeks course of prednisone was conducted in patients with 
paradoxical TB-IRIS (Meintjes et al., 2010). A decreased hospitalisation rate and 
therapeutic procedures were observed following prednisone treatment as a result of the 
latter likely inducing a substantial decrease in serum levels of IP-10, IFN-γ, TNF-α, 
IL-6, IL-10 and IL-12p40 (Meintjes et al., 2012). NSAIDs known to block the 
generation of prostaglandin mediators of inflammation are used as a first-line 
treatment for mild IRIS as opposed to corticosteroids that are required in severe cases 
of IRIS (Meintjes et al., 2012). Overall, in an attempt to restore functional immunity 
and improve the health of HIV-infected subjects, ART can lead to IRIS whose 
treatment with corticosteroids is associated with serious side effects in already 
immunocompromised individuals (Barber et al., 2012; Wilkinson et al., 2015). Thus, 
other therapies may be required for better management of IRIS. 
1.5.8 Adjunct therapies 
ART has succeeded in controlling HIV replication and improving immune function, 
but levels of immune activation do not reach baseline levels observed in HIV-
uninfected individuals, and are associated with non-AIDS related morbidity and 
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mortality in ART-treated patients (Deeks & Phillips, 2009; Paiardini & Müller-
Trutwin, 2013). Thus, the use of other drugs in combination with ART may be 
necessary to reduce immune activation in HIV-infected individuals. In line with this, 
due to their capacity to suppress cellular activation by interfering with the TLR 
signalling pathway within endosomes, two antimalarial drugs namely, chloroquine and 
hydroxychloriquine have been tested in HIV infection (Kyburz et al., 2006; Murray et 
al., 2010). In the absence of ART, chronically HIV-infected individuals on 
chloroquine therapy showed a decrease in the frequency of activated CD38+HLA-
DR+CD8+ T cells as well as proliferating T cells (Murray et al., 2010). In addition, a 
reduced frequency of CD4+Ki67+ T cells, plasma LPS and IL-6 levels were reported 
in ART-treated immunologic non-responders during hydroxychloroquine treatment 
(Piconi et al., 2011). In contrast, Paton and co-workers showed in a randomised 
double-blind placebo-controlled trial that the administration of hydroxycloroquine in 
HIV-infected subjects not receiving ART did not induce a decrease in CD8+ T cell 
activation (measuring CD38 and HLA-DR expression), but induced a reduction in 
CD4+ T cell counts with a concomitant increase in plasma viral load (Paton et al., 
2012). The use of cyclosporin A (an immunosuppressive cyclic oligopeptide known 
to prevent T cell activation and proliferation) has been reported, and while one study 
showed an increase in CD4+ T cell counts in HIV patients taking ART and cyclosporin 
A, other studies demonstrated no immunologic benefit or change in CD4+ T cell 
counts and proviral DNA levels (Rizzardi et al., 2002; Lederman et al., 2006; 
Markowitz et al., 2010). Other compounds such as valganciclovir and adalimumab (an 
anti-TNF monoclonal antibody), aimed at reducing immune activation by treating co-
infections (like CMV) or blocking proinflammatory responses, respectively (Hunt, 
Martin, et al., 2011; Tabb et al., 2013). For instance, acutely SIV-infected rhesus 
macaques treated with adalimumab showed a decrease in expression levels of TNF 
genes and preserved CD4+ T cells but no change in T cell activation and plasma viral 
load compared to untreated animals (Tabb et al., 2013). Furthermore, homeostatic 
cytokines such as IL-7 has been used in conjunction with ART in HIV-infected 
patients, and data showed an increase in naive and TCM CD4+ T cells, suggesting an 
improvement in T cell homeostasis (Levy et al., 2012). Moreover, the administration 
of IL-21 to ART-treated SIV-infected pigtailed rhesus macaques supplemented with 
probiotics demonstrated an increase in the frequency and function of Th17 cells and a 
decrease in microbial translocation (measured by sCD14 and LBP levels) when 
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compared to control animals on ART only (Ortiz et al., 2016). Altogether, these reports 
highlight the benefits of these compounds but nevertheless with limited success, 
implying that more effective strategies need to be developed to reduce immune 
activation in HIV infection while having a positive effect in decreasing viral load and 
increasing CD4+ T cell counts. 
1.5.9 Limitations of ART 
Effective ART clearly suppresses HIV replication in the majority of HIV-infected 
individuals, but despite this, there are some limitations to it. Access to ART is limited 
in developing countries due to the high cost or lower coverage (due to poor health 
infrastructure) and in countries such as South Africa where there is ready access to 
therapy, life-long adherence and the monitoring and toxicities associated with 
treatment represent substantial cost and healthcare challenges (Ford et al., 2011; Sahay 
et al., 2011). In addition, even when viral replication is controlled, there remains an 
increased risk of HIV-associated illnesses such as cancer, cardiovascular diseases and 
other end-organ diseases likely due to sustained immune activation and inflammation 
as a result of ongoing or residual viral replication (Hunt, 2012). Therefore, there is a 
pressing need to eradicate the virus to completely cure HIV infection, something that 
current ART is not able to achieve. However, the establishment of viral reservoirs in 
latently infected memory CD4+ T cells in HIV-infected individuals occurs early in 
infection and is a major obstacle to curing HIV, because these latently infected cells 
are invisible to clearance by the immune system and not susceptible to ARVs, 
representing a potential source of viral replication when treatment is discontinued 
(Chun et al., 1997; Finzi et al., 1997). HIV latency is generated when HIV-infected 
activated CD4+ T cells survive cellular infection to return to a resting memory state, 
or upon interaction of mDC or CCR7 ligands (CCL19 and CCL21) with resting CD4+ 
T cells (Saleh et al., 2007; Siliciano & Greene, 2011; Evans et al., 2013). Strategies 
for HIV cure can be grouped into functional cure or remission, a state of long-term 
control of viral replication without ART, and sterilising cure, representing complete 
purging of the virus (Katlama et al., 2013). A number of studies have proven that the 
commencement of ART during acute infection could restrict seeding of HIV reservoirs 
and possibly control viral replication when ART is interrupted (Strain et al., 2005; 
Archin et al., 2012; Josefsson et al., 2013; Buzon et al., 2014). One key example is the 
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case of the HIV-infected Mississippi baby who initiated ART within 30 hours of life 
for 18 months, after which viral load was suppressed and HIV reservoirs remained 
undetectable for more than 2 years after discontinuation of ART (Persaud et al., 2013). 
In addition, in 14 adult patients from the VISCONTI cohort who started ART within 
2 months of HIV infection for roughly 3 years, viral load was effectively controlled 
for more than 7 years after ART was interrupted (Sáez-Cirión et al., 2013). A French 
teenager was also able to suppress viraemia for 12 years after stopping ART (Hayden, 
2015). Together, these results suggest that there is a possibility to maintain HIV 
replication at very low levels in the absence of ART for a long period of time. However, 
this does not mean that the virus has been completely eradicated in these individuals. 
To date, only one individual, known as the “Berlin patient”, has been scientifically 
verified to be cured from HIV. This HIV-infected individual, who developed acute 
myeloid leukaemia, showed no viral rebound after receiving a stem cell transplant 
from a homozygous donor with a 32 base-pair deletion in CCR5 (CCR5Δ32) following 
cessation of ART (Hütter et al., 2009; Allers et al., 2011). Currently novel therapeutic 
approaches are being tested, including gene therapy approaches and latency reversing 
agents to purge viral reservoirs (Katlama et al., 2013). Interestingly, some of these 
approaches involve the use of activation of the immune system, for example by the 
use of TLR7 agonists. In summary, ARTs are currently limited, but therapies are being 
pursued that have the potential for curing HIV. 
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1.6 Aims and objectives of the thesis 
The overall aim of this thesis was to investigate the impact of antiretroviral therapy for 
HIV on the phenotype and function of T and B cells. Levels of residual immune 
activation, differentiation profiles of T and B cells, and functional T cell responses 
specific for co-pathogens (Mtb and CMV) were evaluated. This was studied in the 
peripheral blood of a cohort of chronically HIV-infected South African women after 
short-term ART, where samples pre-ART and 1 year post-ART were examined, and 
compared to HIV-uninfected individuals from the same community. 
Hypothesis:  
Effective antiretroviral therapy normalises the phenotype of T and B cells, and 
decreases immune activation in both T and B cell subsets. The ability of T cells to 
produce cytokines in response to specific co-pathogens is restored following short-
term ART. 
Objective 1: To determine the activation and memory phenotypes of CD4+ and 
CD8+ T cells during chronic HIV infection and after antiretroviral therapy 
Rationale: Despite the improvement in CD4+ T cell counts upon suppressive ART, 
hyperimmune activation may persist and influence CD4+ T cell recovery. The extent, 
to which specific memory T cell subsets are normalised on ART, and the relationship 
with ongoing immune activation is not fully defined. Therefore, we aimed to assess T 
cell differentiation, activation and proliferation profiles in HIV-infected individuals 
before and after ART initiation. These phenotypic profiles were compared to those in 
age- and sex-matched HIV-uninfected controls. Our findings give insight into the 
reconstitution of particular T cell memory subsets and the extent to which T cell 
activation and proliferation levels decline after 1 year of ART.  
 
This aspect of the study is presented in Chapter 2. 
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Objective 2: To assess whether functional T cell immunity to co-pathogens is 
recovered after successful antiretroviral therapy 
Rationale: HIV infection not only causes the loss of CD4+ T cells, but also 
compromises their function by modifying their phenotype and altering their ability to 
secrete cytokines in response to HIV itself or other pathogens. Even though effective 
ART improves CD4+ T cell counts, its effect on the functional restoration of specific 
immunity to common co-pathogens (in this case Mtb and CMV), and the factors 
associated with this recovery have not been fully characterised. Here, we aimed to 
compare the memory differentiation profile and cytokine production ability of Mtb 
and CMV-specific CD4+ T cells pre- and post-ART in HIV-infected individuals and 
healthy uninfected individuals. Our data give important insights into the restoration of 
antigen-specific T cell responses when HIV replication is controlled by effective ART. 
 
This aspect of the study is presented in Chapter 3 and has been published as: 
Catherine Riou*, Ramla F. Tanko*, Andreia P. Soares, Lindi Masson, Lise Werner, Nigel J. 
Garrett, Natasha Samsunder, Quarraisha Abdool Karim, Salim S. Abdool Karim, Wendy A. 
Burgers. Restoration of CD4+ responses to co-pathogens in HIV-infected individuals on 
antiretroviral therapy is dependent on T cell memory phenotype. Journal of Immunology 
2015; 195:2273-2281. *contributed equally to this work. [See Appendix] 
Objective 3: To identify changes in B cell activation and differentiation profiles 
in HIV-infected persons on suppressive antiretroviral therapy 
Rationale: In addition to T cells, HIV infection severely impacts B cells, resulting in 
skewing of B cell subsets, and impaired B cell and antibody responses. However, the 
extent to which HIV-induced B cell defects are corrected upon ART remains unclear. 
Thus, we aimed to examine the level of B cell activation, proliferation, and memory 
subset distribution prior to initiation of therapy and after suppressive therapy. HIV-
infected individuals were compared to healthy uninfected subjects. The relationship 
between ‘deactivation’ of B cells and T cells (Objective 1) was also determined. Our 
results provide novel information on the recovery of B cell memory subsets, the degree 
to which B cell activation and proliferation declines upon ART, as well as the 
relationship between immune activation in the B cell and T cell compartments.  
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This aspect of the study is presented in Chapter 4 and has been published as: 
Ramla F. Tanko, Andreia P. Soares, Tracey L. Müller, Nigel J. Garrett, Natasha Samsunder, 
Quarraisha Abdool Karim, Salim S. Abdool Karim, Catherine Riou, Wendy A. Burgers. Effect 
of antiretroviral therapy on the memory and activation profiles of B cells in HIV-infected 
African women. Journal of Immunology 2017; 198: 1220-1228. [See Appendix] 
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CHAPTER 2 
Impact of antiretroviral therapy on T cell activation and 
differentiation during chronic HIV infection. 
	
Table of contents 
2.1 Introduction ......................................................................................................... 39 
2.2 Material and Methods ......................................................................................... 41 
2.2.1 Study participants .............................................................................................. 41 
2.2.2 Determination of HIV plasma viral load, CD4 and CD8 counts ...................... 41 
2.2.3 Sample processing ............................................................................................. 42 
2.2.4 Monoclonal antibodies and staining ................................................................. 42 
2.2.5 Gating strategy .................................................................................................. 43 
2.2.6 Statistical analyses ............................................................................................ 45 
2.3 Results ................................................................................................................... 45 
2.3.1 Changes in HIV plasma viral load and T cell counts after ART initiation ....... 45 
2.3.2 Substantial decrease in activation and proliferation of CD4+ and CD8+ T cells 
after ART ....................................................................................................................... 47 
2.3.3 Relationship between CD4+ and CD8+ T cell activation before and after ART . 
  ........................................................................................................................... 49 
2.3.4 Differentiation profiles of CD4+ and CD8+ T cells prior to and after ART .... 51 
2.3.5 Activation levels within CD4+ and CD8+ T cell subsets before and after ART .. 
  ........................................................................................................................... 56 
2.4 Discussion ............................................................................................................. 58	
 
  
 39 
2.1 Introduction  
Chronic HIV infection is characterised by the gradual decline in CD4+ T cells that are 
essential in co-ordinating adaptive immune responses. In the absence of effective 
antiretroviral treatment (ART), this loss in CD4 cells as a consequence of sustained 
viral replication is accompanied by an increase in CD8 counts and a reduced CD4 to 
CD8 ratio (Frazer et al., 1986). A hallmark of HIV infection is chronic immune 
activation, which has a deleterious effect and a fundamental role in HIV pathogenesis, 
by significantly contributing to CD4+ T cell loss and driving disease progression 
(Hazenberg. et al., 2003). The state of immune activation results in increased 
activation, proliferation, depletion and exhaustion of T cells (Hellerstein & McCune, 
1997; Mohri et al., 2001; Hazenberg et al., 2003; Papagno et al., 2004). In addition, 
increased immune activation can cause alterations in T cell phenotype by inducing a 
decrease in naive T cells and a parallel accumulation of more differentiated effector 
cells (Sallusto et al., 1999; Papagno et al., 2004; Appay & Sauce, 2008). This skewed 
differentiation profile may reflect thymic dysfunction, preventing the renewal of naive 
T cells, or antigen-driven differentiation of naive T cells, increasing the proportion of 
effector memory T cells (Douek et al., 1998; Li et al., 2011; Sauce et al., 2011). 
Overall, this results in the loss of memory resources for opportunistic and pathogenic 
infectious agents.  
Numerous drivers of immune hyperactivation during HIV infection have been 
described. These include 1) the interaction of HIV itself either via the envelope 
glycoprotein gp120 or single-stranded HIV RNA motifs that act as ligands for toll-like 
receptors (TLR7/8) on innate cells (Heil et al., 2004; Meier et al., 2007; Del Cornò et 
al., 2016), 2) the process of microbial translocation, where bacterial components enter 
the circulation as a result of leaky epithelium within the gastrointestinal tract and 
activate a range of additional TLRs (Brenchley et al., 2007; Zevin et al., 2016); 3) the 
subsequent release of proinflammatory cytokines by innate cells such as dendritic cells, 
macrophages or monocytes as a result of TLR stimulation (Haas et al., 2011); 4) the 
highly proinflammatory process of pyroptosis of CD4+ T cells after abortive infection 
with HIV (Doitsh et al., 2014); and 5) reactivation of co-infecting, chronic viruses like 
hepatitis C virus (HCV), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and 
herpes simplex virus (HSV) (Doisne et al., 2004; Sheth et al., 2008). All together, 
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these mechanisms contribute to the overactivation of the immune system, promoting 
disease progression. 
With the introduction of ART, the majority of HIV-infected individuals fully suppress 
viral load, display a progressive increase in CD4 counts, and reduced opportunistic 
infections, resulting in a substantial improvement in their health (Guihot et al., 2011; 
Lawn & Wood, 2011; Williams et al., 2011; Delaugerre et al., 2015). However, up to 
one quarter of individuals fail to reconstitute their CD4 counts substantially, as a result 
of delayed initiation of treatment and ongoing immune activation, and hence are at 
high risk of AIDS related morbidities (Corbeau & Reynes, 2011) as well as non-AIDS 
related illnesses, such as certain types of cancer and cardiovascular disease (Hunt, 
2012). Nevertheless, HIV-induced T cell phenotypic defects can be partially corrected 
upon ART. HIV-infected individuals on ART showed an overall decline in CD4+ and 
CD8+ T cell activation (commonly measured by CD38 and HLA-DR expression) and 
proliferation (measured by Ki67 expression), but it still appears to remain higher than 
in HIV-uninfected individuals (Hazenberg et al., 2000; Anthony et al., 2003; Hunt et 
al., 2003; Almeida et al., 2007; Glencross et al., 2008; Hunt et al., 2011). Naive and 
memory CD4+ T cells are also partially normalised in treated-HIV patients (Lepej et 
al., 2006; Rallon et al., 2013; Emu et al., 2014).  
Despite the irrefutable clinical and immunologic benefits of ART, HIV-infected 
individuals on suppressive treatment may still display immune defects. In fact, we still 
do not completely understand the extent to which specific T cell memory subsets are 
recovered upon ART, their relationship with ongoing immune activation, and whether 
the recovery profile is similar between the CD4 and CD8 compartments. African 
cohorts, in particular, are less well-studied than Caucasian cohorts. With this in mind, 
the aim of this study was to determine the effect of ART on the activation, proliferation 
and memory differentiation profiles of CD4+ and CD8+ T cells in chronically HIV-
infected South African women, before and 12 months after the initiation of ART. 
These profiles were compared to age- and sex-matched HIV-uninfected controls from 
the same community. 
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2.2 Material and Methods 
2.2.1 Study participants 
Twenty-eight women were recruited from the Centre of AIDS Programme of Research 
in South Africa (CAPRISA) 002 HIV acute infection cohort in KwaZulu-Natal, as 
described previously (van Loggerenberg et al., 2008; Mlisana et al., 2014). The study 
participants were infected for a median of 4.2 years [Interquartile range (IQR): 2.7-5.6 
years]. To estimate the time of HIV infection, a prospective RNA positive/antibody 
negative result or the midpoint between the last antibody negative test and the first 
antibody positive enzyme-linked immunosorbent assay test were used. ART was 
offered according to the South African National HIV treatment guidelines (at a CD4 
count of <200 cells/mm3 prior to October 2012; <350 cells/mm3 until March 2015). 
The majority of the participants (25/28) were taking standard first-line therapy, namely 
TDF/3TC/EFV (n=14) or TDF/FTC/EFV (n=4) or ddI-EC/3TC/EFV (n=3) or 
TDF/3TC/NVP (n=1) or AZT/3TC/NVP (n=1) or d4T/3TC/EFV (n=1) or 
d4T/3TC/NVP (n=1), while only one individual was on a second-line regimen, 
consisting of AZT/3TC/Lpvr/r (as indicated in Appendix Table 1). Two participants 
switched drug regimens during the study period, namely CAP200 (ddI-EC /3TC/ EFV 
to TDF /3TC/EFV at month 11) and CAP255 (d4T/3TC/EFV to AZT/3TC/EFV at 
month 10). Peripheral blood samples were taken at two time-points pre- and post-ART 
initiation. An additional 23 HIV-uninfected women who were matched for age, gender 
and ethnicity were provided from the CAPRISA 004 1% Tenofovir microbicide gel 
trial (Abdool Karim et al., 2010). These women were either in the pre-intervention or 
in the placebo phase of the trial.  No participants had active TB over the study period 
or any immune reconstitution inflammatory syndrome following ART. Ethical 
approval for the study was obtained from the Research Ethics Committees at the 
University of KwaZulu-Natal and University of Cape Town. All participants provided 
written informed consent prior to participating in the study. 
2.2.2 Determination of HIV plasma viral load, CD4 and CD8 counts 
Plasma HIV viral load and CD4 count were assessed at each study visit. During the 
study period, the viral load PCR assay switched from Roche AMPLICOR HIV-1 
Monitor test version 1.5 (lower detection limit (LDL) of 400 RNA copies/ml) to Roche 
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Taqman version 1.0 in June 2010 (LDL 40 RNA copies/ml), and then to Roche 
Taqman version 2.0 in January 2012 (LDL 20 RNA copies/ml). The FACSCalibur 
TruCOUNT method (BD Biosciences) was used to measure absolute blood CD4+ and 
CD8+ T cell counts. 
2.2.3  Sample processing 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque 
(Amersham Pharmacia) density gradient centrifugation and cryopreserved in freezing 
media consisting of heat-inactivated fetal calf serum (FCS; Invitrogen) containing 
10% dimethylsulfoxide (DMSO; Sigma-Aldrich). Cells were stored in liquid nitrogen 
until use. Cryopreserved PBMC were thawed and rested in R10 (RPMI 1640 plus 10% 
heat-inactivated FCS and 50 U/ml of penicillin-streptomycin) at 37°C with 5% CO2 
for 3 hours before staining. 
2.2.4 Monoclonal antibodies and staining  
All the antibodies used in this study are listed in Table 2.1, together with the 
commercial sources of these antibodies, their corresponding clones and optimal titers, 
determined by titrations for a 50 µl staining volume. Briefly, PBMC were stained with 
a viability dye (Vivid), then labeled with antibodies against surface markers, fixed, 
permeabilised and subsequently stained intracellularly for Ki67. Cells were then 
resuspended in 1X CellFix (BD Biosciences) and kept at 40C until acquisition. 
Samples were acquired within 24 hours on a BD Fortessa using FACSDiva software 
and analysed using FlowJo (version 9.9.3; TreeStar). 
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Table 2. 1. List of antibodies for flow cytometry 
 
aThe viability dye Vivid (Invitrogen) was also detected in the Pacific Blue channel 
2.2.5 Gating strategy 
The gating strategy used to identify T cells and memory subsets is shown in Figure 
2.1. A time gate was first applied to eliminate any potential shifts in fluorescence 
intensity, followed by singlets (to exclude doublets), live cells, lymphocytes and CD3+ 
cells. CD14 and CD19 markers were used to exclude monocytes and B cells, 
respectively, concomitant with exclusion of dead cells. CD3+ T cells were further 
discriminated using CD4 and CD8 markers. Gates were set based on FMO controls. 
Markers Fluorochromes Clone Manufacturer Titer (µl)
T cell panel 
Exclusion CD14 Pacific Bluea Tük4 Invitrogen 1.25
Exclusion CD19 Pacific Bluea SJ25-CI Invitrogen 1.25
Lineage CD3 PE-Cy7 Sk7 BD Biosciences 0.63
Lineage CD4 PE-Cy5.5 S3.5 Invitrogen 0.3
Lineage CD8 Qdot-705 3B5 Invitrogen 0.1
Memory CD27 PE-Cy5 1A4CD27 Beckman Coulter 2.5
Memory CD45RO ECD UCHL1 Beckman Coulter 0.6
Activation HLA-DR APC-Cy7 L243 BD Biosciences 2.5
Activation CD38 APC HIT2 BD Biosciences 10
Proliferation Ki67 FITC 7B11 Invitrogen 0.25
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Figure 2. 1. Gating strategy. PBMC were stained directly ex vivo. Gating is shown for one 
HIV-infected individual before ART initiation. (A) Identification of T cells and subsets. A 
time gate to ensure no shift in fluorescence intensity over time was applied, followed by a 
singlet gate for exclusion of doublets. A dump channel comprising CD14 and CD19 markers 
as well as the viability dye Vivid were used to exclude monocytes, B cells and dead cells, 
respectively. The CD3 marker identified T cells, while CD4 and CD8 markers specifically 
stained for their corresponding CD4+ and CD8+ T cell subsets. (B) Gating to identify T cell 
activation (CD38 and HLA-DR), proliferation (Ki67) and differentiation (CD27 and 
CD45RO). Four distinct T cell subsets were delineated: naive (A. CD27brightCD45RO-), 
early (B. CD27brightCD45RO+), late (C. CD27lowCD45RO+), and terminally 
(CD27lowCD45RO-) differentiated cells. An additional subset, namely intermediate (E. 
CD27dimCD45RO-) was unique to CD8+ T cells.  
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2.2.6 Statistical analyses 
Statistical analyses were performed using Prism (GraphPad version 5.0). The Mann-
Whitney U test and the Wilcoxon Signed Rank test were used for unpaired and paired 
samples, respectively. Correlations between the different groups were determined by 
the non-parametric Spearman Rank correlation test. A p-value of <0.05 was 
considered to be statistically significant. 
2.3 Results 
2.3.1 Changes in HIV plasma viral load and T cell counts after ART initiation 
Twenty-eight HIV-infected women were studied prior to and one year after the 
initiation of ART in this study. We first examined how the study participants 
responded to ART treatment, by analysing clinical parameters associated with immune 
recovery. Pre-ART samples were obtained at a median of 1.9 months (IQR: 0.4-2.7) 
before ART initiation (Appendix Table 1). The median plasma viral load was 38,513 
HIV RNA copies/ml (IQR: 8,205-76,793), while the median CD4 and CD8 counts 
were 279 cells/mm3 (IQR: 228-330) and 1,018 cells/mm3 (IQR: 642-1,395), 
respectively. Prior to ART, viral load inversely correlated with CD4 counts, as 
expected (r=-0.52, p=0.005; data not shown). After a median of 12.2 months of ART 
(IQR: 11.3-12.9), plasma viral load was significantly reduced (p<0.0001; Figure 
2.2A), and was below the detection limit of the assay used (i.e <20 copies/ml, <40 
copies/ml or <400 copies/ml) in the majority of participants (21/28, Appendix Table 
1). The remaining 7 participants still had detectable but low levels of virus in their 
plasma (median: 64 copies/ml). The decrease in plasma viraemia was accompanied by 
a significant increase (p<0.0001; Figure 2.2B) in absolute CD4 counts, which 
occurred in 26/28 individuals. The median increase in the absolute number of 
circulating CD4 cells post-ART was 249 cells/mm3. In contrast to the increase in 
absolute CD4 counts, no significant change was observed in the absolute CD8 counts 
pre- and post-ART (p=0.19, Figure 2.2C). However, it is worth noticing that in the 
majority of subjects (71.4%, 20/28), the absolute CD8 counts decreased (median of 
122 cells/mm3; Figure 2.2C) following ART. These changes in both CD4 and CD8 
counts led to a significant increase in the CD4:CD8 ratio (p<0.0001; Figure 2.2D), 
with a median fold change of 2.5 after 1 year of ART. Of note, 2 participants, CAP248 
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and CAP262 did not reconstitute their CD4 counts. CAP248 was one of the 
participants with low but detectable viral load (121 RNA copies/ml; Appendix Table 
1) after 1 year of ART; and CAP262 exhibited viral suppression, low CD8 count and 
her CD4:CD8 ratio doubled after treatment. However, it is worth noting that both 
participants at later time points (>1 year) recovered their CD4 counts upon ART (data 
not shown). 
Overall, these results demonstrate that in all participants, 12 months of ART 
suppressed HIV replication to a large degree, and led to a significant improvement in 
absolute CD4 counts in most of the treated patients. 
 
Figure 2. 2. Clinical parameters before and after ART. (A) Plasma viral load, (B) absolute 
CD4 count, (C) absolute CD8 count, (D) CD4/CD8 ratio before (pre-ART) and after 12 
months of ART (post-ART) in HIV-infected individuals (n=28). The horizontal dotted line 
indicates the detection limit of the assay. The two grey dots depict two individuals who did 
not reconstitute their CD4 counts after ART. Horizontal solid lines indicate the median. 
Statistical significance was calculated using a t-test. 
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2.3.2 Substantial decrease in activation and proliferation of CD4+ and CD8+ T 
cells after ART 
Excessive immune activation, a major contributor to CD4+ T cell loss and HIV 
pathogenesis, is characterized by increased activation and proliferation of immune 
cells, including T cells (Mohri et al., 2001; Hazenberg et al., 2003). ART has been 
highly successful in reducing T cell activation and proliferation, but normalisation is 
often incomplete and is likely dependent on the timing and duration of ART, and 
whether ART can reverse the immune damage caused by HIV. Thus, to evaluate the 
extent to which ART impacts T cell hyperactivation in our cohort of African women, 
we first measured the expression of activation markers CD38 and HLA-DR pre-and 
post-ART and compared them to profiles obtained in HIV-uninfected controls. Figure 
2.3A shows representative flow cytometry plots of CD38 and HLA-DR expression on 
CD4+ and CD8+ T cells from one HIV-uninfected and one HIV-infected individual 
before and after ART. As expected, the frequency of activated CD4+ T cells were 
significantly higher in HIV-infected individuals prior to ART compared to HIV-
uninfected controls (CD38: medians 8.5% vs 1.6%; HLA-DR: median 7.4% vs 1.5% 
and CD38/HLA-DR co-expression: 1.7% vs 0.1%; p<0.0001; Figure 2.3B). After 
ART, the frequency of activated CD4+ T cells decreased significantly (CD38: median 
5.5%; HLA-DR: median 3.3%; and CD38/HLA-DR: median 0.3%) but still remained 
significantly higher than HIV-uninfected subjects (p<0.0001 for CD38 and 
CD38/HLA-DR, and p=0.0006 for HLA-DR; Figure 2.3B). Similar to CD4+ T cells, 
HIV also induced elevated expression of CD38 and HLA-DR on CD8+ T cells, as 
expected (Hunt et al., 2008). The frequency of activation markers expressed on CD8+ 
T cells was higher than on CD4+ T cells (CD38: medians 14.4% vs 8.5%; HLA-DR: 
medians 23.7% vs 7.4% and CD38/HLA-DR: medians 9.2% vs 1.7%), and while ART 
also induced a significant reduction in CD8+ activation, the levels observed after 12 
months of treatment remained significantly higher than HIV-uninfected individuals 
(Figure 2.3C). Of note, one individual, CAP200, had an increase in CD38 expression 
on both CD4+ and CD8+ T cells post-ART, while the expression of HLA-DR alone 
or co-expressed with CD38 was reduced on CD4+ T cells and remained unchanged on 
CD8+ T cells (Figure 2.3B). This patient switched her drug regimen at 11 months 
(Appendix Table 1).  
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Figure 2. 3. Effect of ART on CD4+ and CD8+ T cell activation levels. (A) Representative 
flow plots of CD38 and HLA-DR expression on T cells from one HIV-uninfected and one 
HIV-infected (pre- and post-ART) individual. (B) Frequencies of CD38+ (teal), HLA-DR+ 
(plum) and CD38+HLA-DR+ (blue) CD4+ and CD8+ T cells in 23 HIV-uninfected (open 
circles) and 28 HIV-infected (closed circles) individuals pre- and post-ART. Horizontal lines 
represent the median. Statistical significance was calculated using the Mann-Whitney U test 
and Wilcoxon Signed Rank for unmatched and matched samples, respectively. 
Next, the effect of ART on T cell proliferation was determined in 18 participants for 
whom Ki67 staining was available. Figure 2.4A shows representative flow cytometry 
plots of CD4+ and CD8+ T cell proliferation measured by Ki67 expression from one 
HIV-uninfected and one HIV-infected subject before and after ART. The frequency of 
Ki67+ T cells was significantly higher in HIV-infected subjects compared to 
uninfected controls (CD4: median 2.9% vs 0.42% and CD8: 2.1% vs 0.38%; 
p<0.0001; Figure 2.4B). Even though ART led to a significant reduction in the 
frequency of Ki67+ T cells (medians of 1% and 0.6% for CD4+ and CD8+ T cells 
with corresponding p-values, p=0.0003 and p=0.0002, respectively), they were still 
significantly elevated compared to the uninfected control group (p<0.0001 for CD4+ 
and p<0.02 for CD8+ T cells). Thus, with the exception of one individual who had a 
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slight increase in Ki67 expression in her CD4 compartment (CAP353), the remaining 
ART-treated patients (n=17) displayed a reduced frequency of proliferating T cells. 
 
Figure 2. 4. Effect of ART on T cell proliferation. (A) Representative flow plots of Ki67 
expression in CD4+ and CD8+ T cells from one HIV-uninfected and one HIV-infected (pre- 
and post-ART) individual. Numbers represent the frequencies of proliferating (Ki67+) T cells. 
(B) Frequencies of Ki67+ T cells in HIV-uninfected (n=23; open circles) and HIV-infected 
pre- and post-ART (n=18; closed circles) individuals. Horizontal lines represent the median. 
Statistical significance was calculated using a Mann-Whitney U test and Wilcoxon Signed 
Rank for unpaired and paired samples, respectively. 
Taken together, these data show that both CD4+ and CD8+ T cells are highly activated 
and have an increased turnover during HIV infection. ART reduces activation and 
proliferation of both CD4+ and CD8+ T cells, but this reduction does not lead to 
normalisation to similar levels in HIV-uninfected individuals. 
2.3.3 Relationship between CD4+ and CD8+ T cell activation before and after ART 
We next investigated the association between CD4+ and CD4+ T cell activation in 28 
HIV-infected individuals pre- and post-ART initiation. A significant positive 
correlation was found between the frequency of CD4+ and CD8+ T cells expressing 
CD38 (p<0.0001, r=0.89; Figure 2.5A), HLA-DR (p=0.0002, r=0.65; Figure 2.5B) 
or co-expressing CD38 and HLA-DR (p<0.0001, r=0.79; Figure 2.5C) pre-ART. 
These positive correlations were also observed after 1 year of ART (CD38: p<0.0001, 
r=0.91; Figure 2.5D; HLA-DR: p<0.0001, r=0.85; Figure 2.5E; and CD38/HLA-DR: 
p<0.0001, r=0.82; Figure 2.5F). Moreover, there was also a positive correlation 
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between the frequencies of proliferating CD4+ and CD8+ T cells pre- and post-ART, 
(n=18, p=0.0005, r=0.74 and p=0.02, r=0.56, respectively; data not shown). 
 
Figure 2. 5. Association between CD4+ and CD8+ T cell activation before and after ART. 
Correlation of the frequency of (A) CD38+ (teal), (B) HLA-DR+ (plum) and (C) CD38+HLA-
DR+ (blue) expressing CD4+ T cells and the frequency of CD38+, HLA-DR+, CD38+HLA-
DR+ on CD8+ T cells (n=28), respectively, in HIV-infected individuals prior to ART initiation. 
Correlation of the frequency of (D) CD38+, (E) HLA-DR+ and (F) CD38+HLA-DR+ 
expressing CD4+ T cells and the frequency of CD38+, HLA-DR+, CD38+HLA-DR+ 
expressing CD8+ T cells (n=28), respectively, post-ART. Statistical significance was 
calculated using a non-parametric Spearman Rank test. The dashed line represents a linear 
regression fit. 
Overall, these findings reveal that the activation and proliferation levels in CD4+ T 
cells reflect those in CD8+ T cells both in ART-naive and in ART-treated HIV-
infected women, where residual activation and proliferation remain in both T cell 
compartments. These data indicate that the ‘de-activation’ rate of CD4+ and CD8+ T 
cells after ART is similar, or alternatively that the factors driving or maintaining 
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activation of T cells post-ART continue to affect both T cell subsets as they did prior 
to ART. 
2.3.4 Differentiation profiles of CD4+ and CD8+ T cells prior to and after ART 
HIV infection results in the skewing of T cell subsets from naive to more differentiated 
(effector and memory) phenotypes, and memory CD4+ T cells are preferentially 
targeted by the virus (Roederer et al., 1995; Brenchley et al., 2004). However, even 
though the imbalance in T cell subset distribution can be corrected upon ART 
(Hellerstein et al., 2003), the extent to which the recovery of the different memory 
subsets occur is still not fully characterised. Therefore, we investigated the impact of 
ART on T cell differentiation in our 28 HIV-treated participants in comparison to 23 
HIV-uninfected controls. Figure 2.6A shows representative flow cytometric plots of 
CD27 and CD45RO expression on CD4+ T cells from one HIV-uninfected and one 
HIV-infected individual (pre- and post-ART). Based on these two markers, four 
separate CD4+ T cell subsets were identified, namely naive (CD27brightCD45RO-), 
early differentiated (ED; CD27brightCD45RO+, comprising central and transitional 
memory subsets), late differentiated (LD; CD27lowCD45RO+ corresponding to 
effector memory cells) and terminally differentiated cells (TD; CD27lowCD45RO-, 
also known as effector cells). Compared to HIV-uninfected controls, HIV-infected 
participants displayed significantly lower frequencies of naive and TD CD4+ T cells 
(Naive: medians 48% vs 38%, p=0.02 and TD: medians 4% vs 1%, p<0.0001; Figure 
2.6B), and higher frequencies of ED and LD CD4+ T cells (ED: medians 33% vs 43%, 
p=0.002 and LD: medians 10% vs 16%, p=0.05; Figure 2.6B), although the latter was 
not statistically different. ART led to a substantial increase in naive CD4+ T cells and 
a concomitant decrease in LD (Naive: medians 38% vs 44%, p=0.006 and LD: medians 
16% vs 11%, p=0.0003) with respect to HIV-untreated subjects. The median 
frequencies of ED and TD CD4+ T cell subsets were comparable pre- and post-ART. 
While ART fully normalised the frequency of naive and LD subsets, the ED and TD 
CD4+ subsets did not return to normal levels observed in HIV-uninfected controls 
(p=0.20, p=0.44, p=0.004 and p<0.0001, respectively). These changes in the 
distribution of CD4+ T cell memory subsets between HIV-uninfected, HIV-untreated 
and HIV-treated participants are further illustrated in Figure 2.6C. 
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Figure 2. 6. Memory profiles of CD4+ T cells before and after ART. (A) Representative 
flow plots of total CD4 subset distribution in one HIV-uninfected and one HIV-infected 
individual pre- and post-ART. Naive: CD27brightCD45RO-, blue; Early Differentiated (ED: 
CD27brightCD45RO+, green); Late Differentiated (LD: CD27lowCD45RO+, red) and 
Terminally Differentiated (TD: CD27lowCD45RO-, grey). The frequencies of each subset are 
indicated. Frequency (B) and absolute number (D) of CD4+ T cell subsets in HIV-uninfected 
(n=23; open circles) and HIV-infected individuals pre-and post-ART initiation (n=28; closed 
circles). Horizontal bars represent the median. Statistical significance was calculated using a 
Mann-Whitney U test and Wilcoxon Signed Rank for unpaired and paired samples, 
respectively. (C) Pie charts showing the overall distribution of CD4+ T cell subsets in HIV-
uninfected (n=23) and HIV-infected participants (n=28; pre- and post-ART). Each slice of the 
pie represents the median proportion of each CD4+ T cell subset, as indicated by the color at 
the bottom of the graph. (E) Fold change in the total, naive, ED, LD and TD absolute CD4+ 
T cell count over 12 months of ART. The vertical dotted line indicates no change from the 
time point prior to ART. The solid lines at 0.8 and 1.2 represent 20% change above which a change 
was considered significant. Statistical comparisons were calculated using a one-way ANOVA test. *p 
< 0.05, **p < 0.01, ***p < 0.001. 
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To take into account variation in absolute CD4 counts pre- and post-ART, the changes 
in CD4+ T cell memory subsets upon treatment were also assessed in absolute number. 
We found a significant increase in the number of naive and ED CD4+ T cell subsets 
(Naive: p=0.0009, ED: p<0.0001; Figure 2.6D) after ART. Relatively small overall 
changes were observed in the median absolute number of LD and TD after ART (LD: 
p=0.02 and TD: p=0.06; Figure 2.6D). Moreover, to evaluate the dynamics of CD4+ 
T cell memory subset reconstitution upon treatment, we examined the fold change in 
absolute number of CD4+ T cell subsets pre- and post-ART. All four subsets expanded 
following 1 year of ART, with naive CD4+ T cells exhibiting the largest expansion 
(median: 2.5), which was higher than the increase in LD and TD CD4+ subsets 
(medians: 1.4, p<0.001 and 1.7, p<0.01 respectively; Figure 2.6E). 
For CD8+ T cells, a similar analysis was performed. An additional CD8+ subset, 
namely intermediate cells (CD27dimCD45RO-) was identified, as shown in the 
representative flow cytometric plots from one HIV-uninfected and one HIV-infected 
individual (pre- and post-ART; Figure 2.7A). As previously described, this subset is 
distinct from effector cells and is characterised by CD57 and CD127 expression, and 
appears to be a differentiation stage between central memory and effector memory 
cells (Burgers et al., 2009). As for CD4+ T cells, HIV infection led to a significantly 
lower frequency of naive CD8+ T cells, and there was a concomitant increase in ED 
and LD CD8+ T cell subsets when compared to HIV-uninfected controls (Naive: 
medians 18% vs 48%, p<0.0001; ED: medians 24% vs 6%, p<0.0001; and LD: 
medians 8% vs 3%, p=0.002; Figure 2.7B). In contrast to CD4+ T cells, although there 
was a trend towards a greater proportion of TD CD8+ T cells, the frequencies did not 
differ significantly between HIV-uninfected and HIV-infected individuals (medians: 
24% vs 33%, respectively; p=0.13). There was also no significant difference in the 
frequency of Inter CD8+ T cells between the HIV-infected and the HIV-uninfected 
groups (medians: 7% vs 9%, respectively; p=0.07). Following suppressive therapy, 
there was a significant increase in naive CD8+ T cell frequency, with a simultaneous 
decrease in ED and Inter CD8+ T cell frequencies relative to HIV-untreated subjects 
(Naive: medians 31% vs 18%, p<0.0001; ED: medians 15% vs 24%, p<0.0001and 
Inter: medians 5% vs 7%, p=0.0005; Figure 2.7B). No substantial difference in the 
frequencies of LD and TD CD8+ T cell subsets was found between pre- and post-ART 
time points (LD: medians 8% vs 8%, p=0.19 and TD: medians 33% vs 29%, p=0.89;). 
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However, ART-induced changes in CD8+ T cell subset frequencies was partial, as 
only naive cells significantly increased but still remained lower compared to HIV-
uninfected subjects (p=0.01). These were compensated by decreases in ED, Inter and 
LD subsets post-ART. (Figure 2.7B & C). 
While the median absolute CD8 count did not differ pre- and post-treatment, 
substantial individual variation was observed amongst participants. Thus, to take this 
into account, changes in the absolute number of each CD8+ memory subsets were 
assessed, and we observed, although not significant as for CD4+ T cells, a trend 
towards an increase in the number of naive CD8+ T cells (p=0.08) after treatment, but 
in slightly fewer individuals (23/28) compared to 26/28 in CD4+ T cells (Figure 2.7D). 
The absolute number of ED CD8+ T cells and inter subset, which constitutes the 
smallest proportion of the CD8+ T cell population significantly decreased in the 
majority of the patients post-ART (ED: 24/28, p<0.0001 and inter: 24/28, p=0.02). In 
contrast, the absolute number of LD and TD remained similar pre- and post-ART (LD: 
24/28, p=0.28 and TD: 21/28, p=0.28). Lastly, to further assess the effect of ART, we 
measured the fold change in absolute number of CD8+ T cell subsets pre- and post-
ART (Figure 2.7E). Only naive CD8+ T cells expanded with a median fold change of 
1.4, while the other four subsets contracted (median fold changes: 0.5, 0.6, 0.7 and 0.8 
for ED, Inter, LD and TD; respectively). The contraction in the ED subset was the 
highest, and differed significantly from the decrease in the TD subset upon ART 
(p<0.05).  
Overall, our results reveal that HIV skews memory T cell profiles and promotes 
excessive differentiation by decreasing the frequency of peripheral naive T cells, while 
augmenting the memory subsets (ED and LD cells). Nevertheless, one year of ART 
was not sufficient for complete normalisation of CD4+ and CD8+ T cell subsets, 
despite suppression of viral load. It will be important to determine whether HIV-
induced defects persist despite successful ART, or if merely a longer period on ART 
may be necessary for full normalisation of T cell subsets. 
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Figure 2. 7. Memory profiles of CD8+ T cells before and after ART. (A) Representative 
flow plots of total CD8 subset distribution in one HIV-uninfected and one HIV-infected 
individual pre- and post-ART. Naive: CD27brightCD45RO-, blue; Early Differentiated (ED: 
CD27brightCD45RO+, green); Intermediate (Inter: CD27dimCD45RO-, brown), Late 
Differentiated (LD: CD27lowCD45RO+, red) and Terminally Differentiated (TD: 
CD27lowCD45RO-, grey). The frequencies of each subset are indicated. Frequency (B) and 
absolute number (D) of CD8+ T cell subsets in HIV-uninfected (n=23; open circles) and HIV-
infected individuals pre-and post-ART initiation (n=28; closed circles). Horizontal bars 
represent the median. Statistical significance was calculated using a Mann-Whitney U test and 
Wilcoxon Signed Rank for unpaired and paired samples, respectively. (C) Pie charts showing 
the overall distribution of CD8+ T cell subsets in HIV-uninfected (n=23) and HIV-infected 
participants (n=28; pre- and post-ART). Each slice of the pie represents the median proportion 
of each CD8+ T cell subset, as indicated by the color at the bottom of the graph. (E) Fold 
change in the total, naive, ED, Inter, LD and TD absolute CD8+ T cell count over 12 months 
of ART. The vertical dotted line indicates no change from the time point prior to ART. The 
solid lines at 0.8 and 1.2 represent 20% change above which a change was considered 
significant. Statistical comparisons were calculated using a one-way ANOVA test. *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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2.3.5 Activation levels within CD4+ and CD8+ T cell subsets before and after ART 
Finally, in order to define whether HIV-induced hyperactivation affects all memory T 
cell subsets to the same extent, we determined HLA-DR expression on each T cell 
memory subsets within CD4+ and CD8+ T cells (n=28; pre- and post-ART), and 
compared them to profiles in HIV-uninfected controls (n=23). During HIV infection, 
for both CD4+ and CD8+ T cells, all antigen-experienced subsets (ED, Inter, LD and 
TD) became activated (3-6 fold greater than the same subsets in HIV-uninfected 
subjects), as shown by a significant upregulation of HLA-DR expression (CD4: 
p<0.0001 for ED, LD and TD; and CD8: ED, Inter, LD, TD: p<0.0001; Figures 2.8A 
& B). With respect to naive cells, naive CD8+ T cells demonstrated~11 fold higher 
levels of activation than the HIV-uninfected group, while naive CD4+ T cells showed 
little or no activation. Following 1 year of ART, HLA-DR expression on all subsets 
was markedly reduced for both CD4+ (decrease of ~2 fold for ED and LD, ~1 fold for 
TD) and CD8+ T cells (decrease of ~3 fold for ED, ~2 fold for Inter, LD and TD). The 
degree of deactivation was comparable across all CD4+ and CD8+ memory subsets. 
Naive CD8+ T cells also deactivated upon ART (decrease of ~4 fold). With regards to 
CD4+ T cells, none of the subsets normalised their activation levels post-ART to HIV-
uninfected levels, whereas in three subsets of CD8+ T cells (ED, LD and TD), 
activation reached similar levels to those in HIV-uninfected individuals (p=0.1 for ED 
and LD; p=0.07 for TD). The reduction in HLA-DR expression post-therapy is further 
demonstrated in Figures 2.8C & D showing the fold change in activation, where 
overall all subsets contracted (CD4 median fold change decrease: Naive 0.48, ED 0.45, 
LD 0.60 and TD 0.75; CD8 median fold changes: Naive 0.2, ED and Inter 0.4, LD and 
TD 0.5). The decrease in HLA-DR expression was more pronounced for CD8+ T cells 
than CD4+ T cells. Taken together, these data suggest that HIV induced activation of 
all T cells, irrespective of their differentiation stage, and these defects within each 
subset appeared to be almost fully normalised in the CD8 compartment (ED, LD and 
TD activation profiles are comparable to HIV-uninfected controls), while the 
restoration was only partial in the CD4 compartment (where activation profiles on all 
memory subsets remained elevated compared to HIV-uninfected controls) after 1 year 
of suppressive therapy. Of note, similar profiles were observed using as the readout 
for activation the marker CD38 (alone or in combination with HLA-DR), as well as 
using the proliferation marker Ki67 (Appendix Figure 1). 
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Figure 2. 8. Activation profiles of CD4+ and CD8+ T cell subsets before and after ART. 
Frequencies of (A) HLA-DR+CD4+ T cells and (B) HLA-DR+CD8+ T cells, in HIV-
uninfected (n=23; open circles) and HIV-infected (pre- and post-ART; n=28; closed circles) 
individuals. Blue, green, brown, red and grey represent the Naive, ED, Inter, LD and TD 
subsets. Data are shown as box and whisker (interquartile range) plots. Statistical significance 
was calculated using a Mann-Whitney U test and Wilcoxon Signed Rank test for unpaired and 
paired samples, respectively. Fold change in HLA-DR frequencies of (C) Naive, ED, LD and 
TD CD4+ T cells and (D) Naive, ED, Inter, LD and TD CD8+ T over 12 months of ART. The 
vertical dotted line indicates no change from the time point prior to ART. Statistical 
comparisons were calculated using a one-way ANOVA test. *p < 0.05, **p < 0.01, ***p < 
0.001. 
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2.4 Discussion 
HIV directly impacts the immune system by inducing a profound loss in CD4+ T cells 
and a state of generalised immune activation, thereby promoting disease progression 
and development of AIDS. Although successful ART improves CD4+ T cell numbers, 
excessive immune activation may persist and influence CD4+ T cell reconstitution and 
the health of the individual. The degree to which specific memory T cell subsets are 
normalised on ART, and the association with sustained immune activation, is not fully 
defined. Therefore, this Chapter focused on the longitudinal assessment of the impact 
of short-term ART on the activation, proliferation and memory differentiation profiles 
of CD4+ and CD8+ T cells in HIV-infected African women (n=28). These profiles 
were compared to age- and sex-matched HIV-uninfected controls from the same 
community (n=23). Our results showed high levels of T cell activation and 
proliferation, as well as perturbations in the differentiation profiles of both CD4+ and 
CD8+ T cell subsets upon HIV infection, as expected. Whilst there was a decrease in 
activation and skewing of T cell memory subsets, one year of ART was insufficient to 
completely normalise these immune defects when compared to HIV-uninfected 
individuals. We found a positive correlation between the levels of activation of CD4+ 
and CD8+ T cell subsets before and after ART initiation, suggesting that similar 
factors may affect both subsets. Lastly, hyperactivation as a result of HIV infection 
was comparable among memory subpopulations within CD4+ and CD8+ T cells, and 
while ART almost completely normalised activation levels of subpopulations within 
the CD8 compartment, this was not the case for CD4+ T cells.  
CD4+ T cell count, plasma viral load and CD4:CD8 ratio are key clinical parameters 
to predict disease progression to AIDS and to evaluate how well HIV patients on ART 
respond to treatment (Taylor et al., 1989). In this study, we confirmed findings from 
other studies that one year of ART induces substantial gains in CD4+ T cell counts 
and effectively suppresses viral load in most HIV-treated individuals (Deeks et al., 
2000; DeHovitz et al., 2000; Kaufmann et al., 2000; Hunt et al., 2003). Regardless of 
the drug regimen, the gain in peripheral CD4+ T cells takes place in more than one 
step (Corbeau & Reynes, 2011). During the first few weeks of therapy, the prompt 
initial increase may be explained by the release of trapped memory CD4+ T cells from 
lymphoid tissues to the bloodstream as a result of reduced immune activation and low 
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expression of adhesion molecules (VCAM-1 and ICAM-1) on the surface of CD4+ T 
cells (Autran et al., 1997; Bucy et al., 1999). A recent study has shown that the 
memory CD4+ T cells released into the blood are predominantly CCR4-expressing 
and have a Th17-like functionality (Mahnke et al., 2016). The second boost in CD4 
counts after several months of therapy is somewhat due to new synthesis of naive 
CD4+ T cells by the thymus, or prolonged CD4+ T cell half life (Bucy et al., 1999; 
Steffens et al., 2001; Kovacs et al., 2001; Mohri et al., 2001). However, it is notable 
that for two participants (CAP248 and 262) no improvement in CD4 count was 
observed after one year of ART, but CD4 recovery occurred at a later stage (> 1 year 
ART; data not shown). Failure or delay to recover CD4+ T cells may be due to multiple 
reasons, including CD4 count and level of T cell activation at the time of ART 
initiation (Kaufmann et al., 2005; Goicoechea et al., 2006; Le et al., 2013), length of 
ART, age (Kaufmann et al., 2002; Allers et al., 2014) and co-infections (Almeida et 
al., 2007; Kaufmann et al., 2011).  
Chronic HIV infection is marked by a state of generalised immune activation, 
manifested by an increase in T cell activation, and an accelerated and constant T cell 
turnover (proliferation and death), which results in the exhaustion of the immune 
system, inhibiting its capacity to replenish the T cell pool (Hazenberg et al., 2000; 
McCune, 2001). As previously reported (Liu et al., 1997; Mohri et al., 2001; 
Hazenberg et al., 2003), our data showed increased CD4+ and CD8+ T cell activation 
and proliferation in chronically HIV-infected women. Interestingly, we found a 
positive association between the frequency of activated CD4+ and activated CD8+ T 
cells, as well as the frequency of proliferating CD4+ and proliferating CD8+ T cells 
pre-ART. Despite this association, there were differences in the activation and 
proliferation of CD4+ compared to CD8+ T cells. Our observation that CD8+ T cells 
were highly activated but there were lower frequencies of proliferation cells compared 
to CD4+ T cells concurs with what has been reported previously (Funderburg et al., 
2008). The difference in CD4+ and CD8+ T cell activation could be as a result of the 
distribution of memory subsets within the compartments, where central and effector 
memory CD4+ T cells entered the cell cycle (Ki67 expression) compared to naive 
CD4+ T cells, whilst effector memory CD8+ T cells were found to express the 
activation marker CD69 (Funderburg et al., 2008),  or alternatively, due to differential 
expression of cytokine receptors between CD4+ and CD8+ T cells (Boyman, 2010). 
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Catalfamo and colleagues reported differences in homeostatic responses between 
CD4+ and CD8+ T cells; CD4+ T cells proliferate in response to CD4+ T cell loss and 
viral load, as opposed to CD8+ T cells, whose proliferation is driven largely by viral 
load (Catalfamo et al., 2008). In our study, we also evaluated whether ART normalised 
the levels of T cell activation and proliferation in HIV-treated individuals to that seen 
in uninfected controls. Our results show a substantial global decrease in the frequency 
of activated (CD38 and/or HLA-DR) and proliferating (Ki67) CD4+ and CD8+ T cells, 
however these parameters remained significantly higher than in HIV-uninfected 
individuals. These findings are consistent with previous reports, suggesting only a 
partial reduction in immune activation (Mohri et al., 2001; Valdez et al., 2002;. Hunt 
et al., 2003; Lim et al., 2007). Upon ART, failure to eradicate viral reservoirs and the 
irreversible damage of the gut epithelium, both established early in HIV infection, are 
a potential source of virus and bacterial components that could account for this 
sustained immune activation despite effective ART (Finzi et al., 1997; Brenchley et 
al., 2007). Consequently, HIV-infected people on ART become at high risk of non-
AIDS related diseases and mortality. In a number of studies, elevated levels of 
inflammation (as measured by IL-6 and C-reactive protein; CRP) and coagulation (D-
dimers) markers were found to independently predict increased mortality and death 
associated with cardiovascular diseases among treated HIV-infected individuals 
(Kuller et al., 2008; Duprez et al. 2012). In addition, the risk of cardiovascular disease 
has been associated with monocyte activation during HIV infection (Funderburg et al., 
2012). 
Based on their differentiation status, T cell subsets can be classified into multiple 
subgroups namely, naive, central memory, transitional memory, effector memory and 
terminal effector cells (Paiardini & Müller-Trutwin, 2013). During HIV infection, 
naive T cells are depleted as a result of reduced thymic output, or elevated 
differentiation of these cells into memory and effector cells due to constant antigen 
exposure and increased immune activation (Nokta et al., 2001). In this study, HIV-
infected women showed skewed T cell differentiation profiles, with a decreased naive 
cell frequency and increased memory subset frequency (ED and LD cells), which 
normalised only partially to levels observed in HIV-uninfected individuals. These data 
are in accordance with previous reports (Robbins et al., 2009; Rallon et al., 2013; 
Serrano-Villar et al., 2014) In addition, there was HIV-induced activation of both 
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naive and memory T cells, as previously reported (Ssewanyana et al., 2009). Our data 
also showed that “de-activation” of all memory T cell subsets occurred upon ART, 
with a more pronounced effect on the CD8 compartment. The imbalance in CD4+ T 
cell homeostasis as a result of continuous destruction of memory CD4+ T cells could 
explain the incomplete recovery of these cells upon ART (Ssewanyana et al., 2009).  
Our study had some limitations. We confined ourselves to HIV-uninfected controls 
matched for age, sex and HIV risk. Using pre-infection samples from the same 
participants who went onto treatment after being infected with HIV would have 
provided a more accurate view of normalisation of T cell activation and differentiation 
profiles upon ART, since there is substantial variation in these profiles in a population. 
It could also be beneficial to include an additional low-risk HIV-uninfected control 
group. Furthermore, memory subsets were identified based on two markers, CD27 and 
CD45RO that cannot discriminate between central memory and transitional memory 
cells found within the ED (CD27brightCD45RO+) subset. Thus, additional markers 
such as CCR7 should be included in future studies to determine the effect of ART on 
these subsets. Moreover, our cohort consisted of women only, and it is worth noting 
that male sex was associated with lower CD4 gains after treatment independent of 
starting CD4 count (Gandhi et al., 2006). In addition, thymic output has been described 
to be reduced in men compared to women, thus testing whether our findings are 
applicable in a cohort of men is warranted (Pido-Lopez et al. 2001; Hunt et al. 2003). 
Lastly, it is important to note that recovery of T cell phenotype from peripheral blood 
does not necessarily mean reconstitution at other immunological sites of importance 
in HIV pathogenesis, such as the gastrointestinal tract, where HIV causes significant 
damages. Previous reports have shown that compared to peripheral blood, CD4+ T 
cells are substantially more depleted in the gastrointestinal tract of HIV-infected 
persons, and that this loss in gut CD4+ T cells is only partially restored upon ART 
(Brenchley et al., 2004; Guadalupe et al., 2003). Thus, to address reconstitution of T 
cells in the gut, studies investigating T cell recovery in gut biopsies could be performed. 
Another important point is that despite the apparent overall normalisation of T cell 
memory profiles upon ART, certain memory T cells specific for opportunistic 
pathogens depleted during HIV infection may not be restored upon ART, raising the 
issue of the ‘quality’ and not just quantity of immune recovery (Geldmacher et al., 
2010; Pauza et al., 2011; Saharia & Koup, 2013), a subject that is dealt with in Chapter 
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3 (Riou, Tanko et al., 2015). Additionally, the effect of ART on the recovery of 
immune cells other than T cells should be investigated for a better assessment of 
functional immune recovery. In this regard, Chapter 4 of this thesis covering our 
recently published study (Tanko et al., 2017) evaluated the influence of ART on B 
cells.  
In summary, our study has demonstrated hyperactivation and skewing of T cell 
memory phenotypes in African women with chronic HIV infection. Administration of 
ART during chronic HIV infection led to successful vial load suppression and CD4+ 
T cell increases. However, T cell activation and proliferation levels remained higher 
than HIV-uninfected subjects and the frequency of T cell memory subsets did not 
completely normalise, implying partial recovery following short-term (1 year) ART. 
In addition, whilst activation levels were nearly completely regularized within 
memory CD8+ T cells, they were only partially restored within memory CD4+ T cells, 
implying differential dynamics of deactivation between the two compartments. A 
follow-up study will be required to determine whether longer-term ART may enable 
full immune normalisation of T cell phenotypes and deactivation in our cohort. 
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CHAPTER 3 
Restoration of CD4+ responses to co-pathogens in HIV-infected 
individuals on antiretroviral therapy is dependent on T cell memory 
phenotype. 
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3.1 Abstract  
Antiretroviral therapy (ART) induces rapid suppression of viral replication and a 
progressive replenishment of CD4+ T cells in HIV-infected individuals. However, the 
effect of ART on restoring pre-existing memory CD4+ T cells specific for common 
co-pathogens is still unclear. To better understand the dynamics of antigen-specific 
CD4+ T cells during ART, we assessed the frequency, functional capacity and memory 
profile of CD4+ T cells specific for Mycobacterium tuberculosis (Mtb) and 
cytomegalovirus (CMV) in 15 HIV-infected individuals before and one year after ART 
initiation. 
After ART initiation, the frequency of Mtb-specific CD4+ T cells showed little change 
whereas CMV-specific CD4+ T cells were significantly lower (p=0.003). There was 
no difference in the polyfunctional or memory profile of antigen-specific CD4+ T cells 
before and after ART. The replenishment of antigen-specific CD4+ T cells correlated 
with the memory differentiation profile of these cells prior to ART. Pathogen-specific 
CD4+ T cells exhibiting a late differentiated profile (CD45RO+CD27-) had a lower 
 65 
capacity to replenish (p=0.019, r=-0.5) compared to cells with an early-differentiated 
profile (CD45RO+CD27+; p=0.04, r=0.45).  
In conclusion, restoration of co-pathogen-specific memory CD4+ T cells during 
treated HIV infection is related to their memory phenotype, where early differentiated 
cells (such as most Mtb-specific cells) have a higher replenishment capacity compared 
to late differentiated cells (such as most CMV-specific cells). These data identify an 
important, hitherto unrecognised, factor that may limit restoration of co-pathogen 
immunity in HIV-infected individuals on ART. 
3.2 Introduction 
The hallmarks of untreated HIV infection are a progressive loss of CD4+ T cells, 
sustained cellular activation and chronic inflammation (Moir et al., 2011; Okoye & 
Picker, 2013; Doitsh et al., 2014). In addition to the numerical depletion of CD4+ T 
cells, HIV can also alter the functional capacity of these cells, impairing their 
proliferative potential, altering their cytokine secretion profiles and changing their 
phenotypic characteristics in response to HIV antigens as well as various co-pathogens 
(Shearer & Clerici, 1991; Luciano et al., 2007; Morou et al., 2014; Boswell et al., 
2014). Both of these quantitative and qualitative alterations can lead to increased 
susceptibility to opportunistic infections, including tuberculosis (TB), Candidiasis and 
Human Papilloma Virus (HPV) infection (Saharia & Koup, 2013). Indeed, HIV is the 
best-recognised risk factor for TB disease even before profound CD4+ T cell 
deficiency (Sonnenberg et al., 2005; Geldmacher et al., 2012). The introduction of 
antiretroviral therapy (ART) has drastically decreased morbidity and mortality in HIV-
infected individuals (Williams et al., 2011), inducing a rapid reduction of plasma viral 
load and a progressive repletion of CD4+ T cells (Guihot et al., 2011). Although the 
clinical benefit of ART is undeniable, the extent to which ART can fully “normalise” 
functional immunity remains unclear (Corbeau & Reynes, 2011). HIV-infected 
individuals on ART exhibit a differential degree of recovery of co-pathogen-specific 
CD4+ T cell responses, depending on the pathogen they target (Schluger et al., 2002; 
Keane et al., 2004; Burgess et al., 2006; Wilkinson et al., 2009; Sutherland et al., 
2010; Hsu et al., 2013; Jambo et al., 2014). For example, it has been shown that the 
restoration of CMV-specific CD4+ T cells occurs early after ART (Hsu et al., 2013), 
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but appears to be short-lived (Keane et al., 2004). Conversely, Candida-specific CD4 
responses recover slowly (Burgess et al., 2006). Contrasting data exist on the degree 
of recovery of Mycobacterium tuberculosis (Mtb)-specific CD4+ T cell responses 
upon ART. Jambo et al. showed in a cross-sectional study that the frequency and 
polyfunctional profile of Mtb-specific CD4+ T cell responses were similar in ART-
naive or treated individuals (Jambo et al., 2014), while Sutherland et al. reported that 
ART increases the polyfunctional capacity of these cells (Sutherland et al., 2010). 
Other studies described only a partial reconstitution of Mtb-specific CD4+ T cell 
responses after ART (Schluger et al., 2002; Wilkinson et al., 2009).  
It is of particular importance to define the factors that associate with successful 
pathogen-specific CD4+ T cell recovery upon ART, as limited “normalisation” of 
functional CD4+ T cell responses could account for sustained incidence of 
opportunistic infections. Several parameters influence the degree and dynamics of 
recovery of the overall CD4+ T cell compartment in response to ART, such as age, 
CD4 count at the time of treatment initiation, and timing of ART initiation after HIV 
infection (Kaufmann et al., 2005; Aiuti & Mezzaroma, 2006; Le et al., 2013). However, 
it is still unclear why CD4+ T cells of different pathogen specificities have different 
profiles of restoration, and the mechanisms mediating this variable recovery of 
memory CD4+ T cells to co-pathogens are still incompletely understood. Thus, to 
better understand the effect of successful ART on the dynamics of recovery of co-
pathogen-specific CD4+ T cells, we compared the magnitude, functional capacity and 
memory differentiation profiles of Mtb- and CMV-specific CD4+ T cells before and 
one year after ART initiation in a cohort of HIV-infected individuals, and HIV-
uninfected controls.  
3.3 Materials and Methods 
3.3.1 Study participants 
Blood samples were collected from 15 women participating in the CAPRISA 002 
study, a cohort study following HIV-infected women from HIV seroconversion until 
five years on treatment. The cohort is situated in KwaZulu-Natal, South Africa, and 
has been previously described (van Loggerenberg et al., 2008; Mlisana et al., 2014). 
Participants were selected based on sample availability. Blood samples from 9 HIV-
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uninfected participants were provided from the CAPRISA 004 vaginal microbicide 
(1% tenofovir) gel trial (Abdool Karim et al., 2010). An additional 14 HIV-uninfected 
participants from CAPRISA 004 were studied for immune activation. HIV-uninfected 
participants were from the same community as the HIV-infected individuals and age-
matched; they were either in the pre-intervention phase or in the placebo arm of the 
trial. For HIV-infected individuals, the time of infection was estimated either as the 
same date as a prospective RNA positive/antibody negative measurement or taken as 
the midpoint between the last antibody negative test and first antibody positive 
enzyme-linked immunosorbent assay test. Participants in the cohort were offered ART 
according to South African national HIV treatment guidelines (at a CD4 count of <200 
cells/mm3 prior to October 2012; <350 cells/mm3 until the present). Eight of the 15 
participants were taking standard first-line therapy (TDF/3TC/EFV), 3 were on ddI-
EC/3TC/EFV, and 1 each on d4T/3TC/EFV, TDF/3TC/NVP, d4T/3TC/NVP and 
AZT/3TC/LPV/r. Two participants switched drug regimens while on study, namely 
CAP200 (EFV/3TC/ddI-EC to EFV/3TC/TDF at month 11), and CAP255 
(EFV/3TC/d4T to EFV/3TC/AZT at month 10). No participants had active TB during 
the study period, or exhibited any immune reconstitution disease upon HIV treatment. 
Ethical approval for the study was obtained from the University of KwaZulu-Natal 
and University of Cape Town Research Ethics Committees. All participants provided 
written informed consent to participate in the study.  
3.3.2 Determination of plasma viral load and CD4 counts 
Plasma HIV viral loads and CD4 counts were quantified at each study visit.  Over the 
course of the study, the viral load PCR assay switched from Roche AMPLICOR HIV-
1 monitor test version 1.5 [lower detection limit (LDL) of 400 RNA copies/ml], to 
Roche Taqman version 1.0 on June 1, 2010 (LDL 40 RNA copies/ml), and then to 
Roche Taqman version 2.0 on January 9, 2012 (LDL 20 RNA copies/ml). Absolute 
blood CD4 and CD8 T cell counts were measured using the FACSCalibur TruCOUNT 
method (BD Biosciences) and expressed as cells/mm3. Plasma samples matching the 
visits where PBMC were tested for antibodies to CMV and CMV DNA.  Seropositivity 
was determined using the Cobas CMV IgG Assay (Roche), and CMV viral load was 
detected and quantified using a CMV R-gene PCR kit (Argene), with a detection limit 
of 30 copies/ml. 
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3.3.3  Cell preparation 
PBMC were isolated by standard Ficoll-Hypaque density gradient centrifugation 
(Amersham Pharmacia) and cryopreserved in 90% heat-activated foetal calf serum 
(FCS, Invitrogen) plus 10% DMSO and stored in liquid nitrogen until needed. 
Cryopreserved PBMC were thawed and rested in R10 [RPMI 1640 containing 10% 
heat-inactivated FCS (Sigma) and 50 U/ml of penicillin-streptomycin] at 37°C and 5% 
CO2 for 8 hours prior to antigen stimulation.  
3.3.4  Antigens and cell stimulation  
Following resting, PBMC were stimulated using Mtb Purified Protein Derivative (PPD, 
10 µg/ml; Statens Serum Institute), a pool of CMV peptides consisting of 138 peptides 
(15mers overlapping by 11 amino acids) covering the entire HCMV pp65 protein (2 
µg/ml; NIH AIDS Reagent Program) and Staphylococcal Enterotoxin B (SEB, 2.5 
µg/ml; Sigma), used as a positive control. Of note, we found no major differences in 
the memory profile, cytokine secretion potential and polyfunctional capacity between 
peptide and protein-stimulated PBMC (Bunjun et al., manuscript in preparation). 
Stimulations were performed in the presence of co-stimulatory antibodies, anti-CD28 
and anti-CD49d (both at 1 µg/ml; BD Biosciences) at 37°C for 16 hours. Brefeldin A 
(BFA; Sigma) was added after 1 hour at a concentration of 10 µg/ml. Surface and 
intracellular cytokine staining was performed at the end of the incubation period. 
Sufficient cells were available for assessing CMV and SEB responses in only 12/15 
HIV-infected participants.  
3.3.5 Surface phenotypic and intracellular cytokine staining and flow cytometry 
The following antibodies were used for surface and intracellular staining: CD3-APC-
H7 (SK7; BD Biosciences), CD4-PE-Cy5.5 (S3.5; Invitrogen), CD8-Qdot 705 (3B5; 
Invitrogen), CD27-PE-Cy5 (1A4CD27; R&D Systems), CD45RO-ECD (UCHL1; 
R&D Systems), IFN-γ-Alexafluor 700 (B27; BD Biosciences), IL-2-APC (MQ1-
17H12; BD Biosciences), TNF-α-PE-Cy7 (MAb11; eBiosciences), CD14-PacBlue 
(Tük4; Invitrogen), CD19-PacBlue (SJ25-CI; Invitrogen) and a violet amine viability 
dye (“Vivid”; Molecular Probes). All antibodies were titrated to obtain optimal 
concentrations prior to use. After stimulation, PBMC were first stained with Vivid for 
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20 min at room temperature. Cells were then surface stained with CD4, CD8, CD45RO, 
CD27, CD14 and CD19 antibodies. Cells were fixed and permeabilised using 
Cytofix/Cytoperm buffer (BD Biosciences) and stained intracellularly with CD3, IL-
2, TNF-α and IFN-γ. Cells were then re-suspended in 1X CellFix (BD Biosciences). 
Samples were acquired on a BD Fortessa using FACSDiva software and analysed 
using FlowJo (version 9.8.2; TreeStar). The gating strategy is presented in Figure 3.1. 
A positive cytokine response was defined as at least twice the background (in the 
presence of co-stimulatory antibodies and no antigen). For phenotyping the memory 
profile of cells producing cytokines, a cut-off of 40 events was used. Polyfunctionality 
of antigen-specific cells was analysed using Pestle (version 1.7) and Spice (version 
5.35) software (Roederer et al., 2011). Immune activation was measured by surface 
staining of unstimulated cells using the CD3, CD4, CD8, CD14 and CD19 antibodies 
listed above, as well as CD38-APC (HIT2) and HLA-DR-APC-Cy7 (L243) (both BD 
Biosciences), along with the inclusion of Vivid. 
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Figure 3. 1. Gating strategy. (A) Singlets were identified in forward scatter plots. Dead cells, 
B cells and monocytes were excluded by Vivid, CD19 and CD14 labelling, respectively. (B) 
Memory subsets were discriminated based on the expression of CD27 and CD45RO, allowing 
for the discrimination of four subpopulations: Naive: CD45RO-CD27+; ED: 
CD45RO+CD27+; LD: CD45RO+CD27- and TD: CD45RO-CD27-. Gates applied for the 
identification of cytokine positive cells were set according to the unstimulated samples (NS). 
3.3.6 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism (version 5.0; San Diego). 
Non-parametric statistical tests were used for all comparisons. The Mann-Whitney U 
test and the Wilcoxon Signed Rank test were used for unmatched and paired samples, 
respectively, and the Kruskal-Wallis ANOVA using Dunn’s test for multiple 
comparisons. Correlations were performed using the Spearman Rank test. A p-value 
of <0.05 was considered statistically significant.  
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3.4 Results 
3.4.1 Effect of ART on the restoration of co-pathogen-specific CD4+ T cells 
In order to better understand the replenishment dynamics of CD4+ T cells specific for 
co-pathogens in HIV-infected individuals on treatment, we studied 15 HIV-infected 
individuals before and after ART initiation. The cohort consisted of women infected 
with HIV-1 for a median of 4.9 years (IQR: 3.8-5.8 years) at the time of treatment 
initiation (Table 3.1). Pre-ART samples were obtained at a median of 1.7 months 
(IQR: 0.8-2.5) prior to starting ART. The median plasma viral load was 21,955 HIV 
RNA copies/ml (IQR: 4,743-52,800), and the median CD4 count was 289 cells/mm3 
(IQR: 193-322).  
Table 3. 1. Characteristics of study participants 
 
After a median of 12 months of treatment (IQR: 11-12.3 months), all individuals 
exhibited some degree of viral suppression (p<0.0001, Figure 3.2A), which was below 
the limit of detection of the assay in 12/15 individuals and <300 RNA copies/ml in the 
remainder. An increase in absolute CD4 count occurred in 13/15 individuals over the 
period measured (p<0.0001, Figure 3.2B). The median fold change in absolute CD4 
count was 1.9 (IQR: 1.6-2.3), and when adjusted for length of treatment, the 
replenishment rate of CD4+ T cells was 20 cells/mm3/month (IQR: 14-26, data not 
shown); this was accompanied by a concomitant doubling of the CD4/CD8 ratio (0.27 
vs. 0.66; p=0.0007, Figure 3.2C). As previously reported (Kaufmann et al., 2005; 
PID Pre-ART duration 
of infection (Years)
Viral Load 
(RNA 
copies/ml)
CD4 count 
(cells/mm3) 
CD4:CD8 
ratio
Months Pre 
ART 
initation 
Viral Load 
(RNA 
copies/ml)
CD4 count 
(cells/mm3) 
CD4:CD8 
ratio
Months post 
ART 
initation 
CAP200 3.8 423,000 135 0.24 2.5 <20 496 0.68 13.5
CAP206 5.2 198,277 289 0.15 0.2 <40 512 0.50 11.0
CAP222 6.1 3,049 319 0.61 3.2 <20 619 1.24 11.3
CAP237 5.2 4,743 308 0.57 0.0 <20 528 1.05 12.0
CAP244 7.3 21,955 318 0.32 0.0 273 647 0.53 12.3
CAP248 6.6 29,258 363 0.26 2.8 121 305 0.27 6.7
CAP255 3.7 8,830 226 0.18 3.8 <20 484 0.53 18.1
CAP257 4.8 52,800 170 0.19 2.0 <20 494 0.47 12.0
CAP262 5.8 1,130 338 1.69 1.7 <20 329 3.13 12.1
CAP267 5.4 41,338 269 0.27 1.3 <20 347 0.35 8.7
CAP268 4.2 4,537 186 0.18 0.9 <20 426 0.63 12.0
CAP276 1.4 22,000 232 0.37 2.3 <400 627 1.03 20.2
CAP277 4.9 7,997 322 0.22 1.0 29 535 0.66 10.0
CAP279 2.7 58,100 193 0.40 0.8 <20 400 1.48 12.0
CAP316 4.1 5,612 436 0.33 2.4 <20 708 0.67 11.8
Median 4.9 21,955 289 0.27 1.7 121 496 0.66 12
Range 1.4 - 7.3 1,130 - 423,000 135 - 436 0.15 - 1.69 0 - 3.8 <20 - 273 305 - 758 0.27 - 3.13 6.7 - 20.2
 POST-ART PRE-ART
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Aiuti & Mezzaroma, 2006; Le et al., 2013), the degree of CD4 reconstitution was 
inversely related to absolute CD4 count at ART initiation (p<0.0001, r=-0.85) and the 
duration of HIV infection (p=0.016, r=-0.61, data not shown). We also measured 
immune activation before and after ART using the markers CD38 and HLA-DR. There 
was a significant reduction in CD4+ and CD8+ T cells co-expressing CD38+ and 
HLA-DR+ (p=0.0002 and p=0.0001, Figure 3.2D), as well as HLA-DR+ alone 
(p=0.0001 for both subsets). Residual levels of immune activation after one year of 
ART remained significantly greater than healthy, HIV-uninfected individuals for both 
markers (Figure 3.2D). We found no association between the degree of CD4 
reconstitution and CD4+ T cell activation before or after ART (data not shown). 
 
Figure 3. 2. Effect of ART on clinical and activation parameters. Plasma viral load (A), 
absolute CD4 count (B) and CD4/CD8 ratio (C) before (Pre-ART) and 12 months after ART 
initiation (Post-ART) in 15 HIV-infected individuals. (D) T cell activation (CD38, HLA-DR) 
is shown for CD4+ and CD8+ T cells. Closed circles depict HIV-infected individuals (n=14) 
and open circles depict HIV-uninfected individuals (n=23). Statistical analysis was performed 
using non-parametric statistical tests (Mann-Whitney and Wilcoxon matched pair tests for 
unmatched and matched samples, respectively). A p-value <0.05 was considered significant. 
Effective ART of 1-year duration results in an overall decline in T cell activation, although 
this still remained higher than in HIV-uninfected individuals.  
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To determine whether the dynamics of co-pathogen-specific CD4+ T cells mirror the 
reconstitution of the total CD4+ T cell population, we measured the magnitude of Mtb- 
and CMV-specific CD4+ T cell responses, as well as SEB-reactive CD4+ cells, before 
and after ART initiation. Figure 3.3A shows representative flow cytometry plots of 
cytokine production (IFN-γ, IL-2 and TNF-α) by CD4+ T cells in response to Mtb, 
CMV and SEB stimulation in one HIV-infected patient (CAP267). At baseline (before 
ART initiation), 11/15 individuals tested had a detectable Mtb response, with a median 
frequency of 0.08% of total CD4+ T cells (range, 0-0.9%; Figure 3.3B). CMV 
responses were detected in 10/12 individuals tested and the median frequency was 
0.35% (range: 0-4.1%). SEB responses were detectable in 12/12 participants with with 
a median frequency of 16% (range: 8.6-32.5%). The frequency of Mtb-specific and 
SEB-responding CD4+ T cells were comparable pre- and post-ART, whilst the 
frequency of CMV-specific CD4+ T cells was significantly lower after treatment 
(median 0.35% vs 0.14%, p=0.003, Figure 3.3C). To take into account variation in 
absolute CD4 counts across the cohort, the absolute number of antigen-specific CD4+ 
T cells was calculated. The number of Mtb-specific and SEB-responding CD4+ T cells 
increased significantly after ART (p=0.033 and p=0.016, respectively), whilst the 
number of CMV-specific CD4+ T cells remained unchanged upon treatment (Figure 
3.3C), consistent with the decreased frequency in the context of increases in absolute 
CD4 numbers. Overall, these data reveal that the dynamics of reconstitution of 
antigen-specific CD4+ T cells vary according to their memory phenotype. As for 
chronic infections, pathogen-specific memory T cells (such as EBV and HCV) are 
maintained with a distinct degree of memory differentiation (Appay et al., 2002a). It 
is thus plausible that the reconstitution potential of cells will vary based on their 
antigen-specificity. 
 74 
 
Figure 3. 3. Effect of ART on Mtb-, CMV- and SEB-specific CD4+ T cell responses. (A) 
Representative flow cytometry plots of the expression of TNF-α, IFN-γ and IL-2 from CD4+ 
T cells after stimulation with Mtb and CMV antigens and SEB, in one study participant. NS 
corresponds to unstimulated PBMC. The frequency of cytokine-producing cells expressed as 
a percentage of the total CD4+ T cell population are indicated. Frequency (B) and absolute 
number (C) of Mtb-, CMV- and SEB-specific CD4+ T cell responses before and after ART. 
Horizontal bars represent the median. Statistical comparisons were performed using a 
Wilcoxon matched pairs test. 
3.4.2 Relationship between the dynamics of restoration of total and co-pathogen-
specific CD4+ T cells 
To further investigate the restoration dynamics of co-pathogen-specific CD4+ T cells, 
we examined the relationship between the fold change in the absolute number of 
antigen-specific CD4+ T cells pre- and post-ART (in individuals with detectable 
antigen responses at both time points, n=11 for Mtb, n=10 for CMV and n=12 for SEB), 
and the absolute total CD4 count variation. Figure 3.4A shows that whilst the 
magnitude of cell replenishment of Mtb-specific and SEB-responding CD4+ T cells 
was comparable to that of total CD4+ T cells (approximately a two-fold increase over 
the 12 months of ART), the extent of restoration of CMV-specific CD4+ T cells was 
significantly lower (p=0.018, p=0.013 and p=0.0008, to Mtb, SEB and total CD4+ 
cells, respectively). Consistent with these observations, the degree of restoration of 
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Mtb- and SEB-responding CD4+ T cells corresponded closely with the overall CD4 
recovery, as measured in fold-change of the absolute CD4 count, with a slope close to 
1 (Figure 3.4B). In contrast, for CMV-specific CD4+ T cell responses the slope was 
0.37, indicating a reduced replenishment rate of these cells compared to the total CD4 
compartment (Figure 3.4B). Of note, whilst all study participants were CMV 
seropositive, none had detectable CMV viral replication at either visit, pre- or post-
ART, indicating that a difference in CMV antigen load at the two visits was not a 
contributing factor to the reduced replenishment capacity of CMV-specific T cells. 
 
Figure 3. 4. Restoration dynamics of Mtb-, CMV- and SEB-specific CD4+ T cells after 
ART. (A) Fold change in the total, Mtb-, CMV- and SEB-specific absolute CD4+ T cell count 
over 12 months of ART. The horizontal dotted line indicates no change from the baseline pre-
ART time point. Statistical comparisons were performed using a non-parametric Mann-
Whitney test. (B) Association between the fold change of the absolute number of antigen-
specific CD4+ T cells and the fold change in the absolute CD4 count pre- and post-ART. 
Statistical associations were performed by a two-tailed non-parametric Spearman rank 
correlation. The solid line represents a linear regression fit, and the dashed line depicts the 
ideal slope of 1. 
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3.4.3 Effect of ART on the functional capacity of co-pathogen-specific CD4+ T cells  
ART has been shown to gradually restore the polyfunctional capacity of HIV-specific 
T cells (Rehr et al., 2008; Mahnke et al., 2012), but the effect of ART on the 
functionality of CD4+ T cells specific for other pathogens is unclear. Thus, we 
evaluated the cytokine secretion profiles of Mtb-, CMV- and SEB-reactive CD4+ T 
cells before and after ART initiation in detail (Figure 3.5). We included 9 HIV-
uninfected individuals in this analysis for comparison. Our first finding was that the 
cytokine production profile of CD4+ T cells varied significantly according to their 
specificity (p=0.002, Figure 3.5A), with Mtb-specific responses consisting of a greater 
proportion of polyfunctional cells producing all three cytokines, in addition to a 
predominant TNF-α monofunctional subset (~40% of the response), whilst CMV-
specific CD4+ responses exhibited predominantly a IFN-γ+TNF-α+ phenotype 
(~60%; Figure 3.5B). ART did not significantly alter the cytokine secretion profile of 
CD4+ T cells from baseline, regardless of their specificity for Mtb, CMV or SEB 
(Figure 3.5A&B). Moreover, the polyfunctional characteristics of Mtb-specific and 
SEB-responsive CD4+ T cell responses were comparable to those observed in HIV-
uninfected individuals. In contrast, CMV responses were significantly skewed in HIV-
infected individuals compared to HIV-uninfected subjects (p=0.016 and p=0.045 for 
pre- and post-ART, Figure 3.5A), with a lower proportion of cells co-producing IFN-
γ, IL-2 and TNF-α, and a higher proportion of IFN-γ monofunctional cells (Figure 
3.5B). These data demonstrate that, unlike for Mtb-specific CD4 responses, HIV 
infection impaired the functional potential of CMV-specific CD4 responses towards a 
less polyfunctional profile, and one year of ART did not restore the CMV functional 
profile.  
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Figure 3. 5. Polyfunctional capacity of Mtb-, CMV- and SEB-specific CD4+ T cells in 
HIV-infected and uninfected individuals pre- and post-ART. Pie charts (A) and graphs (B) 
representing the cytokine secretion ability of Mtb-, CMV- and SEB-specific CD4+ T cell 
responses in HIV-uninfected individuals (n=9) and HIV-infected individuals pre-and post-
ART initiation. Each section of the pie chart represents a specific combination of cytokines, 
as indicated by the color at the bottom of the graph. Horizontal bars depict the median with 
interquartile range indicated. Statistical comparisons were performed using a Wilcoxon rank-
sum test. *p < 0.05, **p < 0.01, ***p < 0.001. 
3.4.4 Impact of the memory phenotype of pathogen-specific CD4+ T cells on their 
replenishment potential upon ART 
Depending on their memory differentiation profile, CD4+ T cells are endowed with 
distinct survival and proliferation capacities (Sallusto et al., 1999, 2004). Thus, to 
investigate whether the cell maturation phenotype could impact the replenishment 
capacity of co-pathogen-specific CD4+ T cells, we first compared the differentiation 
profiles of Mtb- and CMV-specific CD4+ T cells at baseline, prior to ART initiation. 
Figure 3.6A shows a representative contour plot of distinct memory subsets in the 
CD4 compartment pre-ART in one HIV-infected individual. Based on the expression 
of CD45RO and CD27, we were able to discriminate four different memory 
subpopulations (Riou et al., 2012), namely: Naive (CD45RO-CD27+), Early 
Differentiated (ED: CD45RO+CD27+, encompassing central and transitional memory 
Pie Slice
T
2
G
0
20
40
60
80
100
+
+
+
+
+
-
+
-
+
-
+
+
+
-
-
-
+
-
-
-
+
Pie Slice
T
2
G
0
20
40
60
80
100
+
+
+
+
+
-
+
-
+
-
+
+
+
-
-
-
+
-
-
-
+
Mtb 
SEB 
CMV 
Pre-ART Post-ART 
IFN-γ 
IL-2 
TNF-α 
Mtb 
SEB 
CMV 
HIV- 
Pre-ART 
%
 o
f t
ot
al
 a
nt
ig
en
-s
pe
ci
fic
 C
D
4+
 T
 c
el
ls
 
A B 
p=
0.
00
2 
p=
0.
00
2 
p=
0.
00
2 
ART: Pre ART: Post>6M
ART: Pre
HIV: -
HIV- 
HIV+ 
p=0.016 
p=0.045 
Post-ART 
ART: Pre
HIV: -
** 
* 
** 
** 
* 
ART: Pre
HIV: -
 
 
 Pie SliceT
2
G
0
20
40
60
80
100
+
+
+
+
+
-
+
-
+
-
+
+
+
-
-
-
+
-
-
-
+
 
  
 
 
 
 
 
 
n=9 n=11 
n=8 n=10 
n=9 n=12 
Pie Slice
T
2
G
0
20
40
60
80
100
+
+
+
+
+
-
+
-
+
-
+
+
+
-
-
-
+
-
-
-
+
ART: Pre
HIV: +
ART: Post>6M
HIV: +
* ** 
ART: Pre
HIV: +
ART: Post>6M
HIV: +
 78 
subsets), Late Differentiated (LD: CD45RO+CD27-, encompassing effector memory 
cells) and Terminally Differentiated (TD: CD45RO-CD27-, or effector cells). In HIV-
infected subjects, although Mtb- and CMV-specific CD4+ T cells were represented in 
both ED and LD subsets, they comprised significantly distinct profiles (Figure 3.6B, 
left panel). Mtb-specific cells exhibited primarily an early-differentiated profile 
[median 51%, interquartile range (IQR) 42-62], whereas CMV-specific cells 
demonstrated a substantial enrichment of the late differentiated phenotype (median 
73%, IQR 48-86), as previously described (Casazza et al., 2006). Of note, ART did 
not markedly alter the overall memory differentiation profile of Mtb-specific or CMV-
specific CD4+ T cells (Figure 3.7). In addition, HIV-uninfected individuals exhibited 
similarly distinctive memory CD4 differentiation profiles for Mtb and CMV (Figure 
3.6B, right panel).  
 
 
Figure 3. 6. Memory profiles of Mtb- and CMV-specific CD4+ T cells in HIV-infected 
and uninfected individuals. (A) Representative example of total CD4 memory subset 
distribution in one HIV-infected individual. Naive: CD45RO-CD27+, Early Differentiated 
(ED: CD45RO+CD27+), Late Differentiated (LD: CD45RO+CD27-) and Terminally 
Differentiated (TD: CD45RO-CD27-). The frequencies of each subset are indicated. (B) 
Memory profile of Mtb- and CMV-specific CD4+ T cells in HIV-infected individuals pre-
ART (left panel) and HIV-uninfected individuals (right panel). Results are shown as box and 
whisker (10-90 percentile) plots. Each dot depicts an individual and the horizontal bar is the 
median. Statistical comparisons were performed using a one-way ANOVA non-parametric 
Kruskal-Wallis test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 3. 7. Comparison of the memory profile of Mtb- and CMV-specific CD4+ T cells 
pre- and post-ART. Memory profile of total CD4+ T cells (A), Mtb-specific CD4+ T cells 
(B) and CMV-specific CD4+ T cells (C) pre- and post-ART initiation. For comparison the 
memory profile of total and antigen-specific CD4 responses in HIV-uninfected individuals 
(n=9) is presented on each graph with open circles. Each symbol represents one individual. 
Statistical comparisons were performed using a Wilcoxon matched pairs test for comparison 
of pre- and post-ART time points and the Mann Whitney test for comparisons with HIV-
uninfected individuals. * p < 0.05.  
 
We next investigated the relationship between the memory phenotype of pathogen-
specific CD4+ T cells at the time of ART initiation and the capacity of these cells to 
be maintained and/or replenished upon treatment. Figure 3.8A shows that the fold 
change in the absolute number of pathogen-specific CD4+ T cells over 12 months on 
ART inversely correlated with the proportion of cells exhibiting a late differentiated 
phenotype (p=0.019, r=-0.5). Consistent with this, a positive correlation was observed 
between the fold change in the absolute number of pathogen-specific CD4+ T cells 
and the proportion of these cells exhibiting an early-differentiated phenotype (p=0.04, 
r=0.45). Of note, the proportion of late-differentiated Mtb-specific CD4+ T cell 
responses (in the absence of CMV responses) also correlated inversely with the fold 
change in the absolute number of Mtb-specific cells (r=-0.62, p=0.038, data not 
shown), and so too when ‘naïve-like’ Mtb-specific cells were grouped together with 
ED cells, we observed a trend towards a positive association with the fold change in 
the absolute number of Mtb-specific cells (r=0.54, p=0.05, data not shown). This 
relationship between the memory profile and the ART-induced repletion potential of 
pathogen-specific CD4+ T cells is further illustrated in Figure 3.8B, showing specific 
examples from two participants. In CAP257, where the pre-ART CMV-specific CD4 
response showed an enrichment in cells with a late differentiated phenotype (82%), 
their ability to expand over 12 months on ART was considerably lower than Mtb-
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specific CD4 responses, characterised by an early differentiated phenotype (77.4%) 
(Fold change 1.2 for the CMV response vs. 2.8 for the Mtb response). In CAP244, 
where the memory profile of both Mtb and CMV-specific responses were similar 
(~60% of late differentiated cells), the fold change in the absolute number of CD4+ T 
cells to both pathogens was comparable.  
Overall, these data reveal that the ability of co-pathogen-specific memory CD4+ T 
cells to expand upon ART appears to be related to their memory phenotype, where 
early differentiated cells have a higher replenishment capacity compared to late 
differentiated cells.  
 
Figure 3. 8. Relationship between the memory profile of Mtb- and CMV-specific CD4+ 
T cells and the dynamics of restoration of these cells. (A) Association between the 
proportion of antigen-specific CD4+ T cells exhibiting a late differentiated (LD; top panel) or 
early differentiated (ED; bottom panel) profile with the fold change in antigen-specific CD4+ 
T cell absolute count after ART. Statistical associations were performed by a two-tailed non-
parametric Spearman rank correlation. (B) Representative examples of the memory profile of 
Mtb- or CMV-specific CD4+ T cells pre-ART in two individuals. The frequencies of each 
subset are indicated. For each example, the fold change in antigen-specific absolute CD4+ T 
cell count pre-and post-ART is indicated at the top of each plot.  
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3.5 Discussion 
The introduction of ART has changed the clinical pattern of HIV infection 
significantly, with considerable reductions in morbidity and mortality. Whilst it is 
clearly established that ART leads to a progressive replenishment of the CD4+ T cell 
compartment in the majority of cases, the extent to which pre-existing co-pathogen-
specific CD4+ T cells are restored, and the causes of variable restoration, are poorly 
defined. In this study, we investigated the dynamics of restoration of memory CD4+ 
T cells specific for a bacterial co-pathogen (Mtb) and a viral pathogen (CMV) in 15 
HIV-infected individuals in response to ART. Our main finding was that the extent of 
reconstitution of pathogen-specific cells was related to their memory differentiation 
profile at the time of ART initiation, where cells exhibiting an early differentiation 
memory profile (including central memory and transitional memory cells) had a higher 
replenishment potential compared to late differentiated (effector memory) T cells.  
Multiple mechanisms contribute to the increase in CD4+ T cells in blood in response 
to antiretroviral treatment for HIV (Wilson & Sereti, 2013). Over the first few months 
of ART, there is a redistribution of CD4+ T cells from the lymph nodes to the blood 
(Pakker et al., 1998; Bucy et al., 1999), leading to a rapid initial rise in CD4+ counts. 
Moreover, homeostatic cell proliferation (Marchetti et al., 2006), decreased cell death 
(Piconi et al., 2010) and increased thymic output (Delgado et al., 2002; Dion et al., 
2007) also play a role in the replenishment of CD4+ T cells. While the CD4 absolute 
cell count at the time of treatment initiation is one of the main factors dictating the 
level to which CD4+ T cells are restored (Kaufmann et al., 2005; Le et al., 2013), other 
parameters such as the activation level of T cells at the time of treatment (Goicoechea 
et al., 2006), age (Kaufmann et al., 2002; Allers et al., 2014) or active co-infections 
(Almeida et al., 2007; Kaufmann et al., 2011) also influence the degree of 
reconstitution of the CD4 compartment. Thus, CD4+ T cell recovery upon ART 
appears to be dependent on both the extent of immune damage at the time of treatment 
initiation and the regenerative capacities of these cells.  
We demonstrate here that despite successful viral suppression and robust CD4 gains 
in the majority of participants, the dynamics of Mtb- and CMV-specific CD4+ T cell 
recovery were distinct. This shows that not all T cell subpopulations have the same 
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potential to be replenished. Several factors and/or cellular attributes could account for 
these differences. Firstly, the regenerative capacities of pathogen-specific CD4+ T 
cells could be determined by their intrinsic ability to survive or proliferate, and it has 
been clearly established that CD4+ T cells exhibiting an early differentiated memory 
profile have an enhanced survival and proliferative potential compared to cells with a 
late differentiated phenotype (Sallusto et al., 1999, 2004). Our data are in accordance 
with these observations, showing that the extent of replenishment of pathogen-specific 
CD4+ T cells correlates with their memory status, with superior recovery observed for 
antigen-specific CD4+ T cells exhibiting an early memory phenotype. Mechanistically, 
cell responsiveness to common γ-chain cytokines may account for the distinct renewal 
potential of these different cell subsets (Ahlers & Belyakov, 2010, Hodge et al., 2011, 
Prezzemolo et al., 2014). In our study, the replenishment potential of Mtb- or CMV-
specific CD4+ T cells did not associate with their ability to produce IL-2 (data not 
shown), however we have observed that responsiveness to IL-7 distinguishes ED and 
LD CD4+ subsets, with ED memory T cells being more responsive to exogenous IL-
7 and IL-2 (as measured by Stat5 phosphorylation), compared with LD memory CD4+ 
T cells (C. Riou, unpublished observation). Further analysis comparing the level of 
expression of cytokine receptors and cytokine-induced proliferation potential between 
Mtb- and CMV-specific CD4+ T cells would be needed to define the role of these 
signaling pathways in the restoration of immune memory cells upon ART.  
Although Mtb responses displayed primarily an early-differentiated phenotype, there 
were substantial inter-individual differences, ranging from 30% to 75% of the response. 
The CD4+ memory profile is dictated by numerous factors, including continual 
antigen exposure in high burden settings (Schuetz et al., 2012), previous TB, TB 
treatment and cure (Tapaninen et al., 2010; Adekambi et al., 2012; Marin et al., 2012). 
A recent study carried out in a similar geographic setting as the present study noted 
dynamic changes in the T cell response to Mtb in the context of latent TB infection 
and HIV co-infection (Mitchell et al., 2012). It is worth noting that we also detected 
antigen-specific cells with a ‘naïve-like’ phenotype, previously described for Mtb and 
other infections (Caccamo et al., 2006; Marin et al., 2012; Chatterjee et al., 2015). 
Although making up only a minor proportion of the total Mtb- and CMV-specific 
response, these cells expanded post ART in the majority of individuals compared to 
other memory subsets that were characterised by more variable expansion and 
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contraction. For CMV, this expansion led to a significantly greater frequency of this 
subset after ART. These cells may fall within the recently described memory stem cell 
subset, comprising memory cells endowed with a greater ability to proliferate and 
persist long-term compared to central memory (Gattinoni et al., 2011; Lugli et al., 
2013). Thus, the composition of the memory pool at the time of ART initiation may 
influence the restoration of antigen-specific CD4+ T cells.  
To determine whether short-term ART affected not just quantitative but also 
qualitative aspects of co-pathogen immunity, we assessed the ability of cells to 
simultaneously secrete multiple cytokines, which for some infections, such as HIV and 
leishmaniasis, are a correlate of immune control or protection (Betts et al., 2006; 
Darrah et al., 2007). Although the significance of polyfunctional cells in TB is unclear 
(Prezzemolo et al., 2014), we demonstrated that over 50% of Mtb-specific CD4+ cells 
produced three or two cytokines simultaneously, a profile that did not significantly 
change after ART; moreover, this was similar to the profile from HIV-uninfected 
individuals. Our data are in apparent contrast to previous findings (Sutherland et al., 
2010) showing that ART leads to an improved polyfunctional profile in Mtb-specific 
CD4+ T cell after short-term treatment, but this may be due to cohort differences, as 
the participants in that study were characterised by more advanced 
immunosuppression and higher viral loads than in the present study. Since it has been 
reported that the impairment of the functional capacity of Mtb-specific CD4+ T cells 
is related to HIV disease status (Day et al., 2008), it is likely that differences in the 
severity of HIV pathology at the time of treatment initiation between the two studied 
groups could account for these discrepancies. The polyfunctional profile we observed 
for CMV-specific CD4+ cells is consistent with that previously reported (Casazza et 
al., 2006), with simultaneous IFN-γ and TNF-α, and IFN-γ alone dominating the 
response. The CMV profile also did not change after ART, and in this case was less 
polyfunctional compared to HIV-infected individuals. Our study only examined paired 
samples from 12 months after ART, and it is possible that prolonged ART may restore 
CMV functional profiles (Rehr et al., 2008).  
It is important to note that although we demonstrate an expansion of Mtb-specific 
CD4+ T cells after ART, restoration of the magnitude and measures of functionality 
of the Mtb-specific CD4+ Th1 response determined by the production of three 
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cytokines is a coarse measure of functional immunity to TB, and may not reflect 
protective immunity. Several additional CD4+ T cell subsets and cytokines contribute 
to TB immunity ( Scriba et al., 2008; McBride et al., 2013; Wozniak et al., 2010; 
Slight et al., 2013), and we have found an even greater diversity of CD4+ T cell subsets 
specific for Mtb (Riou et al., 2016). An additional issue is that we do not know the 
extent of pathogen-specific CD4+ recovery in tissues upon ART, which appears 
defective for TB in the lungs even after prolonged viral suppression (Jambo et al., 
2014). These considerations may account for the persistently greater susceptibility of 
successfully treated HIV-infected individuals to TB (Girardi et al., 2005). 
Our study had several limitations. We were constrained by the availability of paired 
samples prior to and after ART, limiting us to studying 15 individuals in detail. Testing 
the generalisability of our findings in larger cohorts is warranted. Also, we focused 
our study on short-term restoration of pathogen-specific immunity (after 1 year of 
ART), and although study participants exhibited suppressed HIV replication, 
decreased immune activation and improved CD4 counts, studying responses after 
longer-term therapy may provide further important insights and more definitive 
conclusions on the restoration of pathogen-specific immunity. Furthermore, the 
participants we studied had nadir CD4 counts of >135 cells/mm3 (median 289 
cells/mm3), and we did not have access to participants commencing treatment at lower 
CD4 counts (e.g. <50 cells/mm3). These highly immunocompromised patients would 
be the most relevant group to study with respect to susceptibility to CMV disease. In 
this context, although CMV-specific cells replenished more poorly than Mtb-specific 
cells after ART, they were present at a high frequency prior to ART initiation, that 
may well have been sufficient to provide protective immunity to CMV. While we did 
not observe a correlation between nadir CD4 counts and the degree of antigen 
replenishment likely due to a small sample size analysed, it is still plausible that the 
extent of CD4 depletion at the time of ART initiation could impact the degree and 
dynamics of antigen-specific CD4+ T cell recovery. Moreover, we delineated memory 
subsets based on two markers, CD27 and CD45RO. These markers cannot differentiate 
between central memory and transitional memory cells within the CD27+CD45RO+ 
ED subset, and inclusion of a marker such as CCR7 would afford an additional degree 
of distinction that may reveal further differences in the ability of these memory subsets 
to expand after ART, and should be included in future studies of reconstitution of 
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pathogen-specific immunity. Lastly, it would be of great interest to concomitantly 
evaluate the degree of replenishment of HIV-specific T cells. However, due to sample 
availability, we were not able to investigate the effect of ART on HIV-specific T cell 
responses. It has been shown that ART can induce an initial increase in HIV-specific 
T cell responses, but following complete suppression of HIV viral load there is a 
decline in HIV-specific T cell responses due to insufficient HIV antigen levels 
(Macatangay & Rinaldo, 2015). Further research addressing these important 
limitations is needed to confirm and extend our findings.  
Understanding the host and cellular factors that contribute to successful immune 
restoration on effective antiretroviral treatment for HIV, including both the overall 
CD4+ T cell compartment and co-pathogen-specific CD4 immunity, is of crucial 
importance, as only partial recovery of these cells could result in a persistently 
heightened risk of particular opportunistic infections. In this report, we showed that 
the renewal potential of pre-existing pathogen-specific CD4+ T cells was related to 
their memory differentiation profile. It will be important to determine whether this 
principle holds true in a wider context for other co-pathogens.  Incomplete restoration 
of functional immunity and the persistence of elevated susceptibility to particular co-
infections have implications for targeted interventions in the treated HIV-infected 
population. Overall, our findings underscore the complexity of immune reconstitution 
on ART, and the importance of preserving functional immunity with early ART.  
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CHAPTER 4 
Effect of antiretroviral therapy on the memory and activation profiles 
of B cells in HIV-infected African Women. 
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4.1 Abstract  
HIV infection induces a wide range of effects in B cells, including skewed memory 
cell differentiation, compromised B cell function and hypergammaglobulinaemia. 
However, data on the extent to which these B cell abnormalities can be reversed by 
antiretroviral therapy (ART) are limited. 
To investigate the effect of ART on B cells, the activation (CD86) and differentiation 
(IgD, CD27 and CD38) profiles of B cells were measured longitudinally in 19 HIV-
infected individuals before (median, 2 months) and after ART initiation (median, 12 
months) and compared to 19 age-matched HIV-uninfected individuals, using flow 
cytometry.  
Twelve months of ART restored the typical distribution of B cell subsets, increasing 
the proportion of naive B cells (CD27-IgD+CD38-) and concomitantly decreasing the 
immature transitional (CD27-IgD+CD38+), unswitched memory 
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(CD27+IgD+CD38-), switched memory (CD27+IgD-CD38- or CD27-IgD-CD38-) 
and plasmablast (CD27+IgD-CD38high) subsets. However, B cell activation was only 
partially normalised post-ART, with the frequency of activated B cells 
(CD86+CD40+) reduced compared to pre-ART levels (p=0.0001), but remaining 
significantly higher compared to HIV-uninfected individuals (p=0.0001). Interestingly, 
unlike for T cell activation profiles, the extent of B cell activation prior to ART did 
not correlate with HIV plasma viral load, but positively associated with plasma sCD14 
levels (p=0.01, r=0.58).  
Overall, ART partially normalises the skewed B cell profiles induced by HIV, with 
some activation persisting. Understanding the effect of HIV on B cell dysfunction and 
restoration following ART may provide important insights into mechanisms of HIV 
pathogenesis. 
4.2 Introduction 
Systemic immune hyperactivation is a hallmark of HIV infection, affecting a range of 
immune cells, including both T cells and B cells (Appay & Sauce, 2008). Multiple B 
cell defects have been reported in HIV-infected individuals, including alteration in the 
distribution of B cell memory subsets, with the accumulation of differentiated B cells 
(Moir et al., 2001, 2003, 2008; Malaspina et al., 2006), excessive B cell activation 
(Malaspina et al., 2003; De Milito et al., 2004;) and increased cell turnover (Kovacs 
et al., 2001). These B cell perturbations lead to functional abnormalities, as 
demonstrated by hypergammaglobulinemia, decreased B cell responsiveness to both 
T cell-dependent and T cell-independent antigens (Malaspina et al., 2005; Titanji et 
al., 2006; Hart et al., 2007) and compromised responses to vaccination (French et al., 
1998; Malaspina et al., 2005; Pasricha et al., 2006). 
The specific mechanisms contributing to B cell abnormalities are only partially known, 
and multiple factors may account for their dysfunction. HIV-driven alteration of the 
cytokine and chemokine environment has been described as a source of B cell 
dysfunction (Müller et al., 1998; Malaspina et al., 2006; Swingler et al., 2008; Lantto 
et al., 2015) and it has also been proposed that specific HIV proteins may have a direct 
effect on B cells (Schnittman et al., 1986; Swingler et al., 2003). Several studies, 
performed mostly in cross-sectional Caucasian cohorts, have investigated the effect of 
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antiretroviral therapy (ART) on B cells, reporting that suppressive ART can partially 
or completely normalise B cell phenotypic defects, as shown by the replenishment of 
naive B cells (D’Orsogna et al., 2007; Moir et al., 2008b, 2010; Amu et al., 2014), 
contraction of activated B cells (Moir et al., 2010; Pensieroso et al., 2013; Rethi et al., 
2013; Amu et al., 2014; Abudulai et al., 2016) and increase in B cell survival potential 
(van Grevenynghe et al., 2011). It is still uncertain, however, whether normalisation 
of B cell memory subsets results in improved B cell immune responses to antigens, 
including influenza, measles, pneumococcus and hepatitis B (Kroon et al., 1998; 
Malaspina et al., 2003; Titanji et al., 2006; Hart et al., 2007; Whitaker et al., 2012).  
There is a paucity of published studies on female and African populations with regard 
to B cell activation and restoration of B cell immunity following successful treatment 
of HIV (Béniguel et al., 2004; Longwe et al., 2010). There are cogent reasons to 
believe there may be differences in Africans compared to Caucasian cohorts. African 
cohorts have demonstrated higher baseline levels of T cell activation, significantly 
different T cell memory differentiation profiles (Eggena et al., 2005; Roetynck et al., 
2013), and consistently weaker cellular and humoral reactivity to some vaccines 
(Monath et al., 2002; Muyanja et al., 2014). A variety of factors may influence 
immune activation and therefore normalisation of immune profiles after ART, such as 
genetic, gender and environmental differences, the latter including higher antigenic 
exposure, diet and gut microbiota. Furthermore, a variety of sex-specific differences 
in the response to infections have been described. Women have higher levels of 
immune activation and faster progression of HIV disease than men with the same viral 
load (Meier et al., 2009). These effects have been attributed to oestrogen receptor 
signalling and/or differences in expression of key X-chromosome-expressed immune 
regulators, such as toll-like receptors and CD40L (Hagen & Altfeld, 2016). Additional 
factors such as HIV strains, treatment regimens and delayed access to HIV treatment 
could result in distinct outcomes with respect to immunity after ART. 
Thus, in this study, to define the extent to which ART restores B cell phenotype, we 
measured the memory differentiation and activation profiles of B cells longitudinally 
in chronically HIV-infected African women before and 12 months after ART initiation, 
and compared these profiles to age- and sex-matched HIV-uninfected individuals. 
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4.3 Materials and Methods 
4.3.1 Description of study participants 
Study participants consisted of 19 women from the Centre for the AIDS Programme 
of Research in South Africa (CAPRISA) 002 HIV acute infection cohort in KwaZulu-
Natal, previously described (van Loggerenberg et al., 2008; Mlisana et al., 2014). 
Peripheral blood samples were obtained at two time-points, during chronic infection 
pre-ART initiation, and post-ART initiation. With respect to ART regimens, 15 of the 
19 participants were taking current standard first-line therapy (TDF/3TC/EFV or 
TDF/FTC/EFV), and 1 each were taking D4T/3TC/EFV, D4T/3TC/NVP, 
AZT/3TC/NVP and AZT/3TC/LPV/r. One participant (CAP255) switched ART 
regimens during the study period (D4T/3TC/EFV to AZT/3TC/EFV at month 10). No 
participants had active TB during the study period, or exhibited any immune 
reconstitution inflammatory syndrome upon HIV treatment. An additional 19 HIV-
uninfected women who were matched for age and ethnicity were studied, from the 
CAPRISA 004 1% tenofovir microbicide gel trial (Abdool Karim et al., 2010). These 
women were either in the pre-intervention or in the placebo arms of the trial. For HIV-
infected individuals, either a prospective RNA positive/antibody negative reading or 
the midpoint between the last antibody negative test and the first antibody positive 
enzyme-linked immunosorbent assay test were used to determine the time after 
infection. HAART was given according to the South African national HIV treatment 
guidelines (at a CD4 count of <200 cells/mm3 prior to October 2012; <350 cells/mm3 
until March 2015). Ethical approval for the study was obtained from the Research 
Ethics Committees at the University of KwaZulu-Natal and University of Cape Town. 
All participants provided written informed consent prior to participating in the study. 
4.3.2 Measurements of HIV plasma viral load and CD4 counts 
Plasma HIV viral load and CD4 count were assessed at each study visit. Over the 
course of the study, the viral load PCR assay switched from Roche AMPLICOR HIV-
1 monitor test version 1.5 (lower detection limit (LDL) of 400 RNA copies/ml) to 
Roche Taqman version 1.0 in June 2010 (LDL 40 RNA copies/ml), and then to Roche 
Taqman version 2.0 in January 2012 (LDL 20 RNA copies/ml). The FACSCalibur 
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TruCOUNT method (BD Biosciences) was used to measure blood absolute CD4+ and 
CD8+ T cell counts. 
4.3.3  Sample processing 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque 
(Amersham Pharmacia) density gradient centrifugation and cryopreserved in freezing 
media [heat-inactivated foetal calf serum (FCS; Invitrogen) containing 10% 
dimethylsulfoxide (Sigma-Aldrich)]. Cells were stored in liquid nitrogen until use. 
Cryopreserved PBMC were thawed and rested in R10 (RPMI 1640 plus 10% heat-
inactivated FCS and 50 U/ml of penicillin-streptomycin) at 37°C with 5% CO2 for 3 
hours before staining. 
4.3.4 Antibodies, Surface and Intracellular staining (ICS)  
The following antibodies were used in three different staining panels: CD19 ECD (J3-
119), CD27 PE-Cy5 (1A4CD27; both Beckman Coulter), IgD APC-Cy7 (IA6-2), 
CD10 BV605 (HI10a), CD21 PE-Cy7 (Bu32), CD40 PerCP-Cy5.5 (5C3; all 
Biolegend), CD38 APC (HIT2), CD86 PE (IT2.2), CD3 PE-Cy7 (SK7), HLA-DR 
APC-Cy7 (L243; all BD Biosciences), CD4 PE-Cy5.5 (S3.5), CD8 Qdot-705 (3B5), 
CD19 Pacific Blue (SJ25-CI), CD14 Pacific Blue (Tük4), CD3 Pacific Blue (UCHT1), 
Ki67 FITC (7B11; all Invitrogen) and a violet viability reactive dye (“Vivid”; 
Molecular Probes). All antibodies were titrated prior to use to obtain optimal titres for 
staining. Briefly, PBMC were stained with Vivid, then labelled with antibodies against 
surface markers, fixed, permeabilised and subsequently stained intracellularly with 
Ki67. Cells were then re-suspended in 1X CellFix (BD Biosciences) and kept at 40C 
until acquisition. Samples were acquired on a BD Fortessa using FACSDiva software 
and analysed using FlowJo (version 9.9.3; TreeStar). The gating strategy to identify B 
cell subsets is shown in Figure 4.1. 
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Figure 4. 1. Gating strategies. A time gate was included to ensure no shift in fluorescence 
intensity over time, followed by a singlet gate to exclude doublets from the analysis. CD3 and 
CD14 markers were used to exclude T cells and monocytes, respectively, which were on the 
same channel as the viability dye Vivid, used to exclude dead cells. The core marker CD19 
was used to identify B cells. (A) Identification of B cell memory subsets based on IgD, CD27 
and CD38 expression. (B) Alternative gating strategy based on CD27, CD10 and CD21 
expression to delineate memory B cell subsets. 
4.3.5 Enzyme-linked Immunosorbent assays (ELISA) 
Plasma samples were used to measure soluble CD14 (sCD14, a marker of 
monocyte/macrophage activation) from the same women pre- and post-ART. One 
participant was not included in this analysis due to the sample being unavailable. 
Plasma (n=18) was tested in duplicate using commercially available ELISA kits 
according to the manufacturers’ protocol (R&D Systems). In addition, 30 plasma 
samples from HIV-uninfected women from the same cohort were included. Samples 
were diluted 1:200, data were collected using a SpectraMax Plus reader (Molecular 
Devices) and point-to-point curve fits were used to calculate sCD14 concentrations 
FSC-A 
SS
C
-A
 
Time 
C
D
27
 
FSC-A 
FS
C
-H
 
Ki67 
C
D
86
 
CD86 
C
D
40
 
Gated on CD27- Gated on CD27dim 
Proliferation Activation 
CD27 
FS
C
-A
 
Memory 
CD21 
C
D
10
 
B: Naive (CD10-CD21+CD27-) 
C: Tissue-like memory (CD10-CD21-CD27-) 
A: Immature transitional (CD10+CD27-) 
F: Plasmablasts (CD10-CD21-CD27bright) 
E: Activated memory (CD10-CD21-CD27dim) 
D: Resting memory (CD21+CD27dim) 
Gated on CD27bright 
Gated on CD19+ cells  A 
Gated on CD19+ cells B 
0 100 200 300
0
103
104
105
0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
0 103 104 105
0
103
104
105
0 103 104 105
0
103
104
105
0 102 103 104 105
0
103
104
105
0 103 104 105
0
50K
100K
150K
200K
250K
0 103 104 105
0
102
103
104
105
0 103 104 105
0
102
103
104
105
0 103 104 105
0
102
103
104
105A 
B C neg bright d
im
 
D 
E F 
CD27 
C
D
38
 
IgD 
0 103 104 105
0
103
104
105
0 103 104 105
0
103
104
105
C
el
ls
 
0 103 104 105
0
200
400
600
800
1000
Naive 
IT 
UnSw 
Memo 
PB 
Sw 
Memo 
27+ 
Sw 
Memo 
27- 
 94 
from the standard curves. Data were analysed using SoftMax Pro software (Version 
3.2.1; Molecular Devices). 
4.3.6 Statistical analyses 
Statistical analyses were performed using GraphPad Prism (version 5.0). The Mann-
Whitney U test and the Wilcoxon Signed Rank test were used for unmatched and 
paired samples, respectively. Correlations between the different groups were 
determined by the non-parametric Spearman Rank test. A p-value of <0.05 was 
considered statistically significant. 
4.4 Results 
4.4.1 Effect of antiretroviral therapy (ART) on the memory differentiation and 
activation of B cells 
To define the extent to which ART normalises HIV-induced alteration of B cells, we 
first determined the distribution of B cell subsets in 19 HIV-infected individuals before 
and one year after ART initiation, and compared it to 19 HIV-uninfected matched 
controls. Pre-ART samples were obtained during chronic infection at a median of 4.9 
years [Interquartile range (IQR): 2.8-5.8 years] after the estimated date of HIV 
infection, and a median of 1.5 months (IQR: 0.05-2.7) prior to starting ART. The 
median plasma viral load at this time was 34,325 HIV RNA copies/ml (IQR: 7,997-
78,573), and the median CD4 count was 314 cells/mm3 (IQR: 260-369) (Table 4.1). 
After a median of 12 months of treatment (IQR: 12-13 months), all individuals 
exhibited viral suppression (p=0.0001), the majority to <40 copies/ml, and an increase 
in both absolute CD4 count and CD4/CD8 ratio (both p=0.0001) (Table 4.1 and data 
not shown). 
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Table 4. 1. Clinical parameters of study participants.  
 
* Median and Interquartile range, NA: Not Applicable 
Figure 4.2A shows representative flow plots of each B cell subset from one HIV-
uninfected and one HIV-infected individual pre- and post-ART. Based on the 
expression of CD27, IgD and CD38, six B cell subsets were identified, namely 
immature transitional B cells (CD27-IgD+CD38+), naive B cells (CD27-IgD+CD38-), 
unswitched memory (CD27+IgD+CD38-), CD27+ switched memory B cells (IgD-
CD38-), CD27- switched memory B cells (IgD-CD38-) and plasmablasts (CD27+IgD-
CD38high). There was a marked skewing of B cell subsets in chronic HIV infection 
prior to ART (Figure 4.2B). When compared to HIV-uninfected participants, HIV-
infected individuals were characterised by significantly higher frequencies of 
immature transitional B cells, unswitched memory B cells and plasmablasts (median: 
9.3% [IQR: 6.3-13.3] vs 14.8% [IQR: 10.6-20]; 1.5% [IQR: 1.2-1.7] vs 2.3% [IQR: 2-
5.8] and 0.44% [IQR: 0.3-1] vs 2.1% [IQR: 1.4-4], respectively), and significantly 
lower proportions of naive B cells (median: 65.8% [IQR: 60-72.1] vs 46.9% IQR: 
39.7-55.7) (Figure 4.2B). Additionally, the frequencies of switched memory B cells, 
expressing CD27 or not were comparable in HIV-uninfected and ART naive HIV-
infected individuals (~8% and ~12%, respectively). It is worth mentioning that the 
frequency of un-switched memory B cells in our healthy study population was about 
7 times lower when compared to a previous study reporting that the proportion of 
unswitched memory was comparable to switched memory (representing about 15% of 
total B cells) in a predominantly male cohort from London (Hart et al., 2007). This 
could be explained by major differences in the study cohort such as sex, geographical 
location and low versus high disease burden country. Following 12 months of ART, 
the frequency of immature transitional, naive and unswitched memory B cells were 
normalised, returning to levels comparable to those observed in HIV-uninfected 
individuals (Figure 4.2B). The frequency of plasmablasts was also reduced in 
response to ART (p=0.004), but remained significantly elevated compared to the HIV-
HIV-infected HIV-infected  
(pre-ART) (post-ART)
Sample size 19 19 (paired) 
CD4 count (cells/mm3) * 314 [260-369] 629 [514-696] p=0.0001
CD4/CD8 ratio * 0.23 [0.18-0.33] 0.61 [0.48-0.74] p=0.0001
Viral load (RNA copies/ml) * 34,325 [7,997-78,573] <20 [<20-39] p=0.0001
Duration of ART (months) * NA 12 [12-13]
P-value
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uninfected group. To further define the restoration dynamics of B cell subsets upon 
ART, we compared the fold change in their frequencies pre- and post-ART. After one 
year of ART, only naive B cells displayed an overall expansion (median 1.3 fold [IQR: 
1.2-1.5]); amongst the subsets decreasing upon ART, plasmablasts exhibited the 
largest contraction, with a median fold change of 0.38 [IQR: 0.22-0.72]. The 
contraction of other B cells subsets was more moderate with a median fold change of 
0.51 [IQR: 0.39-0.92] for unswitched memory B cells, 0.65 [IQR: 0.37-0.77] for 
immature transitional B cells, 0.79 [IQR: 0.5-1] for CD27+ switched memory B cells 
and 0.87 [IQR: 0.69-1] CD27- switched memory B cells (Figure 4.2C). Although 
ART had a predominant effect on reducing the frequency of plasmablasts (~60% 
reduction), this was not sufficient for their normalisation with respect to HIV-
uninfected individuals.  
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Figure 4. 2. Effect of ART on the memory differentiation profile of B cells. (A) 
Representative flow plots of CD27, IgD and CD38 expression in B cells from one HIV-
uninfected and one HIV-infected (pre- and post-ART) individual. Numbers represent the 
frequencies of each B cell subset, namely immature transitional (CD27-IgD+CD38+), naive 
(CD27-IgD+CD38-), Unswitched memory (CD27+IgD+CD38-), switched CD27+ memory 
(IgD-CD38-), switched CD27- memory (IgD-CD38-) and plasmablasts (CD27+IgD-
CD38high). (B) Frequencies of B cell subsets in HIV-uninfected (n=19; open circles) and 
HIV-infected pre- and post ART (n=19; closed circles) individuals. Horizontal lines indicate 
the median. Statistical significance was calculated using a Mann-Whitney U test and Wilcoxon 
Signed Rank for unpaired and paired samples, respectively. (C) Fold change in the frequency 
of B cell subsets over 12 months of ART. Data are shown as box and whisker (interquartile 
range) plots. The vertical dotted line indicates no change from the time point prior to ART. 
Statistical comparisons were calculated using a one-way ANOVA test. *p < 0.05, **p < 0.01, 
***p < 0.001. 
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Alternative B cell markers such as CD27, CD10 and CD21 have been used to delineate 
B cell memory subsets (Moir & Fauci, 2009), allowing for the identification of three 
additional B cell memory subsets, namely tissue-like memory (CD10-CD21-CD27-), 
resting memory (CD21+CD27dim) and activated memory (CD10-CD21-CD27dim) B 
cells (Figure 4.1B). The expression of CD10 and CD21 on B cell subsets is shown in 
Figure 4.3. Thus, to validate our data, we defined the evolution of B cell memory 
subpopulations pre- and post-ART using this set of markers in 10 of the HIV-infected 
individuals from our study (Figure 4.4). ART led to a significant reduction in the 
frequencies of tissue-like memory, activated memory B cells and plasmablasts, and an 
increase in the frequencies of naive and resting memory B cells. These observations 
confirm the data described above, and are in line with published data (Moir et al., 
2010). Of note, using this alternative gating strategy, we found no significant 
difference in the frequencies of immature transitional B cells between the two time-
points. This may be due to the small sample size (a subset of n=10) used for this set of 
markers, since further analysis of the same individuals using IgD, CD38 and CD27 
also showed no significant difference in immature transitional B cells (data not shown). 
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Figure 4. 3. Expression of CD10 and CD21 in B cell subsets delineated using IgD, CD27 
and CD38 expression. (A) Representative flow plots from one HIV-infected individual after 
ART. (B) Frequencies of CD10 and CD21 in each B cell subsets in HIV-infected individuals 
post-ART (n=10). The majority (~70%) of immature transitional (IT) B cells express CD10, 
while all other B cell subsets were predominantly negative for this marker. CD10 expression 
on IT B cells may be an underestimation due to non-optimal CD10 separation. (C) Summary 
of the phenotype of B cells subsets. Although the majority of IT B cells express CD21, T1 IT 
B cells are CD21lo. 
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Figure 4. 4. Evolution of B cell subsets defined based on CD27, CD10 and CD21 
expression pre- and post-ART. (A) Frequencies of B cell subpopulations before and after 
ART in 10 HIV-infected participants. Horizontal lines indicate the median. Statistical 
significance was calculated using Wilcoxon paired test. (B) Stacked bar graph showing the 
median frequency of each B cell subset before and after ART. Each colour identifies a B cell 
subpopulation, as indicated in the adjacent key. The gating strategy is shown in Figure 4.1. 
The effect of ART on B cell activation and proliferation were also evaluated. Figure 
4.5A shows representative flow plots of B cell activation, measured as the frequency 
of B cells co-expressing CD86 and CD40, and proliferation (Ki67 expression) from 
one HIV-uninfected and one HIV-infected individual pre- and post-ART. The 
frequency of activated B cells (CD86+CD40+) was significantly higher in HIV-
infected subjects prior to ART compared to HIV-uninfected participants (median: 14% 
[IQR: 9.2-15.6] vs 1.7% [IQR: 1.3-2.3]; Figure 4.5B). In response to ART, the 
frequency of activated B cells was substantially reduced but remained significantly 
higher than HIV-uninfected participants (Figure 4.5B). It is important to mention that 
during HIV infection, activated B cells were mostly confined to switched memory 
cells (i.e. IgD- B cells), with a median of 25% (IQR: 19.6-32) of switched cells co-
expressing CD40 and CD86. On the contrary, the activation level of unswitched B 
cells (i.e. IgD+ B cells) was only marginal, with less that 5% of these cells positive for 
CD40 and CD86 (median: 4.5% [IQR: 2.4-5]; data not shown).  
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Similar to activated B cells, there were significantly more Ki67+ B cells in ART-naive 
HIV-infected individuals compared to HIV-uninfected controls (median: 5% [IQR: 
2.9-7.2] vs 1.3% [IQR: 0.9-1.6]); and while ART led to a significant decline in 
proliferating B cells, they remained elevated compared to the HIV-uninfected group 
(p=0.001, Figure 4.5C). Of note, the frequencies of proliferating (Ki67+) and 
activated (CD86+CD40+) B cells were positively associated with the frequency of 
plasmablasts following ART (p=0.004, r=0.62 and p=0.003, r=0.63, respectively, data 
not shown), suggesting that residual B cell activation and proliferation upon ART may 
be explained by the persistence of an elevated frequency of plasmablasts, consistent 
with our findings presented in Figure 4.2B. 
 
Figure 4. 5. Effect of ART on B cell activation and proliferation. (A) Representative flow 
plots of CD40, CD86 and Ki67 expression in B cells from one HIV-uninfected and one HIV-
infected (pre- and post-ART) individual. Numbers represent the frequencies of activated 
(CD86+CD40+) and proliferating (Ki67+) B cells. (B) Frequencies of CD86+CD40+ B cells 
in HIV-uninfected (n=19; open circles) and HIV-infected pre- and post-ART (n=19; closed 
circles) individuals. (C) Frequencies of proliferating B cells as measured by Ki67 expression. 
Horizontal lines represent the median. Statistical significance was calculated using a Mann-
Whitney U test and Wilcoxon Signed Rank for unpaired and paired samples, respectively. 
Overall, our data show that HIV infection skews the B cell memory differentiation 
profile and causes abnormal B cell activation and proliferation. Defects in B cell 
memory phenotype were largely normalised within one year of ART, while B cell 
activation and proliferative capacities were only partially reduced and longer periods 
of suppressive therapy may be required for normalisation. 
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4.4.2 B cell defects during HIV infection do not directly associate with HIV viral 
load 
It has been clearly established that hyperimmune activation of T cells during HIV 
infection is related to viral replication (Deeks et al., 2004) and is partially normalised 
upon ART (Hunt et al., 2003). This was confirmed in our experimental setting, where 
we had T cell activation data for 18 of the participants in the current study, as well as 
14 additional subjects from the same cohort. The proportion of activated CD4+ T cells 
(measured by the expression of HLA-DR) was positively associated with plasma viral 
load (p=0.001, r=0.54; Figure 4.6A) in HIV-infected subjects pre-ART. While 12 
months of ART led to a substantial reduction in the frequency of HLA-DR expression 
by T cells, T cell activation levels remained significantly higher than HIV-uninfected 
subjects (Figure 4.7). Thus, in order to determine whether HIV load was also the 
driving factor for B cell activation, we examined the relationship between B cell 
phenotype and HIV plasma viral load before ART initiation. As previously stated, 
switched memory B cells (i.e IgD- B cells) are highly activated during HIV infection, 
thus we focused our analyses on this particular subset. Surprisingly, unlike for T cells, 
we found no association between the frequency of activated (CD86+CD40+) switched 
memory B cells and HIV viral load (p=0.71, r=0.39; Figure 4.6B). Moreover, none of 
the B cell memory subset frequencies were found to be associated with viral load (data 
not shown). Finally, the extent of CD4+ or CD8+ T cell activation did not correlate 
with the level of switched B cell activation (p=0.78, r=0.07; Figure 4.6C and data not 
shown). Together, these results show that HIV differentially affects the T cell and B 
cell compartments, where B cell activation does not mirror T cell activation and is not 
directly associated with the levels of HIV. This suggests that additional factors besides 
HIV replication may contribute to B cell activation. 
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Figure 4. 6. Relationship between CD4+ T cell and B cell activation and plasma viral load 
pre-ART. Correlation of (A) the frequency of HLA-DR expressing CD4+ T cells (n=32) and 
(B) the frequency of CD40+CD86+ switched memory B cells (n=18) and plasma viral load in 
HIV-infected individuals prior to ART initiation. (C) Correlation between B cell activation 
(CD86+CD40+) and CD4+ T cell activation (HLA-DR+) in 18 HIV-infected participants 
before ART. Statistical significance was calculated using a non-parametric Spearman Rank 
test. 
 
Figure 4. 7. Effect of ART on CD4+ and CD8+ T cell activation levels measured by HLA-
DR expression. (A) Representative flow plots of HLA-DR expression on T cells from one 
HIV-uninfected and one HIV-infected (pre- and post-ART) individual. (B) Frequencies of 
HLA-DR+ CD4+ and CD8+ T cells in 19 HIV-uninfected (open circles) and 18 HIV-infected 
(closed circles) individuals pre- and post-ART. Horizontal lines represent the median. 
Statistical significance was calculated using Mann-Whitney U test and Wilcoxon Signed Rank 
for unmatched and matched samples, respectively.  
4.4.3 Additional contributors of B cell defects during HIV infection 
The translocation of bacterial products, resulting from HIV-induced damage to the 
gastrointestinal tract, is an important contributor of systemic immune activation 
(Brenchley et al., 2007). Therefore, we investigated the relationship between the 
activation and skewed differentiation profile of B cells and the level of plasma sCD14, 
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a marker of monocyte/macrophage activation, that may be an indicator, in the absence 
of other infections, of microbial translocation. Prior to ART, plasma sCD14 levels 
associated negatively with the frequency of naive B cells (p=0.036, r=-0.50; data not 
shown) and positively with the frequency of immature transitional B cells (p=0.003, 
r=0.75; Figure 4.8A) and the frequency of activated (CD86+CD40+) switched 
memory B cells (p=0.01, r=0.58; Figure 4.8B). Moreover, a positive correlation was 
also observed between sCD14 levels and the frequency of activated HLA-DR+CD4+ 
T cells (p=0.045, r=0.49; Figure 4.8C). It is worth noting that the levels of plasma 
sCD14 were not significantly changed after 12 months of ART (Figure 4.9), and there 
were no associations with residual B cell activation post-ART (data not shown). 
 
Figure 4. 8. Relationship plasma sCD14 levels and B cell phenotype and CD4+ T cell 
activation pre-ART. Correlation of (A) the frequency of immature transitional B cells, (B) 
the frequency of CD86+CD40+ switched memory B cells and (C) and the frequency of HLA-
DR+ CD4+ T cells with plasma sCD14 levels in HIV-infected individuals (n=18 and n=17, 
respectively). Statistical significance was calculated using a non-parametric Spearman Rank 
test. 
 
 
Figure 4. 9. Effect of ART on plasma levels of sCD14. 
Soluble CD14 was measured in 18 HIV-infected women and 
30 HIV-uninfected women from the same community by 
ELISA (R&D Systems). Horizontal black lines represent the 
median. Statistical significance was calculated using a non-
parametric Wilcoxon matched test (pre- and post-ART) and the 
Mann-Whitney test for comparisons with HIV-uninfected 
individuals. 
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Overall, these data suggest a possible impact of microbial translocation on B cell 
dysfunction, as suggested by sCD14 levels correlating with HIV-induced B cell 
skewing and hyperactivation in untreated chronic HIV infection. However, their 
influence may be relatively minor, since there are consistently elevated levels of 
sCD14 after ART, when B cell defects are largely reversed. It is clear that a variety of 
factors may directly or indirectly influence B cell defects during HIV infection. 
4.5 Discussion 
Despite the fact that HIV does not directly infect B cells, the virus causes several B 
cell abnormalities that contribute to HIV pathogenesis (Moir & Fauci, 2013). Whilst 
these B cell defects may be reverted upon antiretroviral therapy (ART), this effect has 
mostly been studied in cross-sectional Caucasian cohorts. Thus, in this study, we 
assessed longitudinally the impact of ART on the memory and activation profile of B 
cells in South African adult women (n=19); and compared these profiles to age-
matched HIV-uninfected women from the same community (n=19). Our data show 
that 1) HIV-induced alterations of B cells did not associate with viral burden but rather 
correlated with plasma sCD14 concentration and 2) 12 months of ART largely 
normalised the distribution of B cell memory subsets whilst activation of B cells was 
only partially reduced.  
HIV induces multiple defects in B cells, altering their memory and activation profiles 
and function ( Moir et al., 2003; Ho et al., 2006; Malaspina et al., 2006; Moir & Fauci, 
2009). In our experimental setting, we showed that, in HIV-infected African women, 
B cells were skewed towards a more differentiated memory phenotype (with the 
accumulation of plasmablasts and the reduction of naive B cells) and were 
hyperactivated (as measured by CD86 expression) when compared to HIV-uninfected 
persons. These observations are in accordance with previous studies performed 
primarily in male Caucasian populations (Malaspina et al., 2003; Moir et al., 2003, 
2008b, 2010; Titanji et al., 2005; Ho et al., 2006), highlighting that similar 
abnormalities occur in African women. To date, the drivers of B cell alterations during 
HIV infection have not been fully elucidated. Even though HIV does not directly target 
B cells for infection, the interaction between HIV and B cells has been previously 
described, where HIV glycoprotein gp120 can bind to B cell receptors (such as CD21, 
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DC-SIGN and variable heavy chain 3 (VH3) immunoglobulin (Ig), resulting in 
polyclonal B cell activation and Ig production (Moir et al., 2000). Furthermore, HIV 
Nef can interact directly with B cells, resulting in suppression of Ig class switching 
(Qiao et al., 2006; Xu et al., 2009). How each of these mechanisms contribute to B 
cell dysfunction is unknown (Moir & Fauci, 2009). 
It has also been proposed that excessive B cell activation may be driven by pro-
inflammatory cytokines, such as IFN-α, TNF-α, IL-6 and IL-10, molecules commonly 
up-regulated during HIV-induced systemic inflammation (Ruffin et al., 2012). HIV 
infection also leads to increased production of B cell-specific growth factors such as 
BLyS/BAFF from macrophages, dendritic cells and granulocytes (Fontaine et al., 
2011; Poudrier et al., 2015; Gomez et al., 2016;), promoting B cell dysregulation right 
from the early stages of infection. Additionally, HIV pathogenesis has also been linked 
to extensive damage to the gastrointestinal tract, leading to the release of bacterial 
products into the circulation (Brenchley et al., 2007). These products may induce 
aberrant B cell activation via TLR signalling (Jiang, 2012), by both direct and indirect 
means. Stimulation of monocytes by bacterial LPS leads to the release of cytokines 
that contribute to the inflammatory environment. Additionally, human B cells express 
a range of TLRs, including high levels of TLR9 (Hornung et al., 2002), and abundant 
bacterial DNA as a result of HIV-induced microbial translocation (Jiang et al., 2009) 
may stimulate B cells directly. In fact, TLR9 stimulation of human B cells promotes 
their activation, proliferation and the generation of plasmablasts (He et al., 2004; Jiang 
et al., 2007). The potential role of microbial products as direct factors fuelling B cell 
hyperactivation is further inferred by the fact that in other chronic diseases leading to 
gut damage (such as inflammatory bowel disease), B cells exhibit aberrant activation 
profiles (Noronha et al., 2009).  
We found an association pre-ART of B cell activation and differentiation profile with 
the concentration of plasma sCD14, secreted upon monocyte/macrophage activation 
by LPS, which may be a surrogate marker of microbial translocation. Interestingly, 
whilst there was a relative normalisation of B cells post-ART, plasma sCD14 
concentration did not decrease overall upon treatment. This phenomenon has been 
observed in several studies, where sCD14 levels remain elevated even after several 
years on ART (d’Ettorre et al., 2014; Hattab et al., 2014; Rudy et al., 2015), and 
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unreversed damage to the gastrointestinal tract has been proposed to account for this. 
These data confirm that in African women, inflammation persists after ART even 
while there is a substantial decrease in cellular activation. The absence of any decrease 
in sCD14 after ART, despite a substantial normalisation of B cells profiles, suggests 
that sCD14 plays only a partial role in contributing to B cell activation. Alternatively, 
we could speculate that microbial translocation and viral-induced factors might act 
synergistically to drive B cell activation and skewing, and ART uncouples this effect 
by suppressing viral replication even in the face of ongoing inflammation. Whilst we 
did not find an association of HIV viral load with B cell dysfunction pre-ART, this 
relationship may not be linear, with a multitude of viral-induced factors influencing B 
cell activation and differentiation directly and indirectly (Haas et al., 2011). Overall, 
this suggests that a combination of inflammatory mediators such as cytokines, B cell 
growth factors and microbial products may directly and indirectly stimulate B cell 
differentiation and proliferation, favouring their functional impairment and exhaustion.  
Several studies have shown that ART leads to a near normalisation of peripheral B cell 
memory subsets (D’Orsogna et al., 2007; Moir et al., 2008b; Amu et al., 2014, 2016) 
and the extent of restoration was linked to the timing of ART initiation ( Pensieroso et 
al., 2009; Moir et al., 2010;), the duration of treatment or related to the age of the 
patients (Amu et al., 2014; Van Epps et al., 2014). Very limited data are available on 
the effect of ART on B cells in African cohorts. To our knowledge, only one cross-
sectional study has investigated how ART influences the restoration of B cell numbers 
in an African adult population (Longwe et al., 2010). It is of importance to define, in 
countries disproportionately affected by the HIV pandemic and where access to ART 
is limited and often started during advanced lymphopenia, whether HIV treatment can 
restore B cell profiles to similar levels observed in HIV-uninfected individuals (of note, 
the CD4 count pre-treatment in the participants included in this study was <350 
cells/mm3). Our data showed that while 12 months of ART largely normalised the 
distribution of memory subsets, B cell activation remained significantly elevated 
compared to HIV-uninfected individuals. The persistence of these cycling, activated 
B cells composed mainly of plasmablasts could reflect residual systemic inflammation, 
despite viral suppression. Indeed, it has been shown that even upon successful ART, 
inflammation, microbial translocation and germinal center destruction still persist 
(Brenchley et al., 2007; Levesque et al., 2009; Klatt et al., 2013; Ghislain et al., 2015). 
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These observations are in line with results reported in Caucasian cohorts (Moir et al., 
2008b, 2010; Fogli et al., 2012), showing that the normalisation of B cell subsets can 
be achieved even when treatment is initiated at a late stage of chronic HIV infection.  
The limitations of this study include a cohort exclusively composed of women; further 
studies could test the generalisability of our findings in men. Additionally, we only 
analysed B cells from peripheral blood and this may not be representative of B cell 
profile within the tissues; it is plausible that B cell residing in germinal center are 
differentially affected during HIV infection and that the extent and/or kinetics of their 
restoration during treatment may differ. For future studies, use of additional 
phenotypic markers such as CD10 and CD24 could improve the definition of B cell 
subsets, in particular immature transitional B cells. Furthermore, we did not examine 
the relationship of relative normalisation of B cell activation and differentiation with 
restoration of functional B cell immunity, which may not always return (Wheatley et 
al., 2016). Further studies of humoral immunity after ART, by investigation of both 
memory B cell responses and long-lived plasma cells to a variety of vaccines and 
infections, are warranted in larger African cohorts. This is particularly important if 
functional B cell immunity is not fully restored and revaccination to certain pathogens 
may be required. In this respect, early ART initiation, compared to those treated during 
chronic HIV infection, has demonstrated a benefit for restoration of B cell 
functionality (Moir et al., 2010).  
In conclusion, our study has shown that the B cell compartment is highly disturbed in 
chronically HIV-infected African women, an understudied group disproportionately 
affected by the HIV pandemic, as it is for Caucasian cohorts. Differences in 
methodology limit our ability to directly compare our results in African women to 
published studies in western cohorts, but we observed a substantial reduction in B cell 
activation and a relative normalisation of skewed B cell subsets as observed in 
Caucasian cohorts, despite the commencement of ART in chronic HIV infection. 
Identifying the drivers of B cell activation and defective differentiation may provide a 
better understanding of the mechanisms associated with B cell dysfunction. This can 
potentially lead to the development of intervention strategies to improve B cell 
function during HIV infection, for both HIV-specific humoral immunity and responses 
to vaccines targeting other pathogens. 
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CHAPTER 5 
Discussion 
Untreated HIV infection is associated with a profound loss in CD4+ T cells and a state 
of generalised immune activation (Okoye & Picker, 2013; Doitsh et al., 2014). 
Excessive activation of the immune system contributes to HIV pathogenesis and 
disease progression by causing several abnormalities in T cell and B cells, affecting 
both their phenotype and function, and hence impairing the generation of effective T 
cell and B cell responses both to HIV itself and other pathogens (Moir & Fauci, 2009; 
Saharia & Koup, 2013; Morou et al., 2014). The era of widespread ART has led to a 
significant decrease in morbidity and mortality, as well as reduced opportunistic and 
other infections in HIV-infected individuals (Guihot et al., 2011; Williams et al., 2011). 
However, despite inhibition of viral replication and improvement in CD4+ T cell 
numbers in the majority of treated patients, excessive immune activation may persist 
and influence CD4+ T cell reconstitution (Corbeau & Reynes, 2011). In addition, the 
extent to which functional immunity is fully restored after ART is not completely 
defined. For example, whether memory T cell and B cell subsets are fully normalised 
on ART, and the association with sustained immune activation, is poorly characterised. 
Furthermore, it is not known whether functional T cell immunity to specific co-
pathogens (Mtb and CMV) are restored upon ART, and what factors are associated 
with this recovery. The overall focus of this thesis was on the assessment of the 
influence of short-term (1 year) ART on the phenotype (activation, proliferation and 
memory differentiation) of T cells and B cells as well as the functional restoration 
(cytokine production) of T cell responses to co-pathogens in HIV-infected African 
women. Studying the changes in HIV-induced phenotypic and functional defects after 
therapy may reveal how these features may influence immunity after treatment, CD4+ 
reconstitution and continued susceptibility to infections.  
The cohort used for these experiments consisted of study participants in the CAPRISA 
acute infection study from the Durban and Vulindlela areas of Kwazulu-Natal, a 
province in South Africa where HIV incidence is the highest, particularly in women 
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(Huerga et al., 2016). The HIV incidence is a staggering estimate between 7 to 10 per 
100 person-years in women aged between 18 and 35 years (Abdool Karim et al., 2012; 
Nel et al., 2012) The CAPRISA acute infection study comprised a large cohort of HIV-
infected women recruited early in HIV infection to study the natural history of HIV 
infection in Southern Africa (van Loggerenberg et al., 2008); all women in the cohort 
were infected with subtype C (Williamson et al., 2003). Participants were followed for 
up to 4 years and roughly half of the women were found to be rapid progressors (CD4 
count <350 cells/µl within 2 years of infection; Mlisana et al., 2014). This is a well-
established cohort and comprehensive studies on these women have been previously 
conducted to characterise adaptive and innate immunity, host genetics and viral factors 
(Abrahams et al., 2009; Burgers et al., 2009; Gray et al., 2009; Mlotshwa et al., 2010; 
Chopera et al., 2011; Gray et al., 2011; Naranbhai et al., 2012; Riou et al., 2014; 
Bandawe et al., 2015). With regards to T cell immunity, one study showed that the 
memory phenotype of HIV-specific CD8+ T cells at 6-9 months after infection 
correlated with viral set point at 12 months (more differentiated HIV-specific CD8+ T 
responses correlated with a higher viral load set point; Burgers et al. 2009). In terms 
of B cell responses to HIV, broadly neutralising antibodies were identified in certain 
individuals in the CAPRISA 002 cohort (Gray et al., 2011). These and other extensive 
studies performed in the CAPRISA 002 cohort have underlined important parameters 
of the immune response to HIV that are associated with disease progression in a cohort 
of African HIV-infected women. In relation to these past findings, our study further 
characterised these women as they initiated ART to determine the degree to which 
functional immune recovery occurred, and what factors influenced this restoration. 
Limited data are available on the effect of ART on T cells and B cells in African 
cohorts, which are less well-studied than Caucasian cohorts. Thus, it was of particular 
importance to assess whether ART could normalise HIV-induced cellular defects, 
particularly in individuals from countries extremely affected by the HIV pandemic, 
and where access to ART is often initiated during advanced lymphopenia (of note, the 
CD4 count pre-ART for the participants in our study was <350 cells/mm3). 
During HIV infection, the process of immune activation induces the activation, 
proliferation and differentiation of T cells, creating more CD4+ target cells for HIV 
and fuelling continued HIV replication (Paiardini & Müller-Trutwin, 2013). The 
attempt to constantly replenish the pool of T cells to balance their loss results in the 
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exhaustion and dysfunction of the immune system (McCune, 2001). Chapter 2 
investigated the effect of HIV on the phenotype of T cells during chronic HIV infection. 
Increased T cell activation, proliferation and differentiation was observed in HIV-
infected individuals compared to uninfected individuals. In addition to T cell defects, 
HIV causes alterations in the phenotype of B cells, inducing B cell dysfunction (Moir 
et al., 2003; Malaspina et al., 2006; Moir & Fauci, 2009). Chapter 4 determined the 
effect of HIV on B cells, and as for T cells, data indicated higher B cell activation, 
proliferation and differentiation in the blood of HIV-infected women compared to 
healthy controls. To date, the mechanisms and drivers of T cell and B cell 
abnormalities during HIV infection are not fully understood. A positive association 
was found between plasma viral load and T cell activation but not B cell activation, 
implying that HIV replication levels have a more direct effect on activating T cells. 
An indirect mechanism mediating immune activation involves severe damage to the 
gastrointestinal mucosal surfaces during HIV infection, resulting in microbial 
translocation, where bacterial components (such as LPS) released into the bloodstream 
mediate immune activation (Brenchley et al., 2007). Human T cells and B cells express 
no or low levels of TLR4 (Hornung et al., 2002) and the fact that we found an 
association between the levels of both activated T and B cells and the concentration of 
plasma sCD14 imply an indirect activation of both subsets, likely through 
monocyte/macrophage activation by LPS, as previously described (Brenchley et al., 
2007; Marchetti et al., 2008; Jiang, 2012). All together, our results indicate that in the 
absence of treatment, individuals with chronic HIV infection in our cohort displayed 
substantial perturbations in both T cell and B cell subsets, likely affecting the function 
of these cells. 
HIV infection does not only result in a global depletion in CD4+ T cells, but memory 
CD4+ T cells specific for the virus and other pathogens (such as Mtb and CMV) are 
also lost, impairing the generation and preservation of T cell responses (Douek et al., 
2002; Geldmacher & Koup, 2012). In this study, Chapter 3 investigated whether pre-
existing memory CD4+ T cells specific for common co-pathogens, Mtb and CMV, are 
recovered upon suppression of HIV by treatment, by assessing their frequency, 
functional capacity and memory profile before and after ART. We found no change in 
the frequency of Mtb-specific CD4+ T cells and a substantial decrease in the frequency 
of CMV-specific CD4+ T cells post-ART, consistent with previous reports (Hsu et al., 
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2013; Jambo et al., 2014). In addition, the polyfunctional profile of both co-pathogens 
did not differ before and after ART. Our data for Mtb are in contrast with Sutherland 
and colleagues, who reported that short-term ART increases the polyfunctional 
capacity of Mtb-specific CD4+ T cells (Sutherland et al., 2010). This may be explained 
by differences in the cohort, as the subjects in their study were characterised by more 
advanced immunosuppression and higher viral loads compared to participants in our 
cohort. Most importantly, our data showed for the first time that the degree of 
replenishment of co-pathogen specific CD4+ T cells is associated with their memory 
status pre-ART, with greater recovery for cells exhibiting an early differentiated 
memory profile (such as most Mtb-specific CD4+ T cells). This suggests that the 
renewal potential of T cells depends on the state in which they are found prior to ART, 
and the targeted pathogen. 
Multiple factors have been associated with the extent of CD4+ T cell recovery in 
treated individuals, including the absolute CD4 count at ART initiation and T cell 
activation levels at the time of treatment (Kaufmann et al., 2005; Goicoechea et al., 
2006; Le et al., 2013). Our sample size was too small to identify whether these factors 
influenced the reconstitution of T cells in treated patients in this cohort. Nonetheless, 
in Chapter 2, we showed that short-term ART substantially but only partially 
normalised T cell activation levels and differentiation profiles compared to uninfected 
controls. The substantial decrease in activation was not just limited to T cells, as a 
significant decrease in B cell activation and a relative normalisation of skewed B cell 
subsets were observed in the same ART-treated individuals (Chapter 4). Together, 
these data indicate that 1 year ART partially normalised both compartments (T cells 
and B cells). However, the fact that ART was initiated during the chronic stage of HIV 
infection may explain in part why complete normalisation did not occur in these 
individuals. In line with this, several studies have reported that the degree of 
restoration of T cell and B cell phenotypes is dependent on the timing of ART initiation, 
where a more complete normalisation of T cell and B cell subsets to levels found in 
healthy individuals occurs when ART is initiated during primary HIV infection 
(Kaufmann et al., 2000; Moir et al., 2010; Allers et al., 2014). In addition, HIV-
infected individuals who initiated ART early (<6 months after infection) exhibited 
reduced T cell activation compared to those who started ART late (≥2 years after 
infection) (Jain et al., 2013). Together, these reports imply that alterations of the 
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immune system are less pronounced in early stages of HIV infection, hence leading to 
a better immune recovery. However, it is important to note that despite early 
administration of ART, levels of T cell activation are still not fully normalised 
(Kaufmann et al., 2000; Jain et al., 2013). 
High levels of immune activation on successful ART have been previously reported 
in HIV-individuals and are associated with cardiovascular disease and mortality 
(Küller et al., 2008; Hunt et al., 2011a; Kaplan et al., 2011; Sandler et al., 2011). To 
date, the mechanisms potentially contributing to this sustained immune activation 
despite effective therapy have not been fully elucidated. Residual viral replication may 
be responsible for prolonged immune activation during ART (Corbeau & Reynes, 
2011). Viral reservoirs established early in HIV infection may persist during 
antiretroviral treatment either because the drugs are unable to reach these sites or due 
to the maintenance of long-lived latently infected cells that allow replication during 
natural homeostatic processes of cell turnover (Chun et al., 1997; Finzi et al., 1997; 
Siliciano et al., 2003; Chomont et al., 2009). In addition, the breach in mucosal 
surfaces in the gastrointestinal tract (gut damage) as a result of HIV infection may be 
irreversible in many patients even with early initiation of ART, suggesting ongoing 
bacterial translocation driving residual immune activation (Brenchley et al., 2007; 
Jenabian et al., 2015). Together, these factors promote HIV persistence and impede 
HIV cure. The size of the latent viral reservoir has been associated with residual 
immune activation and HIV replication during ART, and HIV individuals who 
initiated ART early (<6 months after infection) were found to have lower T cell 
activation levels and a smaller HIV reservoir (Jain et al., 2013; Cockerham et al., 2014; 
Ruggiero et al., 2015). Interestingly, some “shock and kill” strategies to purge HIV 
reservoirs are testing TLR agonists (the very molecules that contribute to immune 
activation during infection) to reactivate virus from latently infected cells. However, 
this method may also contribute to systemic immune activation via TLR signaling 
further sustaining viral replication, and would have to be administered in conjunction 
with ART to prevent the seeding of new reservoirs (Battistini & Sgarbanti, 2014). 
Alternative therapeutic approaches are required for restoring gut damage and 
controlling immune activation, thereby possibly decreasing the size of the HIV 
reservoir (Sandler & Douek, 2012). The most recent WHO guidelines recommend 
ART be initiated regardless of CD4 counts (WHO, 2015), as has now been 
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implemented in South Africa. Earlier treatment may improve the likelihood of full 
immune recovery over time, before irreversible damage to the immune system is 
established. 
Limitations and future studies  
There were a number of limitations to these studies to be highlighted, that can be 
addressed in follow-up studies. Our cohort consisted exclusively of women and 
previously Meier and co-workers showed that women have elevated levels of immune 
activation and faster disease progression rate compared to men with the same viral 
load (Meier et al., 2009). This may imply a differential response to ART with respect 
to the resolution of immune activation between the sexes. Additional studies are 
therefore needed to make our findings generalisable to men. Our study also only 
focused on the analysis of T and B cell subsets from the peripheral blood, and this may 
not be representative of their profile within tissues. It has been previously reported that 
during the course of HIV infection, the majority of CD4+ T cells are lost in secondary 
lymphoid tissues such as the gastrointestinal tract (Brenchley et al., 2004), and the 
extent to which these are repopulated and deactivated is not fully known. In addition, 
structural changes occur in primary lymphoid tissues such as lymph nodes, including 
collagen deposition and formation of hyperplastic germinal centers, where there is 
increased B cell expansion and influx of Tfh cells that provide critical B cell help 
(Hong et al., 2016). However, during HIV infection, both abnormal T cell activation 
and disturbances in memory B cells are associated with altered B cell responses 
(Cagigi et al., 2010; Cubas et al., 2013). Therefore, it may be necessary to evaluate 
the restoration of T and B cell subsets in lymphoid compartments and evaluate B cell 
memory and humoral immunity after ART. This may have implications for 
revaccination to certain pathogens if functional B cell immunity is still absent after 
therapy. Lastly, our study focused on short-term (1 year) treatment of HIV and 
normalisation of T and B cell phenotypes and co-pathogen-specific T cell immunity. 
Thus, studying the effect of longer-term therapy on phenotypic and functional 
recovery of T and B cells may be more conclusive as to whether complete immune 
recovery can occur, particularly in persons that were treated relatively late in HIV 
infection. 
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In summary, this study has shown abnormalities in T and B cells in a cohort of 
chronically HIV-infected African women, as observed previously for Caucasian 
cohorts. ART was administered in chronic HIV infection, which still led to effective 
and rapid viral load suppression and an increase in CD4+ T cell numbers. However, 
we observed only a partial recovery of HIV-induced T cell and B cell perturbations 
(activation and differentiation profiles) following short-term ART relative to healthy 
individuals. In addition, these studies showed that the renewal potential of pre-existing 
pathogen specific CD4+ T cells is related to their memory profile before ART, 
identifying an important factor that may limit restoration of functional immunity in 
HIV-treated individuals. Overall, our data has added to the body of work previously 
done in the CAPRISA 002 cohort by showing that in a cohort of South African women 
1 year after ART, the participants in this cohort were able to partially revert HIV-
induced cellular defects at least in peripheral blood. Understanding the cellular factors 
that contribute to successful immune recovery upon effective HIV treatment and 
identifying the drivers of continued immune activation and defective differentiation is 
of pivotal importance. This may give insights into adjunct therapies to administer in 
combination with ART to fully restore immune function in HIV-infected individuals. 
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Appendix 
Table A.1. Clinical characteristics of study participants 
Sex: 100% female 
Median age for HIV-uninfected individuals: 31(IQR: 27-34) 
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Appendix Figure 1. Activation and proliferation profiles of T cell subsets before and after 
ART. Frequencies of subset distribution (A) CD38+CD4+, (B) CD38+CD8+, (C) 
CD38+HLA-DR+CD4+, (D) CD38+HLA-DR+CD8+, (E) Ki67+CD4+, (F) Ki67+CD8+ T 
cells in HIV-uninfected (n=23; open circles) and HIV-infected (n=28; Closed circles). 
Blueberry, clover, mocha, maraschino and iron represent the Naive, ED, Inter, LD and TD 
subsets. Data are shown as box and whisker (interquartile range) plots. Statistical significance 
was calculated using a Mann-Whitney U test and Wilcoxon Signed Rank for unpaired and 
paired samples, respectively. 
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Restoration of CD4+ Responses to Copathogens in
HIV-Infected Individuals on Antiretroviral Therapy
Is Dependent on T Cell Memory Phenotype
Catherine Riou,*,†,1 Ramla F. Tanko,*,†,1 Andreia P. Soares,*,† Lindi Masson,*,†,‡
Lise Werner,‡ Nigel J. Garrett,‡ Natasha Samsunder,‡ Quarraisha Abdool Karim,‡
Salim S. Abdool Karim,‡ and Wendy A. Burgers*,†
Antiretroviral therapy (ART) induces rapid suppression of viral replication and a progressive replenishment of CD4+ T cells in
HIV-infected individuals. However, the effect of ART on restoring pre-existing memory CD4+ T cells specific for common
copathogens is still unclear. To better understand the dynamics of Ag-specific CD4+ T cells during ART, we assessed the frequency,
functional capacity, and memory profile of CD4+ T cells specific for Mycobacterium tuberculosis and CMV in 15 HIV-infected
individuals before and 1 y after ART initiation. After ART initiation, the frequency of M. tuberculosis–specific CD4+ T cells
showed little change, whereas CMV-specific CD4+ T cells were significantly lower (p = 0.003). There was no difference in the
polyfunctional or memory profile of Ag-specific CD4+ T cells before and after ART. The replenishment of Ag-specific CD4+ T cells
correlated with the memory differentiation profile of these cells prior to ART. Pathogen-specific CD4+ T cells exhibiting a late
differentiated profile (CD45RO+CD272) had a lower capacity to replenish (p = 0.019; r = 20.5) compared with cells with an early
differentiated profile (CD45RO+CD27+; p = 0.04; r = 0.45). In conclusion, restoration of copathogen-specific memory CD4+ T cells
during treated HIV infection is related to their memory phenotype, in which early differentiated cells (such as most M. tubercu-
losis–specific cells) have a higher replenishment capacity compared with late differentiated cells (such as most CMV-specific cells).
These data identify an important, hitherto unrecognized, factor that may limit restoration of copathogen immunity in HIV-
infected individuals on ART. The Journal of Immunology, 2015, 195: 2273–2281.
T he hallmarks of untreated HIV infection are a progressiveloss of CD4+ T cells, sustained cellular activation, andchronic inflammation (1–3). In addition to the numerical
depletion of CD4+ T cells, HIV can also alter the functional ca-
pacity of these cells, impairing their proliferative potential, alter-
ing their cytokine secretion profiles, and changing their phenotypic
characteristics in response to HIVAgs as well as various copathogens
(4–7). Both of these quantitative and qualitative alterations can lead to
increased susceptibility to opportunistic infections, including tuber-
culosis (TB), Candidiasis, and human papilloma virus infection (8).
Indeed, HIV is the best-recognized risk factor for TB disease even
before profound CD4+ T cell deficiency (9, 10). The introduction of
antiretroviral therapy (ART) has drastically decreased morbidity and
mortality in HIV-infected individuals (11), inducing a rapid reduction
of plasma viral load and a progressive repletion of CD4+ T cells (12).
Although the clinical benefit of ART is undeniable, the extent to
which ART can fully normalize functional immunity remains unclear
(13). HIV-infected individuals on ART exhibit a differential degree of
recovery of copathogen-specific CD4+ T cell responses, depending on
the pathogen they target (14–20). For example, it has been shown that
the restoration of CMV-specific CD4+ T cells occurs early after ART
(19), but appears to be short-lived (15). Conversely, Candida-specific
CD4 responses recover slowly (16). Contrasting data exist on the
degree of recovery of Mycobacterium tuberculosis–specific CD4+
T cell responses upon ART. Jambo et al. (20) showed in a cross-
sectional study that the frequency and polyfunctional profile of
M. tuberculosis–specific CD4+ T cell responses were similar in ART-
naive or treated individuals, whereas Sutherland et al. (18) reported
that ART increases the polyfunctional capacity of these cells. Other
studies described only a partial reconstitution of M. tuberculosis–
specific CD4+ T cell responses after ART (14, 17).
It is of particular importance to define the factors that associate
with successful pathogen-specific CD4+ T cell recovery upon ART,
as limited “normalization” of functional CD4+ T cell responses
could account for sustained incidence of opportunistic infections.
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Several parameters influence the degree and dynamics of recovery of
the overall CD4+ T cell compartment in response to ART, such as
age, CD4 count at the time of treatment initiation, and timing of
ART initiation after HIV infection (21–23). However, it is still un-
clear why CD4+ T cells of different pathogen specificities have
different profiles of restoration, and the mechanisms mediating this
variable recovery of memory CD4+ T cells to copathogens are still
incompletely understood. Thus, to better understand the effect of
successful ART on the dynamics of recovery of copathogen-specific
CD4+ T cells, we compared the magnitude, functional capacity, and
memory differentiation profiles of M. tuberculosis– and CMV-
specific CD4+ T cells before and 1 y after ART initiation in a co-
hort of HIV-infected individuals and HIV-uninfected controls.
Materials and Methods
Study participants
Blood samples were collected from 15 women participating in the CAP-
RISA 002 study, a cohort study following HIV-infected women from HIV
seroconversion until 5 y on treatment. The cohort is situated in KwaZulu-
Natal, South Africa, and has been previously described (24, 25). Partic-
ipants were selected based on sample availability. Blood samples from
nine HIV-uninfected participants were provided from the CAPRISA 004
vaginal microbicide (1% tenofovir) gel trial (26). An additional 14 HIV-
uninfected participants from CAPRISA 004 were studied for immune
activation. HIV-uninfected participants were from the same community as
the HIV-infected individuals and age-matched; they were either in the
preintervention phase or the placebo arm of the trial. For HIV-infected
individuals, the time of infection was estimated either as the same date
as a prospective RNA-positive/Ab-negative measurement or taken as the
midpoint between the last Ab negative test and first Ab-positive ELISA
test. Participants in the cohort were offered ART according to South African
national HIV treatment guidelines (at a CD4 count of ,200 cells/mm3
prior to October 2012; ,350 cells/mm3 until the present). Eight of the 15
participants were taking standard first-line therapy (TDF/3TC/EFV), 3
were on ddI-EC/3TC/EFV, and 1 each on d4T/3TC/EFV, TDF/3TC/NVP,
d4T/3TC/NVP, and AZT/3TC/LPV/r. Two participants switched drug
regimens while on study, namely CAP200 (EFV/3TC/ddI-EC to EFV/3TC/
TDF at month 11) and CAP255 (EFV/3TC/d4T to EFV/3TC/AZTat month
10). No participants had active TB during the study period or exhibited any
immune reconstitution disease upon HIV treatment. Ethical approval for
the study was obtained from the University of KwaZulu-Natal and Uni-
versity of Cape Town Research Ethics Committees. All participants pro-
vided written informed consent to participate in the study.
Determination of plasma viral load and CD4 counts
Plasma HIV viral loads and CD4 counts were quantified at each study visit.
Over the course of the study, the viral load PCR assay switched from Roche
AMPLICORHIV-1 monitor test version 1.5 (lower detection limit [LDL] of
400 RNA copies/ml), to Roche TaqMan version 1.0 on June 1, 2010 (LDL
40 RNA copies/ml), and then to Roche TaqMan version 2.0 on January 9,
2012 (LDL 20 RNA copies/ml). Absolute blood CD4 and CD8 T cell counts
were measured using the FACSCalibur TruCOUNT method (BD Bio-
sciences) and expressed as cells/mm3. Plasma samples matching the visits
where PBMC were studied were tested for Abs to CMV and CMV DNA.
Seropositivity was determined using the Cobas CMV IgG Assay (Roche),
and CMV viral load was detected and quantified using a CMV R-gene
PCR kit (Argene), with a detection limit of 30 copies/ml.
Cell preparation
PBMC were isolated by standard Ficoll–Hypaque density gradient cen-
trifugation (Amersham Pharmacia) and cryopreserved in 90% heat-
inactivated FCS (Invitrogen) plus 10% DMSO and stored in liquid nitro-
gen until needed. Cryopreserved PBMC were thawed and rested in R10
(RPMI 1640 containing 10% heat-inactivated FCS [Sigma-Aldrich] and
50 U/ml of penicillin-streptomycin) at 37˚C and 5% CO2 for 8 h prior to
Ag stimulation.
Ags and cell stimulation
Following resting, PBMC were stimulated using M. tuberculosis Purified
Protein Derivative (10 mg/ml; Statens Serum Institute), a pool of CMV
peptides consisting of 138 peptides (15-mers overlapping by 11 aa) cov-
ering the entire HCMV pp65 protein (2 mg/ml; National Institutes of
Health AIDS Reagent Program) and staphylococcal enterotoxin B (SEB;
2.5 mg/ml; Sigma-Aldrich), used as a positive control. Of note, we found
no major differences in the memory profile, cytokine secretion potential,
and polyfunctional capacity between peptide and protein-stimulated PBMC
(R. Bunjun, C. Riou, A.P. Soares, N. Thawer, T.L. Muller, A. Kiravu,
Z. Ginbot, W. Hanekom, G. Walzl, R.J. Wilkinson, and W.A. Burgers, man-
uscript in preparation). Stimulations were performed in the presence of co-
stimulatory Abs anti-CD28 and anti-CD49d (both at 1 mg/ml; BD Biosciences)
at 37˚C for 16 h. Brefeldin A (Sigma-Aldrich) was added after 1 h at a con-
centration of 10 mg/ml. Surface and intracellular cytokine staining was per-
formed at the end of the incubation period. Sufficient cells were available for
assessing CMV and SEB responses in only 12 out of 15 HIV-infected partic-
ipants.
Surface phenotypic and intracellular cytokine staining and
flow cytometry
The following Abs were used for surface and intracellular staining: CD3–
allophycocyanin-H7 (SK7; BD Biosciences), CD4–PE-Cy5.5 (S3.5; Invi-
trogen), CD8-Qdot 705 (3B5; Invitrogen), CD27–PE-Cy5 (1A4CD27;
R&D Systems), CD45RO-ECD (UCHL1; R&D Systems), IFN-g–Alexa
Fluor 700 (B27; BD Biosciences), IL-2–APC (MQ1-17H12; BD Bio-
sciences), TNF-a–PE-Cy7 (MAb11; eBioscience), CD14–Pacific Blue
(T€uk4; Invitrogen), CD19–Pacific Blue (SJ25-CI; Invitrogen), and a violet
amine viability dye (“Vivid”; Molecular Probes). All Abs were titrated to
obtain optimal concentrations prior to use. After stimulation, PBMC were
first stained with Vivid for 20 min at room temperature. Cells were then
surface stained with CD4, CD8, CD45RO, CD27, CD14, and CD19 Abs.
Cells were fixed and permeabilized using Cytofix/Cytoperm buffer (BD
Biosciences) and stained intracellularly with CD3, IL-2, TNF-a, and IFN-g.
Cells were then resuspended in 13 CellFix (BD Biosciences). Samples
were acquired on a BD Fortessa using FACSDiva software and analyzed
using FlowJo (version 9.8.2; Tree Star). The gating strategy is presented in
Supplemental Fig. 1. A positive cytokine response was defined as at least
twice the background (in the presence of costimulatory Abs and no Ag).
For phenotyping the memory profile of cells producing cytokines, a cutoff
of 40 events was used. Polyfunctionality of Ag-specific cells was analyzed
using Pestle (version 1.7) and Spice (version 5.35) software (27). Immune
activation was measured by surface staining of unstimulated cells using the
CD3, CD4, CD8, CD14, and CD19 Abs listed above, as well as CD38-
APC (HIT2) and HLA-DR–allophycocyanin-Cy7 (L243) (both BD Bio-
sciences), along with the inclusion of Vivid.
Statistical analysis
Statistical analyses were performed using GraphPad Prism (version 5.0; San
Diego, CA). Nonparametric statistical tests were used for all comparisons.
The Mann–Whitney U test and Wilcoxon signed-rank test were used for
unmatched and paired samples, respectively, and the Kruskal–Wallis ANOVA
using Dunn’s test for multiple comparisons. Correlations were performed
using the Spearman rank test. A p value ,0.05 was considered statistically
significant.
Results
Effect of ART on the restoration of copathogen-specific CD4+
T cells
In order to better understand the replenishment dynamics of CD4+
T cells specific for copathogens in HIV-infected individuals on
treatment, we studied 15 HIV-infected individuals before and after
ART initiation. The cohort consisted of women infected with HIV-
1 for a median of 4.9 y (interquartile range [IQR]: 3.8–5.8 y) at the
time of treatment initiation (Table I). Pre-ART samples were ob-
tained at a median of 1.7 mo (IQR: 0.8–2.5) prior to starting ART.
The median plasma viral load was 21,955 HIV RNA copies/ml
(IQR: 4,743–52,800), and the median CD4 count was 289 cells/mm3
(IQR: 193–322). After a median of 12 mo of treatment (IQR: 11–
12.3 mo), all individuals exhibited some degree of viral suppres-
sion (p , 0.0001, Supplemental Fig. 2A), which was below the
limit of detection of the assay in 12 out of 15 individuals and
,400 RNA copies/ml in the remainder. An increase in absolute
CD4 count occurred in 13 out of 15 individuals over the period
measured (p , 0.0001; Supplemental Fig. 2B). The median fold
change in absolute CD4 count was 1.9 (IQR: 1.6–2.3), and when
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adjusted for length of treatment, the replenishment rate of CD4+
T cells was 20 cells/mm3/month (IQR: 14–26, data not shown);
this was accompanied by a concomitant doubling of the CD4/CD8
ratio (0.27 versus 0.66; p = 0.0007; Supplemental Fig. 2C). As
previously reported (21–23), the degree of CD4 reconstitution
was inversely related to absolute CD4 count at ART initiation
(p , 0.0001; r = 20.85) and the duration of HIV infection
(p = 0.016; r = 20.61, data not shown). We also measured im-
mune activation before and after ART using the markers CD38
and HLA-DR. There was a significant reduction in CD4+ and
CD8+ T cells coexpressing CD38+ and HLA-DR+ (p = 0.0002 and
p = 0.0001; Supplemental Fig. 2D), as well as HLA-DR+ alone
(p = 0.0001 for both subsets). Residual levels of immune activation
after 1 y of ART remained significantly greater than healthy, HIV-
uninfected individuals for both markers (Supplemental Fig. 2D). We
found no association between the degree of CD4 reconstitution and
CD4+ T cell activation before or after ART (data not shown).
To determine whether the dynamics of copathogen-specific
CD4+ T cells mirror the reconstitution of the total CD4+ T cell
population, we measured the magnitude of M. tuberculosis– and
CMV-specific CD4+ T cell responses, as well as SEB-reactive
CD4+ cells, before and after ART initiation. Fig. 1A shows rep-
resentative flow cytometry plots of cytokine production (IFN-g,
IL-2, and TNF-a) by CD4+ T cells in response to M. tuberculosis,
CMV, and SEB stimulation in one HIV-infected patient (CAP267).
At baseline (before ART initiation), 11 out of 15 individuals tested
had a detectable M. tuberculosis response, with a median fre-
quency of 0.08% of total CD4+ T cells (range, 0–0.9%; Fig. 1B).
CMV responses were detected in 10 out of 12 individuals tested,
and the median frequency was 0.35% (range: 0–4.1%). SEB
responses were detectable in 12 out of 12 participants with a
median frequency of 16% (range: 8.6–32.5%). The frequency
of M. tuberculosis–specific and SEB-responding CD4+ T cells
were comparable pre- and post-ART, whereas the frequency of
CMV-specific CD4+ T cells was significantly lower after treatment
(median 0.35 versus 0.14%, p = 0.003; Fig. 1B). To take into
account variation in absolute CD4 counts across the cohort, the
absolute number of Ag-specific CD4+ T cells was calculated. The
number of M. tuberculosis–specific and SEB-responding CD4+
T cells increased significantly after ART (p = 0.033 and p = 0.016,
respectively), whereas the number of CMV-specific CD4+ T cells
remained unchanged upon treatment (Fig. 1C), consistent with the
decreased frequency in the context of increases in absolute CD4
numbers. Overall, these data reveal that the dynamics of recon-
stitution of Ag-specific CD4+ T cells vary according to their
pathogen specificity.
Relationship between the dynamics of restoration of total and
copathogen-specific CD4+ T cells
To further investigate the restoration dynamics of copathogen-
specific CD4+ T cells, we examined the relationship between
the fold change in the absolute number of Ag-specific CD4+
T cells pre- and post-ART (in individuals with detectable Ag re-
sponses at both time points, n = 11 for M. tuberculosis, n = 10 for
CMV, and n = 12 for SEB), and the absolute total CD4 count
variation. Fig. 2A shows that although the magnitude of cell re-
plenishment of M. tuberculosis–specific and SEB-responding
CD4+ T cells was comparable to that of total CD4+ T cells (an
∼2-fold increase over the 12 mo of ART), the extent of restoration
of CMV-specific CD4+ T cells was significantly lower (p = 0.018,
p = 0.013, and p = 0.0008, to M. tuberculosis, SEB, and total
CD4+ cells, respectively). Consistent with these observations, the
degree of restoration of M. tuberculosis– and SEB-responding
CD4+ T cells corresponded closely with the overall CD4 recov- Ta
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ery, as measured in fold-change of the absolute CD4 count, with
a slope close to 1 (Fig. 2B). In contrast, for CMV-specific CD4+
T cell responses the slope was 0.37, indicating a reduced replen-
ishment rate of these cells compared with the total CD4 com-
partment (Fig. 2B). Of note, although all study participants were
CMV seropositive, none had detectable CMV viral replication at
either visit, pre- or post-ART, indicating that a difference in CMV
Ag load at the two visits was not a contributing factor to the re-
duced replenishment capacity of CMV-specific T cells.
Effect of ART on the functional capacity of copathogen-specific
CD4+ T cells
ART has been shown to gradually restore the polyfunctional capacity
of HIV-specific T cells (28, 29), but the effect of ART on the
functionality of CD4+ T cells specific for other pathogens is un-
clear. Thus, we evaluated the cytokine secretion profiles of
M. tuberculosis–, CMV-, and SEB-reactive CD4+ T cells before
and after ART initiation in detail (Fig. 3). We included nine HIV-
uninfected individuals in this analysis for comparison. Our first
finding was that the cytokine production profile of CD4+ T cells
varied significantly according to their specificity (p = 0.002;
Fig. 3A), with M. tuberculosis–specific responses consisting of
a greater proportion of polyfunctional cells producing all three
cytokines, in addition to a predominant TNF-a monofunctional
subset (∼40% of the response), whereas CMV-specific CD4+ re-
sponses exhibited predominantly a IFN-g+TNF-a+ phenotype
(∼60%; Fig. 3B). ART did not significantly alter the cytokine
secretion profile of CD4+ T cells from baseline, regardless of their
specificity for M. tuberculosis, CMV, or SEB (Fig. 3A, 3B).
Moreover, the polyfunctional characteristics of M. tuberculosis–
specific and SEB-responsive CD4+ T cell responses were com-
parable to those observed in HIV-uninfected individuals. In con-
trast, CMV responses were significantly skewed in HIV-infected
individuals compared with HIV-uninfected subjects (p = 0.016
and p = 0.045 for pre- and post-ART; Fig. 3A), with a lower
proportion of cells coproducing IFN-g, IL-2, and TNF-a, and
a higher proportion of IFN-g monofunctional cells (Fig. 3B).
These data demonstrate that, unlike for M. tuberculosis–specific
CD4 responses, HIV infection impaired the functional potential of
CMV-specific CD4 responses toward a less polyfunctional profile,
and 1 y of ART did not restore the CMV functional profile.
Impact of the memory phenotype of pathogen-specific CD4+
T cells on their replenishment potential upon ART
Depending on their memory differentiation profile, CD4+ T cells
are endowed with distinct survival and proliferation capacities (30,
31). Thus, to investigate whether the cell maturation phenotype
could impact the replenishment capacity of copathogen-specific
CD4+ T cells, we first compared the differentiation profiles of
M. tuberculosis– and CMV-specific CD4+ T cells at baseline, prior
to ART initiation. Fig. 4A shows a representative contour plot of
distinct memory subsets in the CD4 compartment pre-ART in one
HIV-infected individual. Based on the expression of CD45RO and
CD27, we were able to discriminate four different memory sub-
populations (32), namely: naive (CD45RO2CD27+), early differen-
tiated (ED; CD45RO+CD27+, encompassing central and transitional
FIGURE 1. Effect of ART on M. tuberculosis (Mtb)-, CMV-, and SEB-specific CD4+ T cell responses. (A) Representative flow cytometry plots of the
expression of TNF-a, IFN-g, and IL-2 from CD4+ T cells after stimulation withM. tuberculosis (Mtb) and CMVAgs and SEB, in one study participant. NS
corresponds to unstimulated PBMC. The frequency of cytokine-producing cells expressed as a percentage of the total CD4+ T cell population are indicated.
Frequency (B) and absolute number (C) of M. tuberculosis–, CMV-, and SEB-specific CD4+ T cell responses before and after ART. Horizontal bars
represent the median. Statistical comparisons were performed using a Wilcoxon matched-pairs test.
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memory subsets), late differentiated (LD; CD45RO+CD272, en-
compassing effector memory cells), and terminally differentiated
(CD45RO2CD272, or effector cells). In HIV-infected subjects,
although M. tuberculosis– and CMV-specific CD4+ T cells were
represented in both ED and LD subsets, they comprised significantly
distinct profiles (Fig. 4B, left panel). M. tuberculosis–specific cells
exhibited primarily an ED profile (median 51%, interquartile range
[IQR] 42–62), whereas CMV-specific cells demonstrated a substantial
enrichment of the LD phenotype (median 73%, IQR 48–86), as
previously described (33). Of note, ART did not markedly alter the
overall memory differentiation profile of M. tuberculosis–specific or
CMV-specific CD4+ T cells (Supplemental Fig. 3). In addition, HIV-
uninfected individuals exhibited similarly distinctive memory CD4
differentiation profiles for M. tuberculosis and CMV (Fig. 4B, right
panel).
We next investigated the relationship between the memory
phenotype of pathogen-specific CD4+ T cells at the time of ART
initiation and the capacity of these cells to be maintained and/or
replenished upon treatment. Fig. 5A shows that the fold change
in the absolute number of pathogen-specific CD4+ T cells over
12 mo on ART inversely correlated with the proportion of cells
exhibiting a late differentiated phenotype (p = 0.019; r = 20.5).
Consistent with this, a positive correlation was observed between
the fold change in the absolute number of pathogen-specific CD4+
T cells and the proportion of these cells exhibiting an ED phe-
notype (p = 0.04; r = 0.45). Of note, the proportion of LD
FIGURE 2. Restoration dynamics of M. tuberculo-
sis– (Mtb), CMV-, and SEB-specific CD4+ T cells after
ART. (A) Fold change in the total, M. tuberculosis–,
CMV-, and SEB-specific absolute CD4+ T cell count
over 12 mo of ART. The horizontal dotted line indi-
cates no change from the baseline pre-ART time point.
Statistical comparisons were performed using a non-
parametric Mann–Whitney U test. (B) Association
between the fold change of the absolute number of Ag-
specific CD4+ T cells and the fold change in the ab-
solute CD4 count pre- and post-ART. Statistical asso-
ciations were performed by a two-tailed nonparametric
Spearman rank correlation. The solid line represents
a linear regression fit, and the dashed line depicts the
ideal slope of 1.
FIGURE 3. Polyfunctional capacity of
M. tuberculosis– (Mtb), CMV-, and SEB-specific
CD4+ T cells in HIV-infected and uninfected
individuals pre- and post-ART. Pie charts (A) and
graphs (B) representing the cytokine secretion
ability of M. tuberculosis–, CMV-, and SEB-
specific CD4+ T cell responses in HIV-uninfected
individuals (n = 9) and HIV-infected individuals
pre- and post-ART initiation. Each section of the
pie chart represents a specific combination of
cytokines, as indicated by the color at the bottom
of the graph. Horizontal bars depict the median
with interquartile range indicated. Statistical
comparisons were performed using a Wilcoxon
rank-sum test. *p , 0.05, **p , 0.01.
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M. tuberculosis–specific CD4+ T cell responses (in the absence of
CMV responses) also correlated inversely with the fold change in
the absolute number of M. tuberculosis–specific cells (r = 20.62;
p = 0.038; data not shown), and so too when naive-like M. tu-
berculosis–specific cells were grouped together with ED cells, we
observed a trend toward a positive association with the fold
change in the absolute number of M. tuberculosis–specific cells
(r = 0.54; p = 0.05; data not shown). This relationship between the
memory profile and the ART-induced repletion potential of
pathogen-specific CD4+ T cells is further illustrated in Fig. 5B,
showing specific examples from two participants. In CAP257, in
which the pre-ART CMV-specific CD4 response showed an en-
richment in cells with an LD phenotype (82%), their ability to
expand over 12 mo on ART was considerably lower than M. tu-
berculosis–specific CD4 responses, characterized by an ED phe-
notype (77.4%) (fold change 1.2 for the CMV response versus 2.8
for the M. tuberculosis response). In CAP244, in which the
memory profile of both M. tuberculosis and CMV-specific re-
sponses were similar (∼60% of LD cells), the fold change in the
absolute number of CD4+ T cells to both pathogens was compa-
rable.
Overall, these data reveal that the ability of copathogen-specific
memory CD4+ T cells to expand upon ART appears to be related
to their memory phenotype, in which ED cells have a higher re-
plenishment capacity compared with LD cells.
Discussion
The introduction of ART has changed the clinical pattern of HIV
infection significantly, with considerable reductions in morbidity
and mortality. Although it is clearly established that ART leads to
a progressive replenishment of the CD4+ T cell compartment in the
majority of cases, the extent to which pre-existing copathogen-
specific CD4+ T cells are restored, and the causes of variable
restoration, are poorly defined. In this study, we investigated the
FIGURE 4. Memory profiles of M. tuberculosis–
(Mtb) and CMV-specific CD4+ T cells in HIV-infected
and uninfected individuals. (A) Representative example
of total CD4 memory subset distribution in one HIV-
infected individual. Naive (CD45RO2CD27+), ED
(CD45RO+CD27+), LD (CD45RO+CD272), and TD
(CD45RO2CD272). The frequencies of each subset are
indicated. (B) Memory profile of M. tuberculosis– and
CMV-specific CD4+ T cells in HIV-infected individuals
pre-ART (left panel) and HIV-uninfected individuals
(right panel). Results are shown as box and whisker
(10–90 percentile) plots. Each dot depicts an individual,
and the horizontal bar is the median. Statistical com-
parisons were performed using a one-way ANOVA
nonparametric Kruskal–Wallis test.
FIGURE 5. Relationship between the
memory profile of M. tuberculosis– (Mtb)
and CMV-specific CD4+ T cells and the
dynamics of restoration of these cells. (A)
Association between the proportion of Ag-
specific CD4+ T cells exhibiting an LD (top
panel) or ED (bottom panel) profile with the
fold change in Ag-specific CD4+ T cell
absolute count after ART. Statistical asso-
ciations were performed by a two-tailed
nonparametric Spearman rank correlation.
(B) Representative examples of the memory
profile of M. tuberculosis– or CMV-specific
CD4+ T cells pre-ART in two individuals.
The frequencies of each subset are indi-
cated. For each example, the fold change in
Ag-specific absolute CD4+ T cell count pre-
and post-ART is indicated at the top of each
plot.
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dynamics of restoration of memory CD4+ T cells specific for
a bacterial copathogen (M. tuberculosis) and a viral pathogen
(CMV) in 15 HIV-infected individuals in response to ART. Our
main finding was that the extent of reconstitution of pathogen-
specific cells was related to their memory differentiation profile
at the time of ART initiation, in which cells exhibiting an ED
memory profile (including central memory and transitional memory
cells) had a higher replenishment potential compared with LD
(effector memory) T cells.
Multiple mechanisms contribute to the increase in CD4+ T cells
in blood in response to antiretroviral treatment for HIV (34). Over
the first few months of ART, there is a redistribution of CD4+
T cells from the lymph nodes to the blood (35, 36), leading to
a rapid initial rise in CD4+ counts. Moreover, homeostatic cell
proliferation (37), decreased cell death (38) and increased thymic
output (39, 40) also play a role in the replenishment of CD4+
T cells. Although the CD4 absolute cell count at the time of
treatment initiation is one of the main factors dictating the level to
which CD4+ T cells are restored (21, 23), other parameters such as
the activation level of T cells at the time of treatment (41), age
(42, 43), or active coinfections (44, 45) also influence the degree
of reconstitution of the CD4 compartment. Thus, CD4+ T cell
recovery upon ART appears to be dependent on both the extent
of immune damage at the time of treatment initiation and the
regenerative capacities of these cells.
We demonstrate in this study that despite successful viral sup-
pression and robust CD4 gains in the majority of participants, the
dynamics of M. tuberculosis– and CMV-specific CD4+ T cell re-
covery were distinct. This shows that not all T cell subpopulations
have the same potential to be replenished. Several factors and/or
cellular attributes could account for these differences. First, the
regenerative capacities of pathogen-specific CD4+ T cells could be
determined by their intrinsic ability to survive or proliferate, and it
has been clearly established that CD4+ T cells exhibiting an ED
memory profile have an enhanced survival and proliferative po-
tential compared with cells with an LD phenotype (30, 31). Our
data are in accordance with these observations, showing that the
extent of replenishment of pathogen-specific CD4+ T cells cor-
relates with their memory status, with superior recovery observed
for Ag-specific CD4+ T cells exhibiting an early memory phe-
notype. Mechanistically, cell responsiveness to common g-chain
cytokines may account for the distinct renewal potential of these
different cell subsets (46–48). In our study, the replenishment
potential of M. tuberculosis– or CMV-specific CD4+ T cells did
not associate with their ability to produce IL-2 (data not shown);
however, we have observed that responsiveness to IL-7 dis-
tinguishes ED and LD CD4+ subsets, with ED memory T cells
being more responsive to exogenous IL-7 and IL-2 (as measured
by Stat5 phosphorylation), compared with LD memory CD4+ T cells
(C. Riou, unpublished observations). Further analysis comparing the
level of expression of cytokine receptors and cytokine-induced pro-
liferation potential betweenM. tuberculosis– and CMV-specific CD4+
T cells would be needed to define the role of these signaling pathways
in the restoration of immune memory cells upon ART.
Although M. tuberculosis responses displayed primarily an ED
phenotype, there were substantial interindividual differences,
ranging from 30–75% of the response. The CD4+ memory profile
is dictated by numerous factors, including continual Ag exposure
in high burden settings (49), previous TB, TB treatment, and cure
(50–52). A recent study carried out in a similar geographic setting
as the current study noted dynamic changes in the T cell response
to M. tuberculosis in the context of latent TB infection and HIV
coinfection (53). It is worth noting that we also detected Ag-
specific cells with a naive-like phenotype, previously described
for M. tuberculosis and other infections (51, 54, 55). Although
making up only a minor proportion of the total M. tuberculosis– and
CMV-specific response, these cells expanded post-ART in the ma-
jority of individuals compared with other memory subsets, that were
characterized by more variable expansion and contraction. For CMV,
this expansion led to a significantly greater frequency of this subset
after ART. These cells may fall within the recently described memory
stem cell subset, comprising memory cells endowed with a greater
ability to proliferate and persist long-term compared with central
memory (56, 57). Thus, the composition of the memory pool at the
time of ART initiation may influence the restoration of Ag-specific
CD4+ T cells.
To determine whether short-term ART affected not just quan-
titative but also qualitative aspects of copathogen immunity, we
assessed the ability of cells to simultaneously secrete multiple
cytokines, which for some infections, such as HIV and leish-
maniasis, are a correlate of immune control or protection (58, 59).
Although the significance of polyfunctional cells in TB is unclear
(48), we demonstrated that .50% of M. tuberculosis–specific
CD4+ cells produced three or two cytokines simultaneously, a profile
that did not significantly change after ART; moreover, this was
similar to the profile from HIV-uninfected individuals. Our data are in
apparent contrast to previous findings (18) showing that ART leads to
an improved polyfunctional profile in M. tuberculosis–specific CD4+
T cell after short-term treatment, but this may be due to cohort dif-
ferences, as the participants in that study were characterized by more
advanced immunosuppression and higher viral loads than in the
current study. Because it has been reported that the impairment of the
functional capacity of M. tuberculosis–specific CD4+ T cells is re-
lated to HIV disease status (60), it is likely that differences in the
severity of HIV pathology at the time of treatment initiation between
the two studied groups could account for these discrepancies. The
polyfunctional profile we observed for CMV-specific CD4+ cells is
consistent with that previously reported (33), with simultaneous IFN-g
and TNF-a, and IFN-g alone dominating the response. The CMV
profile also did not change after ART and in this case was less pol-
yfunctional compared with HIV-infected individuals. Our study only
examined paired samples from 12 mo after ART, and it is possible
that prolonged ART may restore CMV functional profiles (29).
It is important to note that although we demonstrate an expansion
of M. tuberculosis–specific CD4+ T cells after ART, restoration of
the magnitude and measures of functionality of the M. tubercu-
losis–specific CD4+ Th1 response determined by the production of
three cytokines is a coarse measure of functional immunity to TB
and may not reflect protective immunity. Several additional CD4+
T cell subsets and cytokines contribute to TB immunity (61–64),
and we have found an even greater diversity of CD4+ T cell
subsets specific for M. tuberculosis (C. Riou, N. Strickland,
A.P. Soares, B. Corleis, D.S. Kwon, E.J. Wherry, R.J. Wilkinson,
and W.A. Burgers, submitted for publication). An additional issue is
that we do not know the extent of pathogen-specific CD4+ recovery
in tissues upon ART, which appears defective for TB in the lungs
even after prolonged viral suppression (20). These considerations
may account for the persistently greater susceptibility of success-
fully treated HIV-infected individuals to TB (65).
Our study had several limitations. We were constrained by the
availability of paired samples prior to and after ART, limiting us to
studying 15 individuals in detail. Testing the generalizability of our
findings in larger cohorts is warranted. Also, we focused our study
on short-term restoration of pathogen-specific immunity (after 1 y
of ART), and although study participants exhibited suppressed HIV
replication, decreased immune activation, and improved CD4
counts, studying responses after longer-term therapy may provide
further important insights and more definitive conclusions on the
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restoration of pathogen-specific immunity. Furthermore, the par-
ticipants we studied had nadir CD4 counts of .135 cells/mm3
(median 289 cells/mm3), and we did not have access to partic-
ipants commencing treatment at lower CD4 counts (e.g.,
,50 cells/mm3). These highly immunocompromised patients would
be the most relevant group to study with respect to susceptibility to
CMV disease. In this context, although CMV-specific cells replen-
ished more poorly than M. tuberculosis–specific cells after ART,
they were present at a high frequency prior to ART initiation, which
may well have been sufficient to provide protective immunity to
CMV. Moreover, the extent of CD4 depletion at the time of ART
initiation could impact the degree and dynamics of Ag-specific
CD4+ T cell recovery. Lastly, we delineated memory subsets
based on two markers, CD27 and CD45RO. These markers cannot
differentiate between central memory and transitional memory cells
within the CD27+CD45RO+ ED subset, and inclusion of a marker
such as CCR7 would afford an additional degree of distinction that
may reveal further differences in the ability of these memory subsets
to expand after ART and should be included in future studies of
reconstitution of pathogen-specific immunity. Further research ad-
dressing these important limitations is needed to confirm and extend
our findings.
Understanding the host and cellular factors that contribute to
successful immune restoration on effective antiretroviral treatment
for HIV, including both the overall CD4+ T cell compartment and
copathogen-specific CD4 immunity, is of crucial importance, as
only partial recovery of these cells could result in a persistently
heightened risk of particular opportunistic infections. In this re-
port, we showed that the renewal potential of pre-existing pathogen-
specific CD4+ T cells was related to their memory differentiation
profile. It will be important to determine whether this principle
holds true in a wider context for other copathogens. Incomplete
restoration of functional immunity and the persistence of elevated
susceptibility to particular coinfections have implications for tar-
geted interventions in the treated HIV-infected population. Over-
all, our findings underscore the complexity of immune reconstitution
on ART and the importance of preserving functional immunity
with early ART (66).
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Effect of Antiretroviral Therapy on the Memory and
Activation Profiles of B Cells in HIV-Infected African Women
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Human immunodeficiency virus infection induces a wide range of effects in B cells, including skewed memory cell differentiation,
compromised B cell function, and hypergammaglobulinemia. However, data on the extent to which these B cell abnormalities can
be reversed by antiretroviral therapy (ART) are limited. To investigate the effect of ART on B cells, the activation (CD86) and dif-
ferentiation (IgD, CD27, and CD38) profiles of B cells were measured longitudinally in 19 HIV-infected individuals before (median, 2
mo) and after ART initiation (median, 12 mo) and compared with 19 age-matched HIV-uninfected individuals using flow cytometry.
Twelvemonths of ARTrestored the typical distribution of B cell subsets, increasing the proportion of naive B cells (CD272IgD+CD382)
and concomitantly decreasing the immature transitional (CD272IgD+CD38+), unswitched memory (CD27+IgD+CD382), switched
memory (CD27+IgD2CD382 or CD272IgD2CD382), and plasmablast (CD27+IgD2CD38high) subsets. However, B cell activation was
only partially normalized post-ART, with the frequency of activated B cells (CD86+CD40+) reduced compared with pre-ART levels
(p = 0.0001), but remaining significantly higher compared with HIV-uninfected individuals (p = 0.0001). Interestingly, unlike for
T cell activation profiles, the extent of B cell activation prior to ART did not correlate with HIV plasma viral load, but positively
associated with plasma sCD14 levels (p = 0.01, r = 0.58). Overall, ART partially normalizes the skewed B cell profiles induced by HIV,
with some activation persisting. Understanding the effects of HIV on B cell dysfunction and restoration following ART may provide
important insights into the mechanisms of HIV pathogenesis. The Journal of Immunology, 2017, 198: 000–000.
S
ystemic immune hyperactivation is a hallmark of HIV
infection, affecting a range of immune cells, including both
T cells and B cells (1). Multiple B cell defects have been
reported in HIV-infected individuals, including alteration in the dis-
tribution of B cell memory subsets, with the accumulation of dif-
ferentiated B cells (2–5), excessive B cell activation (6, 7), and
increased cell turnover (8). These B cell perturbations lead to func-
tional abnormalities, as demonstrated by hypergammaglobulinemia,
decreased B cell responsiveness to both T cell-dependent and T cell-
independent Ags (9–11), and compromised responses to vaccination
(9, 12, 13).
The specific mechanisms contributing to B cell abnormalities are
only partially known, and multiple factors may account for their
dysfunction. HIV-driven alteration of the cytokine and chemokine
environment has been described as a source of B cell dysfunction
(5, 14–16); and it has also been proposed that specific HIV pro-
teins may have a direct effect on B cells (17, 18). Several studies,
performed mostly in cross-sectional Caucasian cohorts, have in-
vestigated the effect of antiretroviral therapy (ART) on B cells,
reporting that suppressive ART can partially or completely nor-
malize B cell phenotypic defects, as shown by the replenishment
of naive B cells (19–22), contraction of activated B cells (21–25),
and increase in B cell survival potential (26). It is still uncertain,
however, whether normalization of B cell memory subsets results
in improved B cell immune responses to Ags, including influenza,
measles, pneumococcus, and hepatitis B (6, 10, 11, 27, 28).
There is a paucity of published studies on female and African
populations with regard to B cell activation and restoration of B cell
immunity following successful treatment of HIV (29, 30). There
are cogent reasons to believe there may be differences in African
compared with Caucasian cohorts. African cohorts have demon-
strated higher baseline levels of T cell activation, significantly
different T cell memory differentiation profiles (31, 32), and
consistently weaker cellular and humoral reactivity to some vac-
cines (33, 34). A variety of factors may influence immune acti-
vation and therefore normalization of immune profiles after ART,
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such as genetic, gender, and environmental differences, the latter
including higher antigenic exposure, diet, and gut microbiota.
Furthermore, a variety of sex-specific differences in the response
to infections have been described. Women have higher levels of
immune activation and faster progression of HIV disease than men
with the same viral load (35). These effects have been attributed to
estrogen receptor signaling and/or differences in expression of key
X-chromosome-expressed immune regulators, such as TLR and
CD40L (36). Additional factors such as HIV strains, treatment
regimens, and delayed access to HIV treatment could result in
distinct outcomes with respect to immunity after ART.
Thus, in this study, to define the extent to which ART restores the
B cell phenotype, we measured the memory differentiation and
activation profiles of B cells longitudinally in chronically HIV-
infected African women before and 12 mo after ART initiation,
and compared these profiles to age- and sex-matched HIV-
uninfected individuals.
Materials and Methods
Description of study participants
Study participants consisted of 19 women from the Centre for the AIDS
Program of Research in South Africa (CAPRISA) 002 HIV acute infection
cohort in KwaZulu-Natal, as previously described (37, 38). Peripheral
blood samples were obtained at two time points, during chronic infection
pre-ART initiation, and post-ART initiation. With respect to ART regi-
mens, 15 of the 19 participants were taking current standard first-line
therapy (TDF/3TC/EFV or TDF/FTC/EFV), and four took one of D4T/
3TC/EFV, D4T/3TC/NVP, AZT/3TC/NVP, or AZT/3TC/LPV/r. One par-
ticipant (CAP255) switched ART regimens during the study period (D4T/
3TC/EFV to AZT/3TC/EFV at month 10). No participants had active tu-
berculosis during the study period, or exhibited any immune reconstitution
inflammatory syndrome upon HIV treatment. An additional 19 HIV-
uninfected women who were matched for age and ethnicity were stud-
ied, from the CAPRISA 004 1% tenofovir microbicide gel trial (39). These
women were either in the preintervention or placebo arm of the trial. For
HIV-infected individuals, either a prospective RNA positive/Ab negative
reading or the midpoint between the last Ab negative test and the first Ab
positive ELISA test were used to determine the time postinfection. Highly
active ART was given according to the South African national HIV
treatment guidelines (at a CD4 count of ,200 cells/mm3 prior to October
2012; ,350 cells/mm3 until March 2015). Ethical approval for the study
was obtained from the Research Ethics Committees at the University of
KwaZulu-Natal and the University of Cape Town. All participants pro-
vided written informed consent prior to participating in the study.
Measurements of HIV plasma viral load and CD4 counts
Plasma HIV viral load and CD4 count were assessed at each study visit. Over
the course of the study, the viral load PCR assay switched from Roche
AMPLICOR HIV-1 monitor test version 1.5 (lower detection limit [LDL] of
400 RNA copies/ml) to Roche Taqman version 1.0 in June 2010 (LDL 40 RNA
copies/ml), and then to Roche Taqman version 2.0 in January 2012 (LDL 20
RNA copies/ml). The FACSCalibur TruCOUNT method (BD Biosciences)
was used to measure blood absolute CD4+ and CD8+ T cell counts.
Sample processing
PBMC were isolated by Ficoll-Hypaque (Amersham Pharmacia) density
gradient centrifugation and cryopreserved in freezing media (heat-
inactivated FCS; Invitrogen) containing 10% DMSO (Sigma-Aldrich).
Cells were stored in liquid nitrogen until use. Cryopreserved PBMC
were thawed and rested in R10 (RPMI 1640 plus 10% heat-inactivated FCS
and 50 U/ml of penicillin-streptomycin) at 37˚C with 5% CO2 for 3 h
before staining.
Abs, surface, and intracellular staining
The following Abs were used in three different staining panels: CD19 ECD
(J3-119), CD27 PE-Cy5 (1A4CD27; both Beckman Coulter), IgDAPC-Cy7
(IA6-2), CD10 BV605 (HI10a), CD21 PE-Cy7 (Bu32), CD40 PerCP-Cy5.5
(5C3; all BioLegend), CD38 APC (HIT2), CD86 PE (IT2.2), CD3 PE-Cy7
(SK7), HLA-DR APC-Cy7 (L243; all BD Biosciences), CD4 PE-Cy5.5
(S3.5), CD8 Qdot-705 (3B5), CD19 Pacific Blue (SJ25-CI), CD14 Pa-
cific Blue (T€uk4), CD3 Pacific Blue (UCHT1), Ki67 FITC (7B11; all
Invitrogen), and a violet viability reactive dye (Vivid; Molecular Probes).
All Abs were titrated prior to use to obtain optimal titers for staining.
Briefly, PBMC were stained with Vivid, then labeled with Abs against
surface markers, fixed, permeabilized, and subsequently stained intracel-
lularly with Ki67. Cells were then resuspended in 13 CellFix (BD Bio-
sciences) and kept at 4˚C until acquisition. Samples were acquired on a BD
Fortessa using FACSDiva software and analyzed using FlowJo (version
9.9.3; TreeStar). The gating strategy to identify B cell subsets is shown in
Supplemental Fig. 1.
ELISAs
Plasma samples were used to measure soluble CD14 (sCD14; a marker of
monocyte/macrophage activation) from the same women pre- and post-
ART. One participant was not included in this analysis due to the sam-
ple being unavailable. Plasma (n = 18) was tested in duplicate using
commercially available ELISA kits according to the manufacturer’s pro-
tocol (R&D Systems). In addition, 30 plasma samples from HIV-
uninfected women from the same cohort were included. Samples were
diluted 1:200, data were collected using a SpectraMax Plus reader (Mo-
lecular Devices), and point-to-point curve fits were used to calculate
sCD14 concentrations from the standard curves. Data were analyzed using
SoftMax Pro software (Version 3.2.1; Molecular Devices).
Statistical analyses
Statistical analyses were performed using GraphPad Prism (version 5.0).
The Mann–Whitney U test and the Wilcoxon Signed Rank test were used
for unmatched and paired samples, respectively. Correlations between the
different groups were determined by the non-parametric Spearman Rank
test. A p value ,0.05 was considered statistically significant.
Results
Effect of ART on the memory differentiation and activation of
B cells
To define the extent to which ART normalizes HIV-induced alter-
ation of B cells, we first determined the distribution of B cell subsets
in 19 HIV-infected individuals before and 1 y after ART initiation,
and compared it to 19 HIV-uninfected matched controls. Pre-ART
samples were obtained during chronic infection at a median of
4.9 y (interquartile range [IQR]: 2.8–5.8 y) after the estimated date
of HIV infection, and a median of 1.5 mo (IQR: 0.05–2.7) prior to
starting ART. The median plasma viral load at this time was 34,325
HIV RNA copies/ml (IQR: 7,997–78,573), and the median CD4
count was 314 cells/mm3 (IQR: 260–369) (Table I). After a median
of 12 mo of treatment (IQR: 12–13 mo), all individuals exhibited
viral suppression (p = 0.0001), the majority to ,40 copies/ml, and
an increase in both absolute CD4 count and CD4/CD8 ratio (both
p = 0.0001) (Table I, data not shown).
Fig. 1A shows representative flow plots of each B cell subset
from one HIV-uninfected and one HIV-infected individual pre-
and post-ART. Based on the expression of CD27, IgD, and CD38,
six B cell subsets were identified, namely immature transitional
B cells (CD272IgD+CD38+), naive B cells (CD272IgD+CD382),
unswitched memory (CD27+IgD+CD382), CD27+ switched
memory B cells (IgD2CD382), CD272 switched memory B cells
(IgD2CD382), and plasmablasts (CD27+IgD2CD38high). There
was a marked skewing of B cell subsets in chronic HIV infection
prior to ART (Fig. 1B). When compared with HIV-uninfected
participants, HIV-infected individuals were characterized by sig-
nificantly higher frequencies of immature transitional B cells,
unswitched memory B cells, and plasmablasts (median: 9.3%
[IQR: 6.3–13.3] versus 14.8% [IQR: 10.6–20]; 1.5% [IQR: 1.2–
1.7] versus 2.3% [IQR: 2–5.8] and 0.44% [IQR: 0.3–1] versus
2.1% [IQR: 1.4–4], respectively), and significantly lower propor-
tions of naive B cells (median: 65.8% [IQR: 60–72.1] versus
46.9% [IQR: 39.7–55.7]) (Fig. 1B). Additionally, the frequencies
of switched memory B cells expressing CD27 or not were com-
parable in HIV-uninfected and ART naive HIV-infected individuals
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(∼8 and ∼12%, respectively). It is worth mentioning that the
frequency of unswitched memory B cells in our healthy study
population was ∼7 times lower when compared with a previous
study reporting that the proportion of unswitched memory was
comparable to switched memory (representing ∼15% of total
B cells) in a predominantly male cohort from London (11). Fol-
lowing 12 mo of ART, the frequency of immature transitional,
naive and unswitched memory B cells were normalized, returning
to levels comparable to those observed in HIV-uninfected indi-
viduals (Fig. 1B). The frequency of plasmablasts was also reduced
in response to ART (p = 0.004), but remained significantly ele-
vated compared with the HIV-uninfected group. To further define
the restoration dynamics of B cell subsets upon ART, we com-
pared the fold change in their frequencies pre- and post-ART.
After 1 y of ART, only naive B cells displayed an overall ex-
pansion (median 1.3 fold [IQR: 1.2–1.5]); among the subsets
decreasing upon ART, plasmablasts exhibited the largest con-
traction, with a median fold change of 0.38 (IQR: 0.22–0.72). The
contraction of other B cells subsets was more moderate with a
median fold change of 0.51 (IQR: 0.39–0.92) for unswitched
memory B cells, 0.65 (IQR: 0.37–0.77) for immature transitional
B cells, 0.79 (IQR: 0.5–1) for CD27+ switched memory B cells
and 0.87 (IQR: 0.69–1) CD272 switched memory B cells
(Fig. 1C). Although ART had a predominant effect on reducing
the frequency of plasmablasts (∼60% reduction), this was not
sufficient for their normalization with respect to HIV-uninfected
individuals.
Alternative B cell markers such as CD27, CD10, and CD21 have
been used to delineate B cell memory subsets (40), allowing for the
identification of three additional B cell memory subsets, namely
tissue-like memory (CD102CD212CD272), resting memory
(CD21+CD27dim), and activated memory (CD102CD212
CD27dim) B cells (Supplemental Fig. 1B). The expression of
CD10 and CD21 on B cell subsets is shown in Supplemental Fig.
2. Thus, to validate our data, we defined the evolution of B cell
memory subpopulations pre- and post-ART using this set of
markers in 10 of the HIV-infected individuals from our study
(Supplemental Fig. 3). ART led to a significant reduction in the
frequencies of tissue-like memory, activated memory B cells, and
plasmablasts, and an increase in the frequencies of naive and
resting memory B cells. These observations confirm the data de-
scribed above, and are in line with published data (21). Of note,
using this alternative gating strategy, we found no significant
difference in the frequencies of immature transitional B cells
between the two time points. This may be due to the small sam-
ple size (a subset of n = 10) used for this set of markers, because
further analysis of the same individuals using IgD, CD38, and
CD27 also showed no significant difference in immature transi-
tional B cells (data not shown).
The effects of ART on B cell activation and proliferation were
also evaluated. Fig. 2A shows representative flow plots of B cell
activation, measured as the frequency of B cells coexpressing
CD86 and CD40, and proliferation (Ki67 expression) from one
HIV-uninfected and one HIV-infected individual pre- and post-
ART. The frequency of activated B cells (CD86+CD40+) was
significantly higher in HIV-infected subjects prior to ART com-
pared with HIV-uninfected participants (median: 14% [IQR: 9.2–
15.6] versus 1.7% [IQR: 1.3–2.3]; Fig. 2B). In response to ART,
the frequency of activated B cells was substantially reduced but
remained significantly higher than in HIV-uninfected participants
(Fig. 2B). It is important to mention that during HIV infection,
activated B cells were mostly confined to switched memory cells
(i.e., IgD2 B cells), with a median of 25% (IQR: 19.6–32) of
switched cells coexpressing CD40 and CD86. On the contrary, the
activation level of unswitched B cells (i.e., IgD+ B cells) was only
marginal, with less than 5% of these cells positive for CD40 and
CD86 (median: 4.5% [IQR: 2.4–5]; data not shown).
Similar to activated B cells, there were significantly more Ki67+
B cells in ART-naive HIV-infected individuals compared with
HIV-uninfected controls (median: 5% [IQR: 2.9–7.2] versus 1.3%
[IQR: 0.9–1.6]) and although ART led to a significant decline in
proliferating B cells, they remained elevated compared with the
HIV-uninfected group (p = 0.001, Fig. 2C). Of note, the fre-
quencies of proliferating (Ki67+) and activated (CD86+CD40+)
B cells were positively associated with the frequency of plasma-
blasts following ART (p = 0.004, r = 0.62 and p = 0.003, r = 0.63,
respectively, data not shown), suggesting that residual B cell ac-
tivation and proliferation upon ART may be explained by the
persistence of an elevated frequency of plasmablasts, consistent
with our findings presented in Fig. 1B.
Overall, our data show that HIV infection skews the B cell
memory differentiation profile and causes abnormal B cell acti-
vation and proliferation. Defects in B cell memory phenotype were
largely normalized within 1 y of ART, whereas B cell activation and
proliferative capacities were only partially reduced and longer
periods of suppressive therapy may be required for normalization.
B cell defects during HIV infection do not directly associate
with HIV viral load
It has been clearly established that hyper-immune activation of
T cells during HIV infection is related to viral replication (41) and
is partially normalized upon ART (42). This was confirmed in our
experimental setting, where we had T cell activation data for 18 of
the participants in the current study, as well as 14 additional
subjects from the same cohort. The proportion of activated CD4+
T cells (measured by the expression of HLA-DR) was positively
associated with plasma viral load (p = 0.001, r = 0.54; Fig. 3A) in
HIV-infected subjects pre-ART. Although 12 mo of ART led to a
substantial reduction in the frequency of HLA-DR expression by
T cells, T cell activation levels remained significantly higher than
in HIV-uninfected subjects (Supplemental Fig. 4). Thus, to de-
termine whether HIV load was also the driving factor for B cell
activation, we examined the relationship between B cell phenotype
and HIV plasma viral load before ART initiation. As previously
Table I. Clinical parameters of study participants
HIV-Infected HIV-Infected
p Value(Pre-ART) (Post-ART)
Sample size 19 19 (paired)
CD4 count (cells/mm3)a 314 (260–369) 629 (514–696) p = 0.0001
CD4/CD8 ratioa 0.23 (0.18–0.33) 0.61 (0.48–0.74) p = 0.0001
Viral load (RNA copies/ml)a 34,325 (7,997–78,573) ,20 (,20–39) p = 0.0001
Duration of ART (months)a NA 12 (12–13)
aMedian and interquartile range.
NA, not applicable.
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stated, switched memory B cells (i.e., IgD2 B cells) are highly
activated during HIV infection, thus we focused our analyses on this
particular subset. Surprisingly, unlike for T cells, we found no as-
sociation between the frequency of activated (CD86+CD40+)
switched memory B cells and HIV viral load (p = 0.71, r = 0.39;
Fig. 3B). Moreover, none of the B cell memory subset frequencies
were found to be associated with viral load (data not shown). Finally,
the extent of CD4+ or CD8+ T cell activation did not correlate with
the level of switched B cell activation (p = 0.78, r = 0.07; Fig. 3C,
data not shown). Together, these results show that HIV differentially
affects the T cell and B cell compartments, where B cell activation
does not mirror T cell activation and is not directly associated with
the levels of HIV. This suggests that additional factors besides HIV
replication may contribute to B cell activation.
FIGURE 1. Effect of ART on the memory differentiation profile of B cells. (A) Representative flow plots of CD27, IgD, and CD38 expression in B cells
from one HIV-uninfected and one HIV-infected (pre- and post-ART) individual. Numbers represent the frequencies of each B cell subset, namely immature
transitional (CD272IgD+CD38+), naive (CD272IgD+CD382), Unswitched memory (CD27+IgD+CD382), switched CD27+ memory (IgD2CD382),
switched CD272 memory (IgD2CD382), and plasmablasts (CD27+IgD2CD38high). (B) Frequencies of B cell subsets in HIV-uninfected (n = 19; open
circles) and HIV-infected pre- and post ART (n = 19; closed circles) individuals. Horizontal lines indicate the median. Statistical significance was calculated
using a Mann–Whitney U test and Wilcoxon Signed Rank for unpaired and paired samples, respectively. (C) Fold change in the frequency of B cell subsets
over 12 mo of ART. Data are shown as box and whisker (interquartile range) plots. The vertical dotted line indicates no change from the time point prior to
ART. Statistical comparisons were calculated using a one-way ANOVA test. *p , 0.05, **p , 0.01, ***p , 0.001.
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Additional contributors of B cell defects during HIV infection
The translocation of bacterial products resulting from HIV-induced
damage to the gastrointestinal tract is an important contributor of
systemic immune activation (43). Therefore, we investigated the
relationship between the activation and skewed differentiation
profile of B cells and the level of plasma sCD14, a marker of
monocyte/macrophage activation, which may be an indicator, in
the absence of other infections, of microbial translocation. Prior to
ART, plasma sCD14 levels associated negatively with the fre-
quency of naive B cells (p = 0.036, r = 20.50; data not shown)
and positively with the frequency of immature transitional B cells
(p = 0.003, r = 0.75; Fig. 4A), and the frequency of activated
(CD86+CD40+) switched memory B cells (p = 0.01, r = 0.58;
Fig. 4B). Moreover, a positive correlation was also observed
between sCD14 levels and the frequency of activated HLA-DR+
CD4+ T cells (p = 0.045, r = 0.49; Fig. 4C). It is worth noting that
the levels of plasma sCD14 were not significantly changed after
12 mo of ART (Supplemental Fig. 5), and there were no associ-
ations with residual B cell activation post-ART (data not shown).
Overall, these data suggest a possible impact of microbial
translocation on B cell dysfunction, as suggested by sCD14 levels
correlating with HIV-induced B cell skewing and hyperactivation in
untreated chronic HIV infection. However, their influence may be
relatively minor, because there are consistently elevated levels of
sCD14 after ART, when B cell defects are largely reversed. It is
clear that a variety of factors may directly or indirectly influence
B cell defects during HIV infection.
Discussion
Despite the fact that HIV does not directly infect B cells, the virus
causes several B cell abnormalities that contribute to HIV path-
ogenesis (44). Although these B cell defects may be reverted upon
ART, this effect has mostly been studied in cross-sectional Cau-
casian cohorts. Thus, in this study we assessed longitudinally the
impact of ART on the memory and activation profile of B cells in
South African adult women (n = 19); and compared these profiles
to age-matched HIV-uninfected women from the same community
(n = 19). Our data show that: 1) HIV-induced alterations of B cells
did not associate with viral burden but rather correlated with
plasma sCD14 concentration; and 2) 12 mo of ART largely nor-
malized the distribution of B cell memory subsets whereas acti-
vation of B cells was only partially reduced.
HIV induces multiple defects in B cells, altering their memory
and activation profiles and function (3, 5, 40, 45). In our experi-
mental setting, we showed that in HIV-infected African women
B cells were skewed toward a more differentiated memory phe-
notype (with the accumulation of plasmablasts and the reduction
of naive B cells) and were hyperactivated (as measured by CD86
expression) when compared with HIV-uninfected persons. These
observations are in accordance with previous studies performed
primarily in male Caucasian populations (3, 20, 21, 6, 45, 46),
highlighting that similar abnormalities occur in African women.
To date, the drivers of B cell alterations during HIV infection have
not been fully elucidated. Even though HIV does not directly
target B cells for infection, the interaction between HIV and
B cells has been previously described, where HIV gp120 can bind
to B cell receptors such as CD21, DC-SIGN, and variable H chain
3 (VH3) Ig, resulting in polyclonal B cell activation and Ig pro-
duction (47). Furthermore, HIV Nef can interact directly with
B cells, resulting in suppression of Ig class switching (48, 49).
How each of these mechanisms contributes to B cell dysfunction
is unknown (40).
It has also been proposed that excessive B cell activation may
be driven by proinflammatory cytokines, such as IFN-a, TNF-a,
IL-6, and IL-10, molecules commonly up-regulated during HIV-
induced systemic inflammation (50). HIV infection also leads to
increased production of B cell-specific growth factors such as
BLyS/BAFF from macrophages, dendritic cells, and gran-
ulocytes (51–53), promoting B cell dysregulation right from the
early stages of infection. Additionally, HIV pathogenesis has
also been linked to extensive damage to the gastrointestinal tract,
leading to the release of bacterial products into the circulation
(43). These products may induce aberrant B cell activation via
TLR signaling (54), by both direct and indirect means. Stimu-
lation of monocytes by bacterial LPS leads to the release of
cytokines that contribute to the inflammatory environment. Ad-
ditionally, human B cells express a range of TLRs, including
high levels of TLR9 (55), and abundant bacterial DNA as a result
of HIV-induced microbial translocation (56) may stimulate
B cells directly. In fact, TLR9 stimulation of human B cells
promotes their activation, proliferation, and the generation of
FIGURE 2. Effect of ART on B cell activation and proliferation. (A)
Representative flow plots of CD40, CD86, and Ki67 expression in B cells
from one HIV-uninfected and one HIV-infected (pre- and post-ART) in-
dividual. Numbers represent the frequencies of activated (CD86+CD40+)
and proliferating (Ki67+) B cells. (B) Frequencies of CD86+CD40+ B cells
in HIV-uninfected (n = 19; open circles) and HIV-infected pre- and post-
ART (n = 19; closed circles) individuals. (C) Frequencies of proliferating B
cells as measured by Ki67 expression. Horizontal lines represent the me-
dian. Statistical significance was calculated using a Mann–Whitney U test
and Wilcoxon Signed Rank for unpaired and paired samples, respectively.
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plasmablasts (57, 58). The potential role of microbial products as
direct factors fueling B cell hyperactivation is further inferred by
the fact that in other chronic diseases leading to gut damage
(such as inflammatory bowel disease), B cells exhibit aberrant
activation profiles (59).
We found an association pre-ART of B cell activation and dif-
ferentiation profile with the concentration of plasma sCD14, se-
creted upon monocyte/macrophage activation by LPS, which may
be a surrogate marker of microbial translocation. Interestingly,
although there was a relative normalization of B cells post-ART,
plasma sCD14 concentration did not decrease overall upon treat-
ment. This phenomenon has been observed in several studies,
where sCD14 levels remain elevated even after several years on
ART (60–62), and unreversed damage to the gastrointestinal tract
has been proposed to account for this. These data confirm that in
African women, inflammation persists after ART even when there
is a substantial decrease in cellular activation. The absence of any
decrease in sCD14 after ART, despite a substantial normalization
of B cell profiles, suggests that sCD14 plays only a partial role in
contributing to B cell activation. Alternatively, we could speculate
that microbial translocation and viral-induced factors might act
synergistically to drive B cell activation and skewing, and ART
uncouples this effect by suppressing viral replication even in the
face of ongoing inflammation. Although we did not find an as-
sociation of HIV viral load with B cell dysfunction pre-ART, this
relationship may not be linear, with a multitude of viral-induced
factors influencing B cell activation and differentiation directly
and indirectly (63). Overall, this suggests that a combination of
inflammatory mediators such as cytokines, B cell growth factors,
and microbial products may directly and indirectly stimulate
B cell differentiation and proliferation, favoring their functional
impairment and exhaustion.
Several studies have shown that ART leads to a near normali-
zation of peripheral B cell memory subsets (19, 20, 22, 64); and the
extent of restoration was linked to the timing of ART initiation
(21, 65), the duration of treatment, or the age of the patients (22,
66). Very limited data are available on the effects of ART on
B cells in African cohorts. To our knowledge, only one cross-
sectional study has investigated how ART influences the restora-
tion of B cell numbers in an African adult population (30). In
countries disproportionately affected by the HIV pandemic and
where access to ART is limited and often started during advanced
lymphopenia, it is of importance to define whether HIV treatment
can restore B cell profiles to similar levels observed in HIV-
uninfected individuals (of note, the CD4 count pretreatment in
the participants included in this study was ,350 cells/mm3). Our
data showed that although 12 mo of ART largely normalized the
distribution of memory subsets, B cell activation remained sig-
nificantly elevated compared with HIV-uninfected individuals.
The persistence of these cycling, activated B cells composed
mainly of plasmablasts could reflect residual systemic inflamma-
tion, despite viral suppression. Indeed, it has been shown that even
upon successful ART, inflammation, microbial translocation, and
germinal center destruction still persist (43, 67–69). These ob-
servations are in line with results reported in Caucasian cohorts
(20, 21, 70), showing that the normalization of B cell subsets can
be achieved even when treatment is initiated at a late stage of
chronic HIV infection.
The limitations of this study include a cohort exclusively
composed of women; further studies could test the generalizability
of our findings in men. Additionally, we only analyzed B cells from
peripheral blood and this may not be representative of B cell
profiles within the tissues; it is plausible that B cells residing in
the germinal center are differentially affected during HIV infection
and that the extent and/or kinetics of their restoration during
treatment may differ. For future studies, use of additional phe-
notypic markers such as CD10 and CD24 could improve the
FIGURE 3. Relationship between CD4+ T cell and B cell activation and
plasma viral load pre-ART. Correlation of (A) the frequency of HLA-DR
expressing CD4+ T cells (n = 32) and (B) the frequency of CD40+CD86+
switched memory B cells (n = 19) and plasma viral load in HIV-infected
individuals prior to ART initiation. (C) Correlation between B cell acti-
vation (CD86+CD40+) and CD4+ T cell activation (HLA-DR+) in 18 HIV-
infected participants before ART. Statistical significance was calculated
using a non-parametric Spearman Rank test.
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definition of B cell subsets, in particular immature transitional
B cells. Furthermore, we did not examine the relationship of
relative normalization of B cell activation and differentiation with
restoration of functional B cell immunity, which may not always
return (71). Further studies of humoral immunity after ART are
warranted in larger African cohorts, by investigation of both
memory B cell responses and long-lived plasma cells to a variety
of vaccines and infections. This is particularly important if func-
tional B cell immunity is not fully restored and revaccination to
certain pathogens may be required. In this respect, early ART
initiation, compared with those treated during chronic HIV in-
fection, has demonstrated a benefit for restoration of B cell
functionality (21).
In conclusion, our study has shown that the B cell compartment
is highly disturbed in chronically HIV-infected African women, an
understudied group disproportionately affected by the HIV pan-
demic, as it is for Caucasian cohorts. Differences in methodology
limit our ability to directly compare our results in African women to
published studies in western cohorts, but we observed a substantial
reduction in B cell activation and a relative normalization of
skewed B cell subsets as observed in Caucasian cohorts, despite the
commencement of ART in chronic HIV infection. Identifying the
drivers of B cell activation and defective differentiation may
provide a better understanding of the mechanisms associated with
B cell dysfunction. This can potentially lead to the development of
intervention strategies to improve B cell function during HIV in-
fection, for both HIV-specific humoral immunity and responses to
vaccines targeting other pathogens.
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